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Abstract
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate- 
limiting enzyme in cholesterol biosynthesis, and are widely used to treat 
hypercholesterolaemia, a risk factor for cardiovascular disease. Myopathy (muscle 
toxicity) is an adverse effect that is thought to occur due to the secondary effects of 
inhibiting HMGCR; however the mechanism of this myopathy is not fully understood. 
Therefore, the aim of this study was to use two human cell lines as an in vitro model 
for comparing the effects of a variety of statins on both cholesterol synthesis and 
protein prénylation between the liver, the intended target tissue for therapeutic benefit, 
and skeletal muscle, the major site of toxicity.
Initially, the differentiation of RD rhabdomyosarcoma muscle cells was characterised in 
terms of morphological and molecular changes that occur, using microscopy and 
TaqMan analysis respectively, and a 5-day cell differentiation period was chosen for 
use in later experiments. The initial hypothesis to then be tested was that the process 
of protein prénylation exhibits circadian variation, as has already been shown for 
cholesterol synthesis, and this might enable temporal separation between the 
cholesterol-lowering efficacy and the toxicity of statins. However, the ability of the RD 
cell line to establish and maintain circadian rhythmicity in vitro could not be verified and 
so the circadian contributions to cholesterol metabolism and protein prénylation in liver 
and muscle in this model could not be investigated.
Using the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assay, 
significant, dose-dependent reductions in cell viability were observed in both liver and 
muscle cells on treatment with each of the statins (P = 0.0041, atorvastatin; P < 
0.0001, all other statins, two-way analysis of variance (ANOVA)). However, greater 
cell toxicity was observed with the more lipophilic statins, simvastatin (acid), lovastatin 
(acid) and cerivastatin, and also in RD muscle cells compared to Huh7 liver cells. 
Taken together, these data represent the first comprehensive comparative analysis of 
statin toxicity in human liver and muscle cell lines. Cholesterol metabolism was then 
examined in these cells: Although cholesterol was present in all cell types, the levels in 
RD cells were somewhat lower than in Huh7 cells, probably due to much lower levels
III
of HMGCR as measured at both the transcript and protein level; and 48 hour treatment 
with 10pM simvastatin and pravastatin, and 1pM cerivastatin, seemed to lead to a 
decrease in total cellular cholesterol.
Subsequently, protein was extracted from Huh7 and RD cells treated with simvastatin, 
cerivastatin or pravastatin, and then subjected to analysis by western blot to detect any 
changes in the prénylation status of selected small GTPases. Inhibition of prénylation 
was found by directly analysing changes in the unprenylated form of Rap1A, using a 
specific antibody, and by examining the reduction in membrane association of H-Ras, 
M-Ras and Rab1A. Treatment with simvastatin and cerivastatin inhibited the 
prénylation of Rap1A, and seemed to also affect membrane association of the small 
GTPases H-Ras, M-Ras and Rab1A. In both muscle and liver cells the inhibition of 
prénylation of Rap1A, a Ras-related GTPase, was 10-fold more sensitive to treatment 
with cerivastatin than simvastatin. Inhibition of RaplA prénylation in RD muscle cells 
was also 10-fold more sensitive to simvastatin and 3-fold more sensitive to cerivastatin 
treatment than in liver cells. Hydrophilic pravastatin, which showed the lowest toxicity 
in MTT assays, did not affect the prénylation of any of the small GTPases examined, 
as far as was detectable using western blot analysis.
In conclusion, this work has shown that RD muscle cells show both greater sensitivity 
to the toxic effects of statins and preferential disruption of protein prénylation in 
response to statin treatment when compared to Huh7 liver cells. This further supports 
a mechanism whereby disrupting production of intermediates in the cholesterol 
synthesis pathway, including the isoprenoids used in protein prénylation, is a 
significant cause of statin-induced muscle toxicity. This study also highlights the 
importance of examining the effects of drugs at both the target site of action and at the 
site of toxicity, rather than only studying one site in isolation, in order to gain insight 
into the mechanism of adverse drug effects.
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1 Introduction
1.1 Statins
1.1.1 Clinical Use
Cardiovascular diseases are the leading cause of death worldwide, causing 27% 
and 32% of all deaths of men and women respectively (World Health Organisation 
2008). Lowering cholesterol in the form of low-density lipoprotein (LDL) is a 
common strategy in the fight against cardiovascular disease since an elevated 
concentration of cholesterol in this form is known to be one of the most important 
risk factors (Brown and Goldstein 2004).
The statin class of drugs is currently the first line of treatment for 
hypercholesterolaemia, after numerous large clinical trials have demonstrated the 
benefits of their use (Liao 2002; Ong 2005). In particular, the 4S trial 
(Scandinavian Simvastatin Survival Study 1994) and the West of Scotland 
Coronary Prevention Study (WOSCOPS) (Shepherd et al. 1995) were two trials in 
the 1990s that were very significant in first demonstrating the advantages of statin 
treatment (Ong 2005). It has been shown that statins are very effective at lowering 
blood LDL levels (Weng et al. 2010); in short-term studies LDL cholesterol 
reductions of 17-55 % have been measured in patients, depending on the dose 
and the particular statin used (Table 1-1). Widespread use of statins has also led 
to a decrease in the rates of morbidity and mortality due to atherosclerosis (Stossel 
2008).
Statin Dose LDL
(mg/day) Cholesterol (%)
Lovastatin 20 -29
40 -32
80 -48
Simvastatin 10 -28
20 -35
40 -41
80 -46
Pravastatin 10 -19
20 -24
40 -34
Fluvastatin 20 -17
40 -23
80* -36
Atorvastatin 10 -38
20 -46
40 -51
80 -54
Rosuvastatin^’^ 5 -42
10 -47
20 -53
40 -54
Pitavastatin^ 1 -34
2 -42
4 -47
8 -55
Cerivastatin 0.3 -31
0.4 -36
0.8 -45
* Extended-release formulation (-36%); 40mg twice daily (-32%)
Table 1-1 Percentage change in plasma concentration of low density lipoprotein (LDL) 
cholesterol with approved doses of eight statins in patients with hypercholesterolaemia
Data from (Chong et al. 2001), other than where indicated, obtained from short-term studies 
ranging from 4-10 weeks in duration.  ^ Data from (Mukhtar et al. 2005), obtained from studies of 6 
weeks (rosuvastatin, 20mg and 40mg) or 12 weeks (pitavastatin) in duration.  ^ Data from 
(Blasetto et al. 2003) obtained from a study of 12 weeks in duration (rosuvastatin, 5 mg and 
lOmg).
Statins are used to treat both those with established cardiovascular disease 
(secondary prevention) and those who are healthy but designated ‘high risk’ of a 
cardiovascular event (primary prevention). However, treatment is continually 
expanding to include those at lower risk (Hlatky 2008). This is partially due to the 
results of several recent clinical trials, which have demonstrated the benefits of the 
use of statins in primary prevention (Brugts et al. 2009). One such example is the 
Justification for the use of Statins in Primary Prevention: an Intervention Trial 
Evaluating Rosuvastatin (JUPITER); in which comparison with a placebo group 
showed a reduction in the number of major cardiovascular events, in healthy men 
and women with low LDL levels but elevated levels of the inflammatory biomarker 
high-sensitivity C-reactive protein who were treated with rosuvastatin (Hlatky 2008; 
Ridker et al. 2008). There is currently debate over the potential benefits of statin 
treatment even for those who are considered at low risk and would not be 
considered for such intervention under current guidelines (Mihaylova et al. 2012; 
Taylor et al. 2011).
For this reason, as well as from looking at recent trends (Stagnitti 2008), the use of 
statins seems set to only continue to increase in the coming years. Therefore, it is 
all the more important to have an in-depth understanding of the mechanisms by 
which these drugs exert their cholesterol-lowering and other non-cholesterol 
related effects on the body, and to understand the factors regulating these effects.
1.1.2 Currently Available Statins
Since the first inhibitor of cholesterol synthesis was discovered by Akira Endo in 
1977 (Steinberg 2006), a range of related compounds have been isolated and 
synthesized, and collectively these cholesterol lowering drugs are known as the 
statins. The currently available statins can be divided into two classes -  those 
isolated from fungi or derived from fungal products (type 1 statins) and those which 
are completely synthetic (type 2). Those in the former category include lovastatin, 
simvastatin and pravastatin. Those in the latter category include fluvastatin, 
atorvastatin, rosuvastatin, pitavastatin and cerivastatin (Shitara and Sugiyama
2006). Generic names and the most common UK brand names of statins are listed 
in Table 1-2.
Generic Name Brand Name (Manufacturer)
Atorvastatin Lipitor (Pfizer)
Cerivastatin^ Lipobay (Bayer)
Fluvastatin Lescol (Novartis)
Lovastatin Mevacor (Merck), Altocor, Altoprev
Pitavastatin^ Livazo, Alipza (Kowa Pharmaceutical)
Pravastatin Lipostat (Bristol-Myers Squibb)
Rosuvastatin Crestor (AstraZeneca)
Simvastatin Zocor (Merck), Simvador
Table 1-2 Generic and most common brand names of statins in the United Kingdom
Information taken from the British National Formulary (Joint Formulary Committee 2008). 
 ^Cerivastatin was withdrawn from the worldwide market in 2001 (Bellingham 2001);  ^Pitavastatin is 
not yet commercially available in the UK (Kowa Pharmaceutical Europe 2011 ).
Pitavastatin is the newest statin; it has been available in Japan since 2003 
(Chapman 2010) and is now being marketed as Livazo in an increasing number of 
countries around the world, with the first European launch having taken place in 
Spain in 2011 (Kowa Pharmaceutical Europe 2011). In July 2004 simvastatin 
became available over-the-counter in the United Kingdom (UK), as a 10mg/day 
dose, with a licence for sale to those at moderate (10-15%) ten-year risk of a first 
coronary event (National Institute for Health and Clinical Excellence 2006). This 
controversial decision made the UK the first country to have a non-prescription
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statin (Abrams 2005). Cerivastatin was withdrawn from the worldwide market in 
2001 and is therefore no longer commercially available (Bellingham 2001).
1.1.3 Mechanism of Action
Cholesterol plays a vital role in the body and is essential for normal cell function: It 
is a major constituent of eukaryotic cell membranes, where its sterol ring structure 
provides rigidity (Figure 1-1). This means that the amount of cholesterol present in 
a membrane is important in determining the properties of the membrane. 
Cholesterol is also the precursor to steroid hormones (such as oestrogen, 
progesterone, testosterone and glucocorticoids), vitamin D and bile salts. 
However, in excess it can also contribute to the build up of lipid deposits and 
hardening of the arteries in atherosclerosis, which is thought to often lead to 
cardiovascular disease (Shitara and Sugiyama 2006; Voet and Voet 2004).
CH3
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j
Figure 1-1 The structure of cholesterol
Cholesterol has a polar head group, a sterol ring structure that provides rigidity to cell 
membranes, and a nonpolar hydrocarbon tail. (Voet and Voet 2004).
There are two main sources of cholesterol in the body: cholesterol from the diet 
and cholesterol that has been synthesized internally. Although almost all cells are
able to synthesize cholesterol, the liver is the main site of cholesterol biosynthesis 
in the body and is therefore the main target organ of all of the statins (Catapano
2007).
Cholesterol biosynthesis is a complex pathway involving many enzymes and 
intermediates. All statins act by competitively inhibiting the enzyme 3-hydroxy-3- 
methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR) (Figure 1-2), which 
catalyses the first committed, and rate-limiting, step of cholesterol biosynthesis 
(Shitara and Sugiyama 2006). The resulting decrease in de novo cholesterol 
synthesis leads to upregulation of the LDL receptor (LDLR), through the activation 
of cholesterol-sensing transcription factor sterol regulatory element binding protein 
(SREBP) (Brown and Goldstein 1997). The increase in LDLR then leads to 
increased uptake of cholesterol, in the form of LDL, from the bloodstream into cells, 
resulting in an overall reduction in plasma LDL levels (Brown and Goldstein 2004).
HMG-CoA reductase H2
C OHSCoA
2HC 2HCH2 H2
2 NADPH
2 NADP+CoA
HMG-CoA Mevalonate
Figure 1-2 The conversion of 3-hydroxy-3-methyiglutaryl-CoA (HMG-CoA) to mevalonate Is 
catalysed by the enzyme HMG-CoA reductase (HMGCR)
This reaction is a reduction, requiring NADPH (nicotinamide adenine dinucleotide phosphate), 
and is the rate-limiting step in the biosynthesis of cholesterol. It is also the step where statins 
exert their effect by acting as competitive inhibitors of HMGCR. (Voet and Voet 2004).
The mevalonate pathway (Figure 1-3), the branched pathway that cholesterol 
biosynthesis is a part of, uses common precursors to also synthesize a number of 
essential isoprenoids other than cholesterol. These include dolichol, 
isopentenylpyrophosphate, farnesylpyrophosphate (FPP) and
geranylgeranylpyrophosphate (GGPP). Statin inhibition of HMGCR affects the
level of all common precursors and hence levels of these other isoprenoids. It is 
this which is thought to underlie the major adverse effects of statins (Baker 2005).
Acetyl-CoA ^ Thiolase
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Figure 1-3 The mevalonate pathway; biosynthesis of cholesterol and other essential 
isoprenoids
Statin inhibition of the rate-limiting enzyme HMGCR affects levels of not only cholesterol but also of 
sec-tRNA, ubiquinone, dolichol and prenylated proteins. Dolichol synthesis also uses isopentenyl- 
PP, but arrow not shown for diagram simplicity. Figure produced using the following references: 
(Baker 2005; Goldstein and Brown 1990; Lane and Beese 2006; McTaggart 2006; Shitara and 
Sugiyama 2006; Vaklavas et al. 2009; Voet and Voet 2004).
1.1.4 Similarities and Differences between the Statins
All of the statins have an HMG-like moiety, enabling them to tightly bind to the 
catalytic site of HMGCR and block access for the substrate HMG-CoA, resulting in 
potent, competitive inhibition of HMGCR (Figure 1-4). However, there are 
structural differences between statins that result in differences in their physiological 
properties (Table 1-3). This includes differences in their modes of binding, which 
can be seen from the crystal structures that have been solved for a portion of the 
enzyme bound to each of six different statins (Istvan and Deisenhofer 2001). In 
general the newer statins exhibit a higher affinity for HMGCR and have more 
potent inhibitor effects (Shitara and Sugiyama 2006).
HO,
H2C1
S-CoA
HMG-CoA
,0 HO4 HO,
.0
simvastatin pravastatinlovastatin
fluvastatin cerivastatin pitavastatin
rosuvastatinatorvastatin
Figure 1-4 Chemical structures of the different statins
All of the statins have an HMG-like moiety, which can either be in the lactone form (simvastatin 
and lovastatin) or in the open acid form (all other statins). However, there are also many 
differences in structure which account for the different physiological properties between statins. 
Figure reproduced from (Shitara and Sugiyama 2006).
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statin Simvastatin Lovastatin
(Simvastatin acid) (Lovastatin acid)
Cerivastatin Fluvastatin Atorvastatin Pitavastatin Rosuvastatin Pravastatin
logD (pH 7.0)’ 
logD (pH 7.4)’ 
Lipophilicity
4.4(1.88)
Lipophilic
3.91 (1.51) 
Lipophilic
2.32
1.50-1.75
Lipophilic
1.75
1 .00-1.25
Lipophiiic
1.53
1.00-1.25
Lipophilic
1.5
Lipophilic
-0.25 - -0.50 
Hydrophilic
-0.47 
-0.75--1.00 
Hydrophilic
Uptake^ 
Passive diffusion ? 
Active transport ?
Yes
(OATP1B1)
Yes
(OATP1B1)
Yes
0ATP1B1
Yes
Unknown
?
0ATP1B1 
0ATP2B1 (L/M)
?
0ATP1B1
(0ATP1B3)
No No 
0ATP1B1 0ATP1B1 
0ATP1B3 
0ATP2B1 (L/M) 0ATP2B1 (UM) 
OATP 1 A4 (M) 
0AT3(M)
Metabolism^ CYP3A4
CYP3A5
CYP3A4 (CYP3A4)
CYP2C8
CYP2C9 CYP3A4 (CYP3A4) 
CYP2A9 
CYP2C9 
Minimally; slow
CYP2C9
Minimally
CYP3A4
Sulphation
Minimally
Half-iife (hours)^ 3 3 - 4 2 - 3 < 1 14 11 19 1.8
Bioavaiiability (%)^ < 5 < 5 60 24 12 > 60 20 17
Year introduced^ 1991 1987 1997 
(withdrawn 2001 )
1993 1996 2003 (Japan) 
2011 (EU)
2003 1991
Table 1-3 Summary of the major differences between properties of the statins
 ^ (Shitara and Sugiyama 2006)
 ^(Kitamura et ai. 2008; Knauer et al. 2010; Sakamoto et al. 2008; Shitara and Sugiyama 2006; 
Takeda et al. 2004)
 ^(Chong et al. 2001; Mukhtar et al. 2005; Vaklavas et al. 2009)
(AstraZeneca 2007; Chong et al. 2001 ; Mukhtar et al. 2005)
 ^(AstraZeneca 2007; Recordati 24 October 2008; Staffa et al. 2002)
LogD values reflect the lipophilicity of a statin, with simvastatin and lovastatin being the most 
lipophilic (yellow), and rosuvastatin and pravastatin the least lipophilic (orange). The newest 
statins, atorvastatin, pitavastatin and rosuvastatin, appear to have the longest half-lives in the body. 
Bioavailability refers to the percentage of the drug that becomes available at the target site in the 
body, for example after absorption, and uptake refers to hepatic transport other than where noted: 
L/M=liver and muscle, M=exclusively muscle transport. OATP = organic anion transporting 
polypeptides; OAT = organic anion transporter; GYP = Cytochrome P450.
The statins exhibit varying degrees of lipophilicity and therefore have different 
uptake mechanisms (Table 1-3). Simvastatin and lovastatin are the only statins 
that are administered as prodrugs in an inactive form, containing a lactone ring that 
is converted into the open acid form in the body. This means that simvastatin and 
lovastatin are the most lipophilic; they can cross lipid bilayers by passive diffusion 
and can therefore become widely distributed to a variety of tissues. In contrast, 
pravastatin and rosuvastatin are hydrophilic and rely on transporters for uptake into 
hepatocytes. The other statins have intermediate physicochemical properties 
(Hamelin and Turgeon 1998). Studies have demonstrated that transport of statins 
is mediated by various members of the organic anion transporting polypeptide
(OATP) and organic anion transporter (OAT) families (Hsiang et al. 1999; 
Sakamoto et al. 2008; Takeda et al. 2004; Tokui et ai. 1999). In particular 
0ATP1B1, a transporter exclusive to liver, contributes to varying degrees to the 
hepatic uptake of many of the statins (Kitamura et al. 2008).
The statins are also metabolised differently by the liver (Table 1-3). The 
cytochrome P450 (GYP) family is a large family of haem-containing 
monooxygenase enzymes that catalyse many reactions involved in drug 
metabolism. CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) is 
thought to be involved in the metabolism of approximately half of all drugs in 
current use (Takiguchi et al. 2007), and this includes simvastatin, lovastatin and 
atorvastatin (Bolego et al. 2002). Cerivastatin is metabolised by CYP2C8 as well 
as CYP3A4 and fluvastatin, alone amongst the statins, is metabolised by CYP2C9. 
Pitavastatin, rosuvastatin and pravastatin undergo minimal metabolism by GYP 
enzymes and are therefore not susceptible to many of the metabolism drug-drug 
interactions in the same way as other statins (Shitara and Sugiyama 2006). Both 
cerivastatin and atorvastatin have metabolites that contribute towards their lipid- 
lowering effects (Ghong et al. 2001 ).
All of these differences impact on statin prescribing choices, depending on the 
needs of each individual patient based on their risk profile (Ghong et al. 2001). 
They potentially also impact upon the incidence of adverse effects (Bolego et al. 
2002).
1.2 The Problem of Statin-Induced Myopathy
1.2.1 Myopathy and its Incidence amongst Statin Users
Statins are generally considered to be effective and relatively safe drugs, and are 
well tolerated by most (Law and Rudnicka 2006). However some patients do 
experience side effects, the most significant of which is myopathy. Myopathy is a 
general term used to refer to any disease of the muscles, which encompasses 
everything ranging from mild fatigue and minor muscle aches, pains, cramps and
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weakness to complete collapse of the muscle structure in rhabdomyolysis, which 
requires hospitalisation and in rare cases can prove fatal (Harper and Jacobson
2007).
Muscle complaints, including rhabdomyolysis, have been reported with all statins 
(Bolego et al. 2002) and rhabdomyolysis-related death has been reported with all 
statins other than fluvastatin (Table 1-4). It was the high number of deaths caused 
by rhabdomyolysis following treatment with cerivastatin in the US that prompted its 
withdrawal from the market in 2001 (Bellingham 2001). After cerivastatin, the next 
highest number of fatal cases has been reported in patients taking lipophilic drugs 
simvastatin and lovastatin; and in fact, due to increased risk of myopathy in general 
the highest dose of 80mg simvastatin is now no longer recommended, other than 
in patients who have already had this treatment for more than 12 months with no 
adverse muscle effects (Gotto and Moon 2012). Fluvastatin and pravastatin seem 
to produce the fewest cases of rhabdomyolysis; however these statins are also 
less effective at lowering blood cholesterol than some of the other statins (Table
1- 1).
Lovastatin Pravastatin Simvastatin Fluvastatin Atorvastatin Cerivastatin Total
Date Approved
Fatal Cases of Rhabdomyolysis
No. prescriptions dispensed 
since marketing began (million) 
Reporting Rate (per 1 million 
prescriptions)
08/1987 10/1991 12/1991 12/1993 12/1996 06/1997 
19 3 14 0 6 31
99.197 81.364 116.145 37.392 140.360 9.815 
0.19 0.04 0.12 0 0.04 3.16
73
484.273
0.15
Table 1-4 Reported cases of fatal rhabdomyolysis for all statins dispensed in the United 
States from when these products were launched until 2001
Fatal rhabdomyolysis has been reported with all statins, other than fluvastatin, however different 
statins have different reporting rates. The highest reporting rate of rhabdomyolysis was with 
cerivastatin, prompting its withdrawal from the market in 2001, with the next highest number of 
cases seen with simvastatin and lovastatin. Table reproduced from: (Staffa et al. 2002). Reported 
fatal cases of rhabdomyolysis are those reported to the US Food and Drug Administration (FDA) 
before 2001 and where death resulted either directly or indirectly from rhabdomyolysis. Reporting 
rate is the number of fatal cases divided by the number of prescriptions.
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Myalgia, muscle weakness and aches without elevation of creatine kinase, has 
been estimated to occur in 10-15% of all statin patients (Mohaupt et al. 2009) and 
rhabdomyolysis incidence has been estimated at 3.4 per 100,000 person-years 
(with statins other than cerivastatin) (Law and Rudnicka 2006). However, it is 
difficult to accurately estimate the incidence of all statin-induced myopathy as it is 
well recognised that the less severe muscle effects are under-reported, and that 
incidence of myopathy in controlled clinical trials is artificially depressed, partly 
because many of those who would be more prone to statin-induced myopathy are 
not included in these trials (Vaklavas et al. 2009). It has also been suggested that 
cases of rhabdomyolysis are similarly under-reported (McAdams et al. 2008).
1.2.2 Factors Affecting the Incidence of Statin-Induced Myopathy
Statin-induced myopathy is known to be dose-dependent (Law and Rudnicka 
2006) and any interaction which leads to an increase in statin exposure is a risk 
factor (Kitamura et al. 2008; Knauer et al. 2010; Sidaway et al. 2009).
The lipophilicity of statins such as simvastatin and lovastatin has been suggested 
to account for their higher incidence of adverse muscular side effects, due to their 
high rates of passive diffusion into all tissue, including muscle (Vaklavas et al. 
2009). However, transporters such as 0AT1, OATP 1 A4 and 0ATP2B1 have been 
reported to be expressed in muscle tissue and recognise statins as substrates, and 
could therefore play a role in determining muscle statin exposure (Table 1-3). The 
importance of these transporters in the development of muscle toxicity is not yet 
entirely clear (Knauer et al. 2010; Shitara and Sugiyama 2006; Sidaway et al. 
2009), although it has been shown that some genetic polymorphisms affecting 
transporters, and therefore drug disposition, can affect patient risk of developing 
myopathy. One such example is a single nucleotide polymorphism (SNP) in the 
solute carrier organic anion transporter family, member 1B1 {SLC01B1) gene, 
encoding the transporter 0ATP1B1, that has been associated with a higher risk of 
myopathy in response to simvastatin treatment (Link et al. 2008; Voora et al.
2009). Due to these findings a diagnostic test has now been launched, enabling
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the use of SLC01B1 genotyping to identify those at high risk (Isis Innovation 
2012).
Myopathy risk is also increased by drug interactions that can occur when statins 
are administered as part of combination therapy, particularly with drugs that can 
affect statin metabolism and therefore statin exposure (Knauer et al. 2010). Many 
drugs, including cyclosporine, azole antifungals, macrolides and calcium channel 
blockers, can inhibit the activity of CYP3A4, an enzyme important for the 
metabolism of many of the statins (Table 1-3). In fact, it has been estimated that 
interactions with drugs known to inhibit CYP3A4 activity underlie 60% of 
rhabdomyolysis cases associated with simvastatin, lovastatin or atorvastatin 
(Vaklavas et al. 2009). Similarly, fluvastatin may interact with inhibitors of 
CYP2C9, such as omeprazole and ritonavir (Chong et al. 2001), and with other 
substrates of CYP2C9, such as warfarin, fluconazole and diclofenac (Bolego et al.
2002).
The risk of rhabdomyolysis is substantially higher on co-treatment with a statin and 
a fibrate, particularly gemfibrozil (Harper and Jacobson 2010; Law and Rudnicka 
2006; Mastaglia and Needham 2012). Gemfibrozil has been shown to inhibit 
CYP2C8, one of the enzymes involved in the metabolism of cerivastatin, which 
could account for the higher incidence of rhabdomyolysis in patients treated with 
both cerivastatin and gemfibrozil. Gemfibrozil is also a substrate of CYP3A4 and 
can inhibit the glucuronidation of statins (Prueksaritanont et al. 2002).
There are many patient characteristics which are thought to affect myopathy risk. 
These include several underlying medical conditions that can predispose a patient 
towards developing statin-induced myopathy, such as hepatic dysfunction, 
hypothyroidism and metabolic muscle diseases. Women and those of more 
advanced age are thought to be at higher risk of experiencing statin-induced 
myopathy (Harper and Jacobson 2010). In addition lifestyle choices, such as
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performing strenuous exercise and the consumption of alcohol, can also increase 
risk.
Time of dosing may impact upon tolerability of statins, as has already been 
demonstrated with a number of other drugs such as non-steroidal anti­
inflammatory drugs (NSAIDS) and cancer therapeutics, due to the impact of 
circadian rhythms on wide-ranging aspects of physiology (Levi and Schibler 2007). 
This will be discussed further in section 1.4.
1.3 The Mechanism of Statin-Induced Myopathy
There continues to be much debate over the precise mechanism of statin-induced 
myopathy. Co-treatment with statin and mevalonate, the product of HMGCR, has 
been shown to prevent the development of myopathy in vivo (Westwood et al.
2008) and so the current consensus seems to be that the decreased production of 
essential isoprenoids in the mevalonate pathway is the most likely underlying 
cause of myopathy (Baker 2005; Mastaglia and Needham 2012; Sathasivam 2012; 
Vaklavas et al. 2009). There is varying evidence for the involvement of each of the 
products and intermediates of this pathway (Vaklavas et al. 2009).
1.3.1 Decreased Membrane Cholesterol
There is evidence to suggest that a decreased level of cholesterol is not in itself the 
cause of myopathy, although this was initially thought to be the case (Baker 2005; 
Nishimoto et al. 2003). Skeletal myopathy is associated with mevalonic aciduria, a 
disorder caused by deficiency of mevalonate kinase which is an enzyme important 
at an early stage of the cholesterol biosynthesis pathway (Figure 1-3). In contrast, 
syndromes caused by deficiencies in terminal enzymes (distal enzymopathies) in 
cholesterol biosynthesis do not show myopathy among their clinical manifestations 
(Baker 2005).
In addition, inhibitors of squalene synthase do not cause muscle toxicity in vitro 
(Flint et al. 1997) and they have in fact shown some protective effect on statin- 
induced myopathy (Nishimoto et al. 2007). Unlike statins, they do not lead to a
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decrease in mevalonate (Elsayed and Evans 2008) since squalene synthase is the 
first enzyme downstream of the branch point in the mevalonate pathway and hence 
is the first enzyme solely committed to cholesterol synthesis (Charlton-Menys and 
Durrington 2008). There has therefore been considerable interest in squalene 
synthase inhibitors (Nishimoto et al. 2007; Nishimoto et al. 2003; Tavridou et al.
2006) however TAK-475 (lapaquistat), the only squalene synthase inhibitor to have 
progressed as far as phase III clinical trials in Europe and the United States, was 
recently discontinued from clinical development (Takeda 28 March 2008).
Consequently, it seems more likely that myopathy results from reductions in 
products and intermediates of the mevalonate pathway other than cholesterol. 
This means that potential candidates could include ubiquinone, dolichol, 
selenocysteine tRNA and the isoprenoids farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP).
1.3.2 The Role of Ubiquinone
Ubiquinone (also known as coenzyme Q10, coQ10) is synthesized from GGPP, in 
a multistep side-branch of the mevalonate pathway (Figure 1-3), and its role in 
myopathy is unclear. CoQIO acts as an electron carrier during oxidative 
phosphorylation and so is essential for mitochondrial energy production 
(Traustadottir et al. 2008). It has therefore been proposed that statin inhibition of 
coQIO production could lead to myopathy due to muscle mitochondrial dysfunction 
(Marcoff and Thompson 2007; Sathasivam 2012).
It is well known that statins decrease plasma levels of coQIO, however it has yet to 
be shown conclusively that levels are also lowered in muscle and that lower 
muscle mitochondrial coQIO leads to myopathy (Marcoff and Thompson 2007). 
Several clinical trials investigating the effects of coQIO supplementation alongside 
statin therapy have proved inconclusive (Schaars and Stalenhoef 2008) and 
evidence thus far seems to suggest that coQIO depletion is only likely to play a
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major role in myopathy in patients who already have depleted levels of coQ10 due 
to pre-existing conditions (Oh et al. 2007; Schaars and Stalenhoef 2008).
1.3.3 Dolichol and Glycosylation
Statins have been shown in vitro to affect N-linked glycosylation (Mullen et al. 
2010; Siddals et al. 2004), the most common form of glycosylation in mammals 
(Martin-Rendon and Blake 2003). Glycosylation, the addition of oligosaccharides 
to polypeptides to form glycoproteins, is an important co-translational covalent 
modification for the correct biological functioning of many proteins. Dolichol, a 
product of the mevalonate pathway, is vital in this process as it acts as a carrier for 
the 14 sugar oligosaccharide that is the precursor of all N-linked oligosaccharide 
chains (Baker 2005; Vaklavas et al. 2009).
It is thought that a reduction in dolichol synthesis could result in myopathy due to 
an impaired response to growth factors such as insulin-like growth factor-1 (IGF-1). 
IGF-1 is well known to have proliferative effects in skeletal muscle, as well as a 
role in muscle fibre regeneration (myoregeneration) after injury (Barton et al. 2012), 
and statins have been shown to affect the N-linked glycosylation and processing of 
IGF receptors in adipocytes (Siddals et al. 2004).
Many other cellular proteins could additionally be affected, for example the 
glycoprotein dystroglycan which mediates communication between the 
extracellular matrix and the cytoskeleton. This process is thought to also be 
important in myoregeneration (Cohn et al. 2002) and defects in posttranslational 
processing of dystroglycan have been linked to a variety of muscle disorders 
(Martin-Rendon and Blake 2003; Muntoni et al. 2004).
1.3.4 Selenoproteins
There are estimated to be approximately 25 human selenoproteins, which are 
proteins containing selenium usually in the form of selenocysteine (Muttenthaler 
and Alewood 2008). Selenocysteine is considered to be the 21®^  amino acid in 
ribosome-mediated protein synthesis (Stadtman 1996) and its incorporation into
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proteins in selenoprotein synthesis is mediated by selenocysteine tRNA (Sec 
tRNA). Sec tRNA inserts a selenocysteine where there is a UGA codon in the 
messenger RNA. UGA is usually a stop codon; therefore incorrect decoding by 
sec tRNA can lead to premature termination of translation and production of 
truncated proteins.
It is known that isopentylation of adenosine 37 in sec tRNA is important for efficient 
decoding. This modification is catalysed by the enzyme isopentenyl 
pyrophosphate: tRNA isopentenyltransferase and uses isopentenyl-PP, an 
intermediate of the mevalonate pathway, as a substrate. Lovastatin treatment has 
been shown to lead to a reduction of sec tRNA with this modification and to reduce 
the ability of cells to synthesize selenoproteins (Warner et al. 2000).
Evidence for the potential importance of this selenoprotein deficiency for statin 
myopathy is that mutations in the gene for selenoprotein N (SEPN1) have been 
linked to a range of congenital muscular disorders. Selenoprotein N is an 
endoplasmic reticulum glycoprotein postulated to be important for regulating 
intracellular calcium release via the ryanodine receptor intracellular calcium release 
channel; its correct function is therefore thought to be important for muscle fibre 
formation (myogenesis) and for myoregeneration (Jurynec et al. 2008; Petit et al.
2003).
Further evidence is provided by reports that statin-induced myopathy shares many 
similarities with myopathy resulting from selenium deficiency (Moosmann and Behl
2004). In addition, statin treatment has been shown to lead to a reduction in the 
activity of the selenoprotein glutathione peroxidase, leading to increased oxidative 
stress in human HepG2 liver cells (Kromer and Moosmann 2009). It is therefore 
possible that deficiency in selenoprotein synthesis could likewise lead to an 
increased vulnerability to oxidative stress in muscle.
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1.3.5 Protein Prénylation
Protein prénylation is known to be a very important process physiologically and it is 
thought that prenylated proteins account for up to 2% of total cellular protein. 
Prénylation involves the post-translational covalent addition of the prenyl groups 
farnesyl (15-carbon) or geranylgeranyl (20-carbon) to cysteine residues at or near 
the C-terminus of proteins via thioether linkages. The addition of these lipophilic 
groups is thought to be essential for the biological function of many proteins, by 
enabling them to anchor to cell membranes and hence specifying their cellular 
localisation. This is important for cellular protein-protein interactions and 
membrane-associated protein trafficking (McTaggart 2006). These prenyl groups 
are donated by the isoprenoids farnesylpyrophosphate (FPP) or 
geranylgeranyl pyrophosphate (GGPP) respectively and, since both are 
intermediates in the mevalonate pathway, statin use is thought to lead to a 
decrease in protein prénylation.
There are three distinct protein prenyltransferase enzymes that catalyse the 
addition of prenyl groups to proteins: farnesyltransferase (FT),
geranylgeranyltransferase-l (GGT-I) and geranylgeranyltransferase-lI (GGT-II). FT 
and GGT-I both catalyse the addition of a prenyl group to the cysteine of a C- 
terminal CAAX protein motif, (where C is cysteine, A is an aliphatic residue and X 
can be a wide variety of different amino acids (McTaggart 2006)). They are 
therefore known as the CAAX prenyltransferases. They are zinc metalloenzymes 
and heterodimers that share an a subunit but have different p subunits. It is 
thought that the p subunits of these enzymes contain the substrate binding sites 
(Casey and Seabra 1996) and that it is these different p subunits which provide the 
different substrate specificities (Terry et al. 2006). GGT-II (also known as Rab 
GGT) consists of distinct a and p subunits. In a complex with Rab escort protein 
(REP) it catalyses the addition of geranylgeranyl groups onto two cysteine residues 
in the C-terminal recognition sequences CC or CXC, or a range of other similar C- 
terminal motifs (Maurer-Stroh et al. 2003).
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Substrates of FT include small G protein Ras and the nuclear lamins, and 
substrates of GGT-I include Ras-related GTPases, such as those of the Ras, Rap, 
and Rho subfamilies, and the y subunits of heterotrimeric G-proteins (Casey and 
Seabra 1996; Lane and Beese 2006). GGT-II catalyses the addition of prenyl 
groups onto small G proteins of the Rab subfamily (Casey and Seabra 1996; 
Leung et al. 2006). There is increasing evidence to suggest that disruption of the 
prénylation of these various targets plays an important role in statin-induced 
myopathy (Blanco-Colio et al. 2002; Matzno et al. 2005; Sakamoto et al. 2011).
1.3.5.1 Lamins
Lamins are intermediate filament proteins that are the main structural component 
of the nuclear lamina, adjacent to the inner nuclear membrane. In addition to its 
structural role, the nuclear lamina has important roles in chromatin organisation, 
cell division and gene transcription (Davies et al. 2009), and lamins are thought to 
also mediate the targeting of integral membrane proteins to the inner nuclear 
membrane (Wilson 2000). The importance of functional lamins for proper muscle 
function is emphasised by the fact that mutations in the gene coding for lamins A 
and C are known to cause a variety of muscle disorders, including Emery-Dreifuss 
muscular dystrophy (Wilson 2000).
Lamins are substrates of FT (Lane and Beese 2006) and they undergo post­
translational modification by farnesylation, which is thought to be important for the 
targeting of the lamins to the inner nuclear membrane (Davies et al. 2009). Lamins 
B1 and B2 are farnesylated (Farnsworth et al. 1989; Rusinol and Sinensky 2006) 
and prelamin A, a precursor to lamin A, undergoes farnesylation-dependent 
processing to form the functional protein (Davies et al. 2009). It has been shown in 
vitro that treatment with lovastatin inhibits processing of prelamin A (Beck et al. 
1990), results in nuclear accumulation of prelamin A (Sinensky et al. 1994) and 
prevents the assembly of lamin A into the nuclear lamina (Lutz et al. 1992). It is 
unclear how disruption of lamin function could lead to myopathy, but it is possible 
that resulting disruption of nuclear stability could make muscle cells less able to
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sustain the forces from muscle contraction and more susceptible to apoptosis 
(Lammerding et al. 2004).
1.3.5.2 Small G Proteins
Small G-proteins, or small GTPases (guanine nucleotide-binding proteins), are 
monomeric proteins that cycle between an inactive guanosine diphosphate (GDP) 
bound state and an active guanosine triphosphate (GTP) bound state and have 
important roles in cellular signal transduction. Small G-proteins are a major target 
for prénylation. There are known to be over 100 small G-proteins in eukaryotes, 
divided into superfamilies and subfamilies. The most well studied of the small G- 
proteins are those in the Ras superfamily, including the Ras, Rho and Rab 
subfamilies (reviewed by (McTaggart 2006)).
// Ras small GTPases
Ras small G proteins have key roles in many signalling cascades, transducing 
receptor activation to effects on gene transcription and cellular proliferation. The 
best known of these is the mitogen-activated protein (MAP) kinase cascade. In 
this cascade, upon activation of a tyrosine kinase receptor Ras becomes activated 
and can bind to Raf proteins. These in turn phosphorylate and activate MEK 
(mitogen-activated protein kinase kinase), which then phosphorylates and activates 
MAP kinase (MAPK). MAPK then translocates to the nucleus where it activates 
various transcription factors (Matozaki et al. 2000; Vojtek and Der 1998).
Ras proteins are further substrates of FT (Casey and Seabra 1996), with the 
exception of K-RasB which can undergo geranylgeranylation by GGT-I in the 
presence of FT inhibitors (Whyte et al. 1997). The farnesylation of Ras is vital for 
its membrane localisation, and therefore also for its activation and function in 
downstream signal transduction (Dirks and Jones 2006). In vitro experiments have 
shown a reduction in Ras farnesylation in mouse myoblasts on simvastatin 
treatment, which could be rescued by co-incubation with farnesol (Mullen et al.
2010), and in rat skeletal myoblasts treated with a range of statins membrane-
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bound Ras was activated and detached, leading to cell death by apoptosis (Matzno 
et al. 2005).
/77 Rho Subfamily GTPases
Members of the Rho subfamily, such as Rho, Rac and cdc42, are involved in 
regulating cytoskeleton organisation. Their roles include regulating the formation 
of actin stress fibres and focal adhesions, as well as regulating microtubule 
stability. They can also have effects on gene expression (Fukata et al. 2003; 
Matozaki et al. 2000). Rho family proteins are substrates of GGT-I and usually 
undergo geranylgeranylation. Exceptions to this include proposed prénylation by 
FT, in addition to GGT-I, when these proteins are overproduced (Casey and 
Seabra 1996) and RhoB, which can be either farnesylated or geranylgeranylated 
by GGT-I (Armstrong et al. 1995).
There is varying evidence for the importance of disrupted prénylation of Rho 
proteins in statin-induced myopathy, in vitro treatment with statins leads to 
fragmentation of actin and collapse of the microtubule network (Bifulco et al. 1993; 
Liao 2002; Matzno et al. 1997) which can be reversed by mevalonate treatment 
(Bifulco et al. 1993; Liao 2002). In rat primary neurons, statin treatment has been 
shown to cause a decrease in membrane-bound Rho A as well as disruption of the 
microtubule network (Meske et al. 2003). Simvastatin and fluvastatin treatment 
similarly led to a change in localisation of Rho A from the membrane to the cytosol 
and apoptosis in rat myoblasts, which could be rescued on co-addition of GGPP. 
A Rho-kinase inhibitor mimicked the statin-induced apoptosis and a similar change 
in Rho A localisation was observed in rat skeletal muscle in vivo (Itagaki et al.
2009). It has also been reported that myopathy resulting from treatment with 
colchicine, a drug that disrupts microtubule dynamics, results in similar pathology 
to statin-induced myopathy (Baker et al. 2004).
Moreover, statins have been shown to induce apoptosis in vitro in a range of 
different cells (Dirks and Jones 2006). One study has provided evidence that 
treatment of vascular smooth muscle cells with statins in vitro leads to a
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downregulation of the anti-apoptotic protein Bcl-2 (B-cell lymphoma 2), via 
inhibition of the prénylation of Rho A, and that the resulting apoptosis can be 
rescued by addition of mevalonate, FPP or GGPP (Blanco-Colio et al. 2002). 
However, in contrast to this, another study found levels of membrane-bound Rho to 
be unaffected by statin treatment in rat myoblasts. The authors therefore 
suggested that statin-induced apoptosis of skeletal muscle is not caused directly by 
depletion of Rho, and they proposed that depletion of Rho may only be important in 
mediating the pleiotropic effects of statins in other tissues (Matzno et al. 2005).
an Rab Subfamily GTPases
Small G-proteins in the Rab subfamily are important in organelle biogenesis and 
intracellular trafficking of vesicles. There are numerous different isoforms, each of 
which has a different intracellular localisation and regulates a different trafficking 
step. Rab proteins are geranylgeranylated by GGT-II, which is an important 
modification for Rab protein localisation and therefore function (Leung et al. 2006).
Recent studies have demonstrated that inactivation of Rab proteins could play a 
crucial role in statin-induced morphological changes in muscle. Treatment with 
perillyl alcohol, an inhibitor of GGT-I and GGT-II, has been shown to mimic the 
effect of statins in isolated rat skeletal myofibres by inducing vacuolisation, 
degeneration and swelling of organelles. These effects could be rescued by co­
addition of GGPP but not FPP, and could not be reproduced by specific inhibition 
of GGT-I or FT (Sakamoto et al. 2007). More recently, specific small molecule 
inhibition of GGT-II has been shown to produce similar effects to simvastatin 
treatment in mouse myotubes, in lowering the levels of cellular ATP (Wagner et al.
2011), whilst fluvastatin has been shown to inhibit translocation of RablA to the 
membrane in rat skeletal myofibres, an effect which could be rescued on co­
treatment with GGPP. Treatment with Brefeldin A, a specific suppressor of the 
trafficking step regulated by RablA, reproduced the effects of vacuolation and 
myofibre cell death seen with fluvastatin treatment (Sakamoto et al. 2011 ).
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Therefore, although there is debate over which of the small G-proteins are the 
most important, (Matzno et al. 2005; Sakamoto et al. 2007) it does seem very likely 
that reduced prénylation plays an important role in statin-induced myopathy, most 
likely through the resulting disruption of muscle fibre stability, apoptosis of muscle 
fibres and defects in myoregeneration. However, the majority of studies described 
here only examine the effects of statins on prénylation in muscle, as a site of statin 
toxicity, and do not compare this to effects in the liver, as the target organ of the 
statins. They also tend to only use one or a small number of statins.
1.3.6 Pleiotropic Effects of Statins
Although reductions in the other isoprenoids of the mevalonate pathway may be 
the main cause of statin-induced myopathy it is thought that these effects, 
particularly those effects on the reduced prénylation of small G proteins (Liao and 
Laufs 2005), may also contribute to the variety of pleiotropic effects observed. 
These pleiotropic effects of the statins are independent of cholesterol lowering and 
include reduced inflammation (Liang et al. 2006), decreased oxidative stress 
(Makabe et al. 2010; Schupp et al. 2008), improved endothelial function (Jacobson 
2008), vasorelaxant effects (Yaktubay Dondas et al. 2011), anti-thrombotic effects 
(Jacobson 2008; Mason 2006) and effects on improving stability of atherosclerotic 
plaques (Abela et al. 2011; Mason 2006).
Therefore, although the statins are used primarily as lipid lowering drugs, there has 
been evidence indicating that they may also prove useful for treating conditions 
other than hypercholesterolaemia. There has been interest in the use of statins as 
anti-cancer agents, to be used in combination with chemotherapy or radiation. 
This is because statins have been shown to have anti-proliferative effects, to inhibit 
pathways associated with the invasion and metastasis of cancer cells and also to 
induce apoptosis in a variety of malignant tumour cells, including acute 
myelogenous leukaemia cells, possibly through decreased geranylgeranylation of 
proteins. Whereas apoptosis of healthy muscle fibres leading to myopathy is an 
unwanted side-effect, the apoptosis of cells in certain diseased tissue may prove
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beneficial for treating cancers. These anti-tumour effects have been demonstrated 
both in vitro and in vivo in animal models (Chan et al. 2003; Xia et al. 2001). 
Statins could be used to help overcome multidrug resistance, a significant problem 
during cancer treatment, through their inhibition of efflux transporters (Sieczkowski 
et al. 2010). It has also been suggested that statins may prove useful as a 
treatment for numerous other medical conditions, including asthma (Chiba et al.
2010), multiple sclerosis (Kuipers et al. 2006), their use may lead to a decreased 
risk of Alzheimer’s disease (Cordle et al. 2005; Ostrowski et al. 2007) and they 
may be beneficial for patients with heart failure (Gullestad et al. 2007).
In summary, although the use of statins can be greatly beneficial, the reality of 
muscle toxicity continues to represent a problem in terms of both patient health and 
compliance. Therefore, it is important to fully understand the mechanism of this 
toxicity in order to find ways to reduce or avoid it whilst maintaining therapeutic 
doses. Should a patient experience myopathy, this is often managed by switching 
them either to a different statin or to a lower dose of the same statin (Harper and 
Jacobson 2010). However, as previously mentioned in section 1.2.2, there may 
also be potential for simply managing the problem of myopathy temporally, by 
attempting to time treatment with respect to circadian biology.
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1.4 Circadian Rhythms
Daily rhythms are known to regulate a multitude of biological processes including 
the daily sleep-wake cycle, body temperature, feeding, hormone secretion, glucose 
homeostasis, cell-cycle progression and metabolism (Takahashi et al. 2008). 
These circadian rhythms are endogenously generated, persist in the absence of 
external cues and have a period of approximately 24 hours (circa = about; Diem = 
a day) (Hirota and Fukada 2004). They are beneficial to organisms as they allow 
their behaviour to be anticipatory of and adaptive to regular and predictable daily 
environmental changes (Wu et al. 2010). The ubiquitous nature of this regulation 
also has implications for the efficacy and toxicity of xenobiotics (Baraldo 2008; Levi 
and Schibler 2007).
1.4.1 Chronotherapy
Chronotherapy is the name given to the optimising of treatment by taking into 
account the temporal changes in drug pharmacokinetics and pharmacodynamics, 
as well as in the condition being treated, usually with the result of increased 
efficacy and/or reduced toxicity (Levi and Schibler 2007). Its importance in clinical 
practise is gradually being acknowledged (Baraldo 2008; Zmrzljak and Rozman
2012), and there are several cases where changing the timing of treatment is 
already making a difference in terms of both efficacy and toxicity (Levi and Schibler
2007). One such example is the decreased toxicity when changing to evening 
dosing of the NSAIDS (Non-steroidal anti-inflammatory drugs) indomethacin and 
ketoprofen in patients with hip or knee osteoarthritis. This is thought to be due to 
24-hour variations in both the pharmacokinetics of these drugs and in joint pain. 
Greater efficacy and reduced toxicity has also been observed in response to 
colorectal cancer treatment administered using a chronomodulated time schedule 
as opposed to a constant rate infusion (Levi and Schibler 2007; Takahashi et al.
2008). In addition, there are numerous examples of where the potential for 
chronotherapy is currently being investigated, including treatment for asthma 
(Ohdo 2010), for hypertension (Portaluppi and Smolensky 2010) and treatment
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with a variety of chemotherapeutic agents (innominate et al. 2010; Ohdo 2010; 
Shukla et al. 2011).
The case of statins could potentially be another example of where changing the 
time of dosing may prove beneficial. It is known that in humans cholesterol 
synthesis peaks in the night/early morning (midnight - 4:00 am) (Galman et al. 
2005; Jones and Schoeller 1990; Parker et al. 1982) and so it is thought that for 
maximum LDL-lowering efficacy it is best for statins with short half-lives 
(simvastatin, lovastatin, fluvastatin, cerivastatin) to be taken in the evening, but that 
the statins with longer half-lives, such as atorvastatin and rosuvastatin, can be 
taken in either the morning or evening (Martin et al. 2002; Muck et al. 2000; 
Plakogiannis and Cohen 2007; Plakogiannis et al. 2005). However, most of these 
studies looking into the effect of temporal dosing of statins focus primarily on 
temporal changes in their LDL-lowering efficacy, and do not also examine temporal 
changes in statin related muscle toxicity. It is therefore important to fully 
understand circadian changes that occur at the molecular level and how these 
changes might relate to statin treatment and the mevalonate pathway.
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1.4.2 The Molecular Basis of Mammalian Circadian Rhythms
Molecular clocks are responsible for the generation of circadian rhythms, where the 
molecular mechanism underlying oscillations within the molecular clock is thought 
to involve many transcriptional -  translational feedback loops (Figure 1-5). Key in 
these feedback loops are the basic helix-loop-helix-PAS transcription factors 
BMAL1 (brain and muscle arnt-like protein-1) and CLOCK (circadian locomotor 
output cycles kaput) (Takahashi et al. 2008).
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Figure 1-5 The mammalian molecular oscillator
In a network of transcriptional - translational feedback loops the BMAL1: CLOCK heterodimer 
activates transcription of core clock genes Per, Cry, Rev-erba, and Rora by binding to E-box 
elements. These gene products then activate or repress their own transcription through effects on 
BMAL1 and/or CLOCK (RRE = retinoic acid-related orphan receptor response element). BMAL2 and 
NPAS2 are alternative dimérisation partners for CLOCK and BMAL1 respectively. Post-translational 
modifications, such as phosphorylation by CK15, CKIe and AMPK and degradation mediated by 
SCF ubiquitin E3 ligases FBXL3 and p-TrCP, ensure that the cycle has a period of approximately 24 
hours. The core clock machinery also regulates the expression of many other clock-controlled genes 
(Ccg) which have roles in numerous biological processes. Figure produced using (Crumbley and 
Burris 2011; Crumbley et al. 2010; Ko and Takahashi 2006; Kohsaka and Bass 2007; Lamia et al. 
2009; Shi et al. 2010; Virshup and Forger 2007).
Heterodimeric complexes of BMAL1 and CLOCK (BMAL1: CLOCK) activate 
transcription of the genes encoding period homologues (Per 1-3) and 
cryptochrome (Cry1 and Cry2) via binding to E-box elements (CACGTG) within 
enhancer and promoter sequences (Albrecht 2012). As PER and CRY proteins 
accumulate, they form protein complexes and translocate back to the nucleus 
where they repress their own transcription by interacting with the BMAL1 : CLOCK 
complex (PER/CRY loop, bottom of Figure 1-5). The resulting decrease in PER 
and CRY protein levels, then allows BMAL1 and CLOCK to activate transcription of 
Per and Cry genes again, and the cycle continues (Levi and Schibler 2007). 
NPAS2 (neuronal PAS domain protein 2) has been reported to also dimerise with 
BMAL1 to form an active transcriptional complex in the absence of CLOCK 
(DeBruyne et al. 2006; DeBruyne et al. 2007), and likewise BMAL2 can act as an 
alternative dimérisation partner for CLOCK (Sasaki et al. 2009; Shi et al. 2010).
BMAL1 : CLOCK also activates expression of the transcription factors Rora (retinoic 
acid-related orphan nuclear receptor a) and Rev-erba (reverse erythroblastosis 
virus aj (Ko and Takahashi 2006). RORa and REV-ERBa then compete to bind to 
retinoic acid-related orphan receptor response elements (RREs) in the promoters 
of Bmall (Preitner et al. 2002) and Npas2 (Crumbley et al. 2010), whereupon 
RORa activates transcription and REV-ERBa represses transcription (ROR/REV- 
ERB loop, top of Figure 1-5). REV-ERBa has also been shown to regulate the 
expression of Clock (Crumbley and Burris 2011 ) and to interact with PER2 thereby 
coordinating these two feedback loops (Schmutz et al. 2010).
In addition, there are a number of other important feedback mechanisms. DBP (D 
site of albumin promoter (albumin D-box) binding protein) and E4BP4 are members 
of the PAR (proline and acidic amino acid-rich) basic leucine zipper transcription 
factor family. They antagonistically compete for D-box elements (Mitsui et al. 2001) 
and regulate expression of Perl (Yamaguchi et al. 2000) as well as many clock 
controlled genes (ccg) (Noshiro et al. 2007). Basic helix-loop-helix transcription 
factors DEC1 (deleted in oesophageal Cancer 1) and DEC2 have been suggested
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to act as negative feedback regulators, as Dec1 expression is controlled by 
BMAL1:CL0CK, and DEC1 and DEC2 inhibit BMAL1:CL0CK function (Hirota and 
Fukada 2004; Honma et al. 2002)
Post-translational modifications, such as phosphorylation and ubiquitination, modify 
the activity and stability of clock proteins to ensure that a complete cycle takes 
approximately 24 hours (Hirota and Fukada 2004). The phosphorylation of PER 
proteins by casein kinase 1 epsilon and casein kinase 1 delta (CK1s and CK15) 
(Akashi et al. 2002; Lowrey et al. 2000; Xu et al. 2005) has been shown to regulate 
both their nuclear translocation (Akashi et al. 2002; Takano et al. 2004; Vielhaber 
et al. 2000) and their stability (Meng et al. 2008). Degradation is determined by 
subsequent recognition of phosphorylated PER proteins by the Skp1-Cul1-F-Box 
protein (SCF) ubiquitin E3 ligases |3-transducin repeat containing protein 1 (p- 
TrCP1) and p-TrCP2 (Ohsaki et al. 2008; ReischI et al. 2007; Shirogane et al.
2005). Stability of the CRY proteins is regulated through phosphorylation by 
adenosine monophosphate-activated protein kinase (AMPK) (Lamia et al. 2009) 
and by the SCF ubiquitin E3 ligase F-box and leucine-rich repeat protein 3 (FBXL3) 
(Busino et al. 2007; Godinho et al. 2007; Siepka et al. 2007) (Figure 1-5). It has 
been suggested that CRY and BMAL1 may also be substrates of CKIs (Eide et al. 
2002).
1.4.3 Hierarchy of the Mammalian Circadian Timing System
A master clock resides in the suprachiasmatic nucleus (SCN) within the anterior 
hypothalamus in the brain (Ko and Takahashi 2006). This clock is synchronised 
with the external 24-hour day via a number of environmental cues, or zeitgebers, 
the most important of which is thought to be light (Dibner et al. 2010; Hirota and 
Fukada 2004).
However, it has also been shown that there are molecular clocks in many 
peripheral tissues that regulate local rhythms (Yamazaki et al. 2000; Yoo et al.
2004), including in the liver (Oishi et al. 2005), heart (Leibetseder et al. 2009),
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adipose tissue (Zvonic et ai. 2006), the vasculature (Reilly et al. 2007) and skeletal 
muscle (Zhang et al. 2009). These peripheral clocks are thought to be self- 
sustaining (Tahara et al. 2012; Yoo et al. 2004) but entrained both by neural and 
humoral signals originating from the master clock in the SCN (Hirota and Fukada 
2004; Yamazaki et al. 2000) as well as by feeding (Damiola et al. 2000; Yamajuku 
et al. 2012). In vitro a serum pulse is able to synchronise the endogenous rhythms 
of a population of cells in culture (Balsalobre et al. 1998) and to date circadian 
rhythmicity has been observed in a wide variety of cell types (Balsalobre et al. 
1998; Chalmers et al. 2008; Huang et al. 2009; Lemos et al. 2007; Li et al. 2008; 
Maronde and Motzkus 2003; Otway et al. 2009; Takiguchi et al. 2007).
The output of the clock is driven by the expression of many clock controlled genes 
(cog), which show 24 hour cycles in their expression but are not themselves part of 
the core clock mechanism (Bozek et al. 2009). Circadian cycling has been shown 
to occur at both the transcript level, where studies have indicated that 
approximately 10% of genes in a variety of tissues are transcribed in a circadian 
manner (Akhtar et al. 2002; Panda et al. 2002; Storch et al. 2002), and at the 
protein level, where 20% of all soluble proteins in mouse liver have been found 
subject to circadian control (Reddy et al. 2006). Circadian regulation has been 
shown to have tissue specific differences (Panda et al. 2002; Storch et al. 2002) 
and to include genes from most functional categories, including metabolism 
(McCarthy et al. 2007).
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1.4.4 Circadian Controi of Choiesteroi Metaboiism
Many of the genes encoding enzymes and other proteins that are involved in the 
regulation of cholesterol metabolism have been shown to exhibit rhythmic patterns 
of expression (Figure 1-6).
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Figure 1-6 Daily rhythmicity in key enzymes and receptors involved in the regulation of 
cholesterol levels or statin metabolism
(A) 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) activity in rat liver 
(Balasubramaniam et al. 1994), (B) low-density lipoprotein receptor (LDLR) expression in rat liver 
(Balasubramaniam et al. 1994), (G) CypYa and Cyp8b mRNA levels, as measured in rat liver by 
northern blots (upper panels) and quantitative real time RT-PCR (lower graphs) (Noshiro et al. 
2004) and (D) CYP3A4 mRNA levels in HepG2 liver cells (Takiguchi et al. 2007).
HMGCR has been shown to exhibit diurnal variation (Panda et al. 2002). 
Experiments in mouse liver have shown approximately a 2-fold difference in Hmgcr 
transcript levels between peak and nadir (Oishi et al. 2005) and in rat liver a 6-fold 
difference in activity between peak and nadir has been reported (Figure 1-6A) 
(Balasubramaniam et al. 1994). It has also been shown that LDLR expression 
exhibits diurnal variation (Figure 1-6B) that is independent of cellular cholesterol
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levels, where in rat liver LDLR expression has shown a 2-3 fold difference between 
peak and nadir (Balasubramaniam et al. 1994).
Cholesterol-7a-hydroxylase (CYP7A1) and sterol-12a-hydroxylase (CYP8B1) are 
two enzymes that are important for the conversion of cholesterol into bile acids in 
the liver, which is the most important route for metabolism and excretion of 
cholesterol in mammals. Both of these enzymes have been shown to exhibit 
diurnal mRNA expression patterns (Figure 1-6C) in the livers of both mice and rats 
(Noshiro et al. 2004; Noshiro et al. 2007) and the expression of Cyp7a1 has been 
shown to be regulated by a number of transcription factors, most notably by DBP, 
DEC2 and REV-ERBa, many of which are directly regulated by the CL0CK:BMAL1 
heterodimer (Noshiro et al. 2007) (section 1.4.2).
The circadian rhythmicity of cholesterol metabolism has been further highlighted by 
in vivo studies investigating the output of core clock transcription factors REV- 
ERBa (Le Martelot et al. 2009) and RORa (Kang et al. 2007). In mouse liver REV- 
ERBa was shown to modulate the activity of both the transcription factor SREBP, 
which regulates the expression of many genes involved in cholesterol metabolism 
including HMGCR and LDLR (Brown and Goldstein 1997), and of the nuclear 
receptor liver-X-receptor (LXR), which regulates Cyp7A1 expression (Le Martelot 
et al. 2009). ROR transcription factors were found to similarly regulate the 
expression of Cyp8b1 (Kang et al. 2007).
It is also of interest to consider that circadian rhythmicity has been observed in 
CYP3A4, the cytochrome P450 enzyme involved in metabolism of simvastatin, 
lovastatin, cerivastatin and atorvastatin (section 1.1.4). In synchronised HepG2 
liver cells, mRNA levels (Figure 1-6D), protein levels and metabolic activity of 
CYP3A4 were observed to fluctuate rhymically with a period of about 24 hours; a
2-fold difference was observed in CYP3A4 transcript level between peak and nadir, 
whilst increases and decreases in protein expression seemed to correspond to 
similar oscillations in enzymatic activity, as measured by the 6|3-hydroxylation of
32
testosterone (Takiguchi et ai. 2007). In addition, the expression of CYP2C8, an 
enzyme also involved in the metabolism of cerivastatin, has been reported to be 
regulated by the core clock transcription factor RORa (Chen et al. 2009b).
Taking all of this into consideration, it therefore seems likely that other aspects of 
the mevalonate pathway, for example protein prénylation, may exhibit circadian 
rhythmicity in the same way as has been demonstrated for cholesterol metabolism.
1.5 Initial Hypothesis and Objectives
The initial hypothesis for this project was therefore that:
• Protein prénylation, postulated to play an important role in statin-induced 
myopathy, is under circadian variation as has already been shown for other 
aspects of the mevalonate pathway.
It may therefore prove possible to achieve greater separation between the 
cholesterol-lowering efficacy of statins and muscle toxicity by changing the time of 
treatment.
Aims and Obiectives:
The initial aim was to use liver and muscle cells in culture as a model system for 
comparing the effects of temporal statin administration on both cholesterol and 
isoprenoid biosynthesis. This was to be achieved via the following objectives;
Objective 1 : characterise RD muscle cells and their differentiation process
• Induce RD cell differentiation using serum deprivation
• Measure mRNA expression of key differentiation markers
• Confirm expression of core clock genes and key cholesterol metabolism 
genes
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Objective 2: verify the ability of HepG2 (liver) and RD (muscle) cells to establish 
and maintain a circadian cycle
• Synchronise cells using the serum pulse technique
• Measure mRNA expression of core clock genes and key cholesterol
metabolism genes
• Confirm transcript measurements at the protein level through western 
blotting
Objective 3: assess whether circadian changes in gene expression translate to 
circadian changes in cellular function.
At key points in the circadian cycle measure:
• HMGCR activity
• cholesterol level
• level of isoprenoids (F-PP and GG-PP)
• prenylated proteins in bound and soluble cell fractions
Objective 4: examine the effect of statin treatment on outputs measured in 
objectives 2 and 3.
Objective 5: combine all data using computer modelling software to determine 
whether greater separation can be achieved between efficacy and toxicity.
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2 Materials and Methods
2.1 Materials
Unless otherwise stated in Table 2-1, all chemicals and materials were purchased 
from Sigma-Aldrich (Dorset, UK) and were of molecular biology standard.
Item Supplier
Cell Culture
RD cells and 3T3-L1 cells 
HepG2 cells 
Huh7 cells
Dulbecco’s modified eagle medium 
(DMEM), foetal bovine serum (FBS), 
horse serum, penicillin, streptomycin, 
non-essential amino acids, trypsin-EDTA
Phosphate buffered saline tablets
American Type Culture Collection 
(Teddington, UK)
European Collection of Cell Cultures 
(Salisbury, UK)
Dr S. Hood, GlaxoSmithKline (Ware, UK) 
Invitrogen GIBCO (Paisley, UK)
Oxoid (Basingstoke, UK)
Xenoblotics
Simvastatin (sodium salt), simvastatin 
lovastatin (sodium salt), lovastatin 
pravastatin, fluvastatin
Atorvastatin, rosuvastatin
Cerivastatin, simvastatin (sodium salt), 
pravastatin
FTI-277 trifluoroacetate salt, GGTI-2133, 
perillyl alcohol
Calbiochem, Merck (Nottingham UK)
Molekula Limited (Dorset, UK)
Sequoia Research Products Limited 
(Pangbourne, UK)
Sigma-Aldrich (Dorset, UK)
35
RNA Analysis
DNase/RNase free tips and 
Eppendorf tubes
Axygen (Union City, USA).
Fastrak Pipette Tips (RTPCR) Alpha Laboratories (Eastleigh, UK)
NucleoSpin II RNA extraction kit Macherey-Nagel (Düren, Germany)
RNase-free DNase 1, 10 x DNase buffer, 
DNase stop solution, 
human genomic DNA, 
mouse genomic DNA
Promega (Southampton, UK)
RNAse-free water, dNTPs, random 
hexamers. Superscript II, DTT, 
RNase OUT
Invitrogen GIBCO (Paisley, UK)
White Thermo-fast 96 PCR detection 
plates, ABsolute QPCR ROX mix, 
ABsolute QPCR seal
Abgene (Epsom, UK)
TaqMan primers and probes MWG Eurofins (Ebersberg, Germany).
Protein Anaiysis
Complete, mini, EDTA-free protease 
inhibitor cocktail tablets
Roche (Lewes, UK)
ProteoExtract Native Membrane Protein 
Extraction Kit
Calbiochem, Merck (Nottingham, UK)
Folin-Ciocalteau’s phenol reagent Sigma-Aldrich (Dorset, UK)
Bis-acrylamide stock solution (2% w/v) 
Acrylamide stock solution (40% w/v)
VWR (Lutterworth, UK)
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Novex Sharp Protein Standard Invitrogen (Paisley, UK)
PVDF Western Blotting Membrane, Roche (Lewes, UK)
Primary and secondary antibodies 
(unless otherwise stated)
Santa Cruz Biotechnology (Heidelberg, 
Germany)
Myogenin antibody
Myosin heavy chain 3 antibody
Developmental Studies Hybridoma Bank 
(Iowa City, USA)
p-actin antibody (mouse monoclonal) Sigma-Aldrich (Dorset, UK)
Lactate dehydrogenase antibody (goat 
polyclonal)
Abeam (Cambridge, UK)
ECL Plus Western Blotting Detection 
System
GE Healthcare (Chalfont St Giles, UK)
Choiesteroi Quantification
Amplex Red Cholesterol Assay Kit Invitrogen Molecular Probes 
(Eugene, USA)
Table 2-1 Suppliers of specialist materials used in this work
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2.2 Methods
2.2.1 Cell Culture of Immortalised Cell Lines and Cell-Based Procedures
Cell culture materials were purchased from Invitrogen GIBCO, (Paisley, UK) unless 
otherwise stated.
2.2.1.1 RD Cell Culture
The human embryonal rhabdomyosarcoma (RD) cell line is a prototypic, 
immortalised cell line derived from embryonal rhabdomyosarcoma tissue 
(McAllister et al. 1969). It is used as an in vitro model of skeletal muscle as these 
cells express a number of muscle-specific proteins (Kobayashi et al. 2008). RD 
cells were routinely cultured in Dulbecco’s modified eagle medium (DMEM) with 
phenol red containing 4.5g/L glucose and L-glutamine, supplemented with 10% 
foetal bovine serum (FBS), lOOU/ml Penicillin and 10OU/ml Streptomycin.
2.2.1.2 Huh7 Cell Culture
The human hepatoma cell line, Huh7, is a differentiated, immortalised liver cell line 
derived from a hepatocellular carcinoma. These cells produce a variety of plasma 
proteins and enzymes that would be expected in liver cells in vivo (Nakabayashi et 
al. 1982). Huh7 cells were cultured in DMEM with phenol red containing 4.5g/L D- 
glucose and L-glutamine, supplemented with 10% FBS, 1% non-essential amino 
acids (NEAA), lOOU/ml Penicillin and lOOU/ml Streptomycin.
2.2.1.3 HepG2 Cell Culture
The human hepatoma cell line, HepG2, is a differentiated, immortalised liver cell 
line derived from a hepatoblastoma (Aden et al. 1979; Knowles et al. 1980). 
HepG2 cells were cultured in DMEM with phenol red containing 4.5g/L D-glucose 
and L-glutamine, supplemented with 10% FBS, 1% non-essential amino acids 
(NEAA), lOOU/ml Penicillin and lOOU/ml Streptomycin.
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2.2.1.4 3T3-L1 Cell Culture
The 3T3-L1 cell line is a murine preadipocyte cell line (Mackall et al. 1976) that has 
frequently been used to study diabetes, obesity and other metabolic disorders 
(Carlotti et al. 2004). 3T3-L1 cells were cultured in DMEM with phenol red
containing 4.5g/L D-glucose and L-glutamine, supplemented with 10% FBS, 1% 
sodium pyruvate, lOOU/ml Penicillin and lOOU/ml Streptomycin.
2.2.1.5 Sub-Culturing Cells
Cells were passaged when they reached approximately 70-80% confluence. The 
medium was first aspirated from the flasks. Cells were then washed in sterile 
phosphate buffered saline (PBS) and 3-4ml trypsin-EDTA solution added (for a 
75cm^ vented tissue culture flask (T75)). After coating the base of the flask, most 
of the trypsin solution was aspirated off before leaving the flask at 37°C for 
approximately 5 minutes, or until cells had detached from the bottom of the flask. 
After cell detachment, cells were resuspended in fresh complete medium, to 
inactivate the trypsin-EDTA, and pipetted up and down, to break up any cell 
clumps. The cell suspension was then pipetted into a fresh T75 flask, containing 
complete medium, to give the required cell split ensuring that the total volume in 
the flask was 15ml. The precise ratio for cell splitting varied between 1:2 and 1:10, 
depending on the cell type and the experiment being carried out. Cells were kept 
in an incubator at 37°C with 5% CO2.
For a 25cm^ vented tissue culture flask (T25), a final volume of 5ml in each flask 
was used and 1ml of trypsin solution was used to detach cells. In a 6-well plate, 
the final volume in each well was 2.5ml. All 6-well and 96-well plates were kept in 
a humidified chamber in an incubator at 37°C with 5% CO2.
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2.2.1.6 Counting Cells using a Haemocvtometer
Cells were detached from the culture flask by trypsinisation (section 2.2.1.5) and 
resuspended in fresh complete medium. After moistening the edges, a cover slip 
was affixed to the haemocytometer by applying gentle pressure, and 8.5pL of cell 
suspension was pipette into each chamber. In each chamber, the cells in 3 
different large squares were counted and an average taken. After taking any 
dilutions into account, this value represented the number of cells x 10"^  per ml in the 
original cell suspension.
2.2.1.7 Storage of Cells in Liguid Nitrogen
For long term storage, cells at an early passage number were detached from the 
culture flask by trypsinisation (section 2.2.1.5) and counted using a 
haemocytometer (section 2.2.1.6). Cells were then pelleted by centrifugation at 
500g for 3 minutes and resuspended in sufficient freezing medium (90% DMEM, 
10% dimethyl sulphoxide, DMSO) to give 1x10® cells/ml. 1ml aliquots in cryovials 
were transferred to the NALGENE cryo freezing container for storage at -80°C for 
24 hours, to allow slow freezing, before storage in liquid nitrogen until further use.
2.2.1.8 Recovery of Cells from Liguid Nitrogen
A cryovial, containing 1ml of cell suspension, was thawed from liquid nitrogen in a 
37°C water bath. Once thawed, the cell suspension was transferred to a sterile 
tube containing 9ml of pre-warmed complete medium and centrifuged at 125g for 7 
minutes. The supernatant was removed and the cell pellet resuspended in 8ml 
fresh pre-warmed complete medium, which was then placed in a T25 culture flask. 
Medium was changed the following day, to remove any remaining traces of DMSO 
and unattached cells. Once the cells were 70-80% confluent they were trypsinised 
and transferred to a T75 culture flask.
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2.2.1.9 RD cell Differentiation
RD cells were grown to confluence in T25 culture flasks, 6-well plates or 96-well 
plates and then induced to differentiate by changing the medium to low serum 
medium (1% FBS; Figure 2-1). In a preliminary experiment, to characterise the 
differentiation process, cells were grown in T25 flasks and every 2 days cell 
photographs were taken and RNA extracted for analysis by quantitative RT-PCR 
(see section 2.2.2). After day 0, low-serum medium was refreshed just before 
taking cell photographs, in all flasks other than those being used to extract RNA 
that day, and every day after day 4. Scale bar on the cell photographs was derived 
from comparison with the literature (Vachon et al. 1996).
T = 0 2 4 6 8 10 (Days)
I  I  I  I  I  I
I__________________ IL
Cells grown to Low-serum differentiation
confluence in 
standard growth 
medium
Figure 2-1 Protocol for differentiation of RD ceiis
RD cells were grown to confluence in standard growth medium (10% FBS) and at T = 0 medium 
was changed to low-serum medium (1% FBS). At indicated 2-day intervals, cells were 
photographed and total RNA extracted for analysis by quantitative RT-PCR (TaqMan).
As a result of this analysis, it was decided that a period of 5 days in low-serum 
medium would be used for the differentiation of RD cells for future experiments. In 
the remainder of this thesis, the term "RD-D" is used to refer to RD cells that have 
undergone this 5-day differentiation protocol prior to use. “RD-U” refers to 
undifferentiated RD cells that have not undergone differentiation in low-serum 
medium prior to use.
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2.2.1.10 Synchronising Cells using a Serum Pulse
The serum pulse technique (Figure 2-2 and Figure 2-3) is a way of synchronising 
the molecular clocks in individual cells in a cell culture, using shock with a high 
concentration of serum, in order to study their circadian rhythms (Balsalobre et al. 
1998).
In an initial pilot study 3T3-L1, HepG2 and Huh7 cells were seeded at densities of 
2 X 10®, 1 X 10® and 2x10® cells per well respectively on 6-well plates, using 1 
plate per time point per cell type. All cells were grown to 2 days post-confluence, 
after which the medium was changed to medium containing 50% horse serum 
(T=0). After 2 hours medium was changed to serum-free medium, after which the 
medium was not changed again for the remainder of the experiment (Figure 2-2). 
RNA was extracted from 4 wells of 3T3-L1 and HepG2 cells at T=0, 14, 26, 36 and 
from Huh7 cells at T=0, 12, 18 and 26 and analysed by quantitative RT-PCR 
(TaqMan; section 2.2.2).
A ] 3T3-L1 and  t = 0 14 26 36 (hours)
HeoG2 cells I  I I I
Cells grown to 2 days 50% 
post-confluence horse serum-free medium
serum
B] H uh7  ce lls  T= 0 12 18 26 (hours)
I  I I I
Cells grown to 2 days 50% 
post-confluence horse serum-free medium 
serum
Figure 2-2 Protocol for pilot serum pulse experiment
At indicated intervals total RNA was extracted from A] 3T3-L1 and Huh7 cells, B] Huh7 cells for 
analysis by quantitative RT-PCR (TaqMan).
Subsequently RD and Huh7 cells were grown in 6-well plates, using 1 plate per 
time point per cell type: Huh7 cells were seeded at a density of 2 x 10® cells per 
well and grown to 2 days post-confluence. RD cells were seeded at a density of 3 x 
10® cells per well and used immediately following a 24 hour period for cell
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attachment (RD-U), and were seeded at 1 x 10® cells per well and allowed to 
differentiate for 5 days (RD-D; section 2.2.1.9). Medium was changed to medium 
containing 50% horse serum (T=0). After 2 hours medium was changed to serum- 
free medium, after which the medium was not changed again for the remainder of 
the experiment (Figure 2-3). Every 4 hours starting from T = 0, for each cell type, 
RNA was extracted from 4 wells for analysis by quantitative RT-PCR (TaqMan; 
section 2.2.2).
T =  0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 (hours)
J l IL
Cells grown to: 50%
• 2 days post-confluence horse serum-free medium
(Huh7 cells), serum
• confluence (RD-U cells)
• differentiated (RD-D cells)
Figure 2-3 Protocol for serum pulse of Huh7 and RD cells
At indicated 4-hour intervals total RNA was extracted for analysis by quantitative RT-PCR (TaqMan).
2.2.1.11 Treatment of Cells with Xenoblotics
Cells were seeded as required in 96-well plates or 6-well plates (sections 2.2.1.10, 
2.2.1.12, 2.2.3.1, 2.2.4.1), with a final medium volume of 200pl in each well of a 96- 
well plate, 2.5ml in each well of a 6-well plate or 5ml in each T25 flask. Seeding 
densities ranged from 2 x 10® -  1 x 10"^  in 96-well plates and 1-4 x 10® in 6-well 
plates.
After 24 hours, medium was aspirated from each well and replaced with serum-free 
medium containing either xenobiotic or vehicle control (see Table 2-2), which was 
prepared as follows: Each xenobiotic was dissolved in a relevant solvent (see 
Table 2-2) to give a stock solution of lOOmM. This was then further diluted as 
needed, in the solvent, to give concentrations of xenobiotic that were 1000-fold 
more concentrated than that required in the final medium. These stocks were then 
diluted in serum-free medium by 1:1000, in order to maintain the percentage of 
solvent in the final medium at 0.1%. lOOpI of xenobiotic/control-containing serum- 
free medium was added to each well of a 96-well plate, or 2.5ml to each well of a
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6-well plate. Note that the sodium salts, of simvastatin and lovastatin, are referred 
to as their acid forms (in contrast to the lactone form) in subsequent chapters.
Xenobiotic Solvent
Simvastatin (sodium salt) DMSO
Simvastatin Ethanol
Lovastatin (sodium salt) Ethanol
Lovastatin DMSO
Cerivastatin Water
Atorvastatin DMSO
Fluvastatin Water
Rosuvastatin DMSO
Pravastatin Water
FTI-277 Water
GGTI-2133 DMSO
Perillyl Alcohol Water
Table 2-2 Solvents used for xenoblotics
Relevant solvent was also used as the related vehicle control.
2.2.1.12 Assessing Cell Viability using the MTT Assav
The 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assay is a 
colorimetric assay that is used to quantitatively assess metabolic and cellular 
viability. The tétrazolium bromide (MTT) salt is reduced by dehydrogenase 
enzymes, in active mitochondria in living cells, to form a water-insoluble, coloured 
formazan salt. The amount of formazan generated, and absorbance measured, is 
directly proportional to the number of viable cells, over the range 200 - 50,000 cells 
per well (Mosmann 1983).
In these experiments, RD cells were seeded at a density of 2 x 10® cells per well 
on 96-well plates and left to differentiate for 5 days in low-serum medium (RD-D;
section 2.2.1.9). Huh7 and RD-U cells were seeded on 96-well plates 24 hours
prior to experiment, at densities of 5 x 10® cells per well and 1x10"^ cells per well 
respectively.
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Cells were exposed to various statin concentrations or a vehicle control (see 
section 2.2.1.11) for 48 hours. lOpI of MTT solution (5mg/ml MTT dissolved in 
PBS and then filter sterilised) was added to each well for the final 2.5 hours of the 
48 hour dosing period. Medium was then replaced with lOOpI DMSO per well and 
the absorbance read at 540nm in the Multiskan RC microplate reader 
(ThermoFisher Scientific, Loughborough, UK). Absorbance measured was 
expressed as a percentage of the vehicle control (defined as 100%). At each statin 
concentration, mean absorbance values were calculated from each independent 
experiment, which were then combined to generate final data.
2.2.2 RNA Analysis
For RNA work, all tips and Eppendorf tubes used were DNase/RNase free. For 
TaqMan, non-filter tips and Eppendorf tubes were autoclaved prior to use.
2.2.2.1 RNA Isolation
Total RNA was extracted from 3T3-L1, HepG2, Huh7, RD-U and RD-D cells using 
the Nucleospin II RNA extraction kit according to the manufacturer’s instructions; 
Cells were first lysed by the addition of the lysis buffer provided (RA1) and the 
viscosity reduced by passing each lysate through a 21 gauge needle several times. 
The lysate was then filtered using a provided NucleoSpin Filter, to further reduce 
viscosity and remove cellular debris. The flow-through from this column was 
loaded onto a NucleoSpin RNA II Column, in order to bind the RNA to the silica 
membrane, after the adjustment of the binding conditions with the addition of 
ethanol. Membrane desalting buffer was then added to the column, followed by a 
centrifugation step at 11,000g for 1 minute to dry the membrane. Each column 
was washed with provided wash buffers RA2 and RA3, before the final elution of 
pure RNA in 60pl RNAse-free water.
Total RNA concentration was measured using a NanoDrop spectrophotometer 
(NanoDrop Technologies, Delaware, USA) using the A260/280 and A260/230 
ratios as an indication of RNA quality. For pure RNA the expected 260/280 ratio is
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in the region of 1.8-2.0 and the expected 260/230 ratio is approximately 2.0. RNA 
absorbs light with an absorption peak at 260nm and so if the 260/280 ratio is much 
lower than this it is an indication that there may be protein contamination in the 
sample as protein absorbs light at 280nm. If the 260/230 ratio is much lower, this 
may be an indication of sample contamination by for example thiocyanate ions, 
which are present in the buffers RA1, RA2 and MDB that are used in the RNA 
extraction (NanoDrop 2007).
RNA quality was also checked by running 1pg of each sample on a 1% agarose 
gel, containing ethidium bromide (0.5pg/ml), in 1xTAE buffer (0.04M Tris acetate, 
0.01M EDTA). Samples were diluted in RNAse free water to 1pg in a total volume 
of 10pl. This was then mixed with 2pi Orange G loading dye (0.25% Orange G, 
50% glycerol) and the full 12pl loaded into the wells. Bands were visualised under 
UV light using the Gene Genius Bio Imaging System (Syngene, Cambridge, UK). 
If the RNA was intact and of good quality then sharp bands representing 28S and 
18S ribosomal RNA (rRNA) were present on the resulting gel (Figure 2-4), with no 
obvious low molecular weight smear which would indicate degraded RNA (Applied 
Biosystems 2009). RNA was stored at -80°C.
Markers RNA samples
Figure 2-4 Example of how an agarose gel can be used to give an indication of RNA quality
RNA samples shown here were extracted from RD muscle cells on days 6 and 8 of differentiation 
(N=4). Arrows indicate bands representing 28S and 18S rRNA. If RNA is intact these bands 
should be sharp with more 28S present than 18S (approximately twice as much 28S), as is shown 
here.
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2.2.2.2 DNase Treatment
All RNA samples were DNase treated to remove contaminating genomic DNA. 
3pg total RNA, 2pl 10 x DNase buffer and 2pl RNase-free DNase I were added to 
the volume of RNAse-free water required to bring the total reaction mixture to a 
total volume of 20pl. This reaction mixture was incubated at 37°C for 30 minutes, 
followed by a heat inactivation step by the addition of 2pi DNase stop solution 
(20mM EGTA) and incubation at 65°C for 10 minutes.
2.2.2.3 cDNA Synthesis
4pl of the DNA-free RNA solution was added to 1.5pl dNTP mix (in which each 
dNTP was at a concentration of lOmM), 1.5pl random hexamers (150ng/pl) and 5pl 
RNase-free water. This was incubated at 65®C for 5 minutes, to denature the 
RNA, and then cooled on ice for 2 minutes. 8pl of a reverse transcriptase (RT+) 
mix was then added to each RNA/primer mix, where this RT+ mix contained 4pi 5 x 
FS buffer (first strand synthesis buffer; supplied with Superscript II Reverse 
Transcriptase enzyme), 2pl 0.1M DTT, 1pl RNase OUT, 0.75pl water and 0.25pl 
Superscript II for each reaction. This was then incubated at 25°C for 10 minutes, 
42°C for 50 minutes and 70°C for 15 minutes. In a similar way, a reverse 
transcriptase negative (RT-) control was also prepared using each RNA sample, 
where the RNase OUT and Superscript II had been replaced by RNase-free water. 
All RT+ and RT- reaction mixes were then diluted by adding 80pi RNase-free water 
and stored at -20°C.
2.2.2.4 Quantitative Reverse Transcriptase Polymerase Chain Reaction
5pl of either RT+ or RT- sample was pipetted into each well of a white Thermo-fast 
96 PCR detection plate followed by 20pl of reaction mix; where this reaction mix 
was made up beforehand in bulk and contained 1 pi forward and reverse primers 
(each primer at lOpmol/pl), 0.5pl probe (5pmol/pl), 6pl sterile water and 12.5pl 
ABsolute QPCR ROX mix per reaction. Each plate was sealed with an ABsolute 
QPCR seal, briefly centrifuged and run on the ABI Prism 7000HT sequence 
detection system (Applied Biosystems, California, USA) using the cycle: 2 minutes
47
at 50°C, 15 minutes at 95®C, 40 cycles of 15 seconds at 95°C and 1 minute at 
60°C. Relative transcript expression was calculated by comparison with a 
standard curve, made up of 10®, 10"^ , 10®, 10^ and 10”* copies of human or mouse 
genomic DNA. For each primer/probe set used, duplicate no template controls 
(NTC) were also run, where 5pi sterile water was used in place of RT+ or RT- 
sample. Expression data were normalised, as indicated, to that of glyceraldehyde
3-phosphate dehydrogenase (GAPDH), 18S ribosomal RNA (rRNA) or p-actin.
All gene-specific primers and probes used were designed using Vector NTI 
Advance 11 (Invitrogen) and Primer Express Version 2.0 (Applied Biosystems), 
and ordered from MWG Eurofins (Ebersberg, Germany). Primer and probe 
sequences are given in Table 2-3 and Table 2-4. Primer sets were designed to be 
within an exon as this meant that genomic DNA could be used for creating the 
standard curve. Genomic DNA is easy to work with and, provided that genomic 
DNA from the correct species is being used, it should contain all of the target 
genes in varying amounts, removing the need to create a different standard curve 
using cDNA for each target gene to be analysed.
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2.2.3 Protein Analysis
2.2.3.1 Total Protein Extraction using RIPA Buffer
HepG2, Huh7, RD-U and RD-D cells were grown in T25 flasks or 6-well plates 
and total protein was extracted from cells using RIPA buffer 
(RadiolmmunoPrecipitation Assay Buffer; 1% Nonidet-P40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate (SDS) in 1x PBS, with 1 
complete, mini, EDTA-free protease inhibitor cocktail tablet per 10ml buffer). 
Medium was aspirated off cells and cells were washed twice with PBS before 
the addition of ice cold RIPA lysis buffer (1ml per T25 flask or 300pl per well of 
a 6-well plate). Flasks or plates were left on ice for 30 minutes to allow cell 
lysis. After this time, lysate was homogenised and the DNA sheared using a 25 
gauge needle, before being centrifuged for 15 minutes at 15,000g at 4®C. The 
supernatant from this step contained the total cell protein, which was stored at - 
20°C for regular use or at -80°C for longer term storage. Each sample was 
used a maximum of 3 times, to minimise the effects of freeze-thawing. Samples 
to be used more frequently than this were frozen in aliquots.
2.2.3.2 Membrane Protein Extraction
Huh7, RD-U and RD-D cells were grown in 6-well plates and membrane protein 
extracted using the ProteoExtract Native Membrane Protein Extraction Kit. 
Medium was aspirated off the cells and cells were washed twice using 0.8ml ice 
cold wash buffer (provided in the kit). 4pi Protease Inhibitor Cocktail was added 
to the wall of each well followed by 0.8ml Extraction Buffer I. Plate was swirled, 
to ensure mixing and covering of the cells, before incubation on ice for 10 
minutes under gentle agitation. After incubation, supernatant enriched in 
cytosolic proteins was removed and stored at -20°C until use. 2pl Protease 
Inhibitor Cocktail and 0.4ml Extraction Buffer II was then similarly added to each 
well, and plates incubated on ice for 30 minutes under gentle agitation. 
Supernatant, enriched in integral membrane proteins and membrane associated 
proteins, was then removed and stored at -20°C until use. If cells started to 
detach from the plate after any wash steps or incubation steps, cell suspension 
was removed, centrifuged for 15 minutes at 15,000g at 4°C and protocol
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continued using the resulting pellet. All cytosolic and membrane samples were 
also only used a maximum of 3 times, to minimise the effects of freeze-thawing. 
Samples to be used more frequently than this were frozen in aliquots.
2.2.3.3 Protein Quantification using the Lowry Method
Protein was quantified using the Lowry method (Lowry et al. 1951). This is a 2- 
step method. Firstly, copper ions complex with the protein, under alkaline 
conditions. Subsequently, Folin-Ciocalteau’s phenol reagent is added and 
becomes reduced, changing from a yellow to a blue colour, which can be 
measured spectrophotometrically.
A bovine serum albumin (BSA) standard curve (0 -  250pg/ml) was prepared by 
dilution of BSA stock solution of 250pg/ml in 0.5M NaOH. 30pl of standards 
and samples (diluted as necessary in 0.5M NaOH) were pipetted, in triplicate, 
into separate wells of a clear flat-bottomed 96-well plate. Blanks were also 
prepared, in triplicate, containing 195pi 0.5M NaOH (or protein extraction buffer 
at the appropriate dilution). 150pl of freshly prepared copper solution (1 0 ml 2 % 
Na2COs, 0 .1 ml 1 % CUSO4.5 H2O, 0 .1 ml 2 % KNaC4H4 0 6  4 H2O) was added to 
each well of standard or sample and the plate was left to stand, at room 
temperature, for 10 minutes. Then 15pl of Folin-Ciocalteau’s phenol reagent 
(2x stock diluted 1:1 in distilled water) was added to each well of standard or 
sample and mixed well. Plate was left for at least 30 minutes, at room 
temperature, and absorbance read at 490nm on a Bio-Tek ELxSOO microplate 
reader. Values were corrected for background absorbance, by subtracting 
average absorbance value for the blanks, and protein concentrations were 
determined by comparison to the standard curve.
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2.2.3.4 Concentrating Protein Samples
Samples were concentrated, as needed, prior to analysis. 0.1ml 0.15% 
deoxycholate was added to each 1ml protein sample. This was mixed using a 
vortex and left to stand at room temperature for 10 minutes. Then, 0.1ml 72% 
trichloroacetic acid was added and again mixed by vortexing, followed by 
centrifugation for 30 minutes at 11,000g at 4®C. Supernatant was removed and 
pellet was resuspended in required volume of NaOH, to allow protein 
concentration to be remeasured using the Lowry method (section 2.2.3.3). In 
order to neutralise the alkaline before further analysis, an equal volume of 1M 
Tris/HCI was then added to each sample.
2.2.3.5 Separation of Proteins by SDS-PAGE
Proteins were separated according to their molecular weight by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). For proteins 40-100 
kilodaltons (kDa) in size a resolving gel of 12.5% (12.5% acrylamide, 0.3% 
bisacrylamide, 0.1% SDS, 0.4M Tris-HCI pH 8.8, 0.16% ammonium persulphate 
(APS) and 0.16% tetramethylethylenediamine (TEMED)) and a stacking gel of 
6% (6% acrylamide, 0.16% bisacrylamide, 0.1% SDS, 0.2M Tris-HCI pH 6.8, 
0.24% APS, 0.4% TEMED), made up in 1.5mm glass plates, were used. For 
proteins less than 40kDa in size, a 20% resolving gel was used (20% 
acrylamide, 0.53% bisacrylamide, 0.1% SDS, 0.33M Tris-HCI pH 8.8, 0.16% 
ammonium persulphate (APS) and 0.16% TEMED). Protein samples (amount 
used specified in individual figure legends) were mixed with an equal volume of 
loading buffer (60mM Tris-HCI pH 6.8, 12% glycerol, 2% SDS, 0.003% pyronin 
Y, 0.7M p-mercaptoethanol (BME)) and heat denatured at 60°C for 10 minutes 
before being placed on ice. Denatured protein samples were then loaded onto 
the gel, alongside lOpI Novex Sharp Protein Standard. Gels were run at 
120mA in 1x running buffer (25mM Tris-HCI pH 8.3, 192mM glycine, 0.1% SDS) 
for approximately 1 hour, or until the dye front neared the end of the glass 
plates.
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2.2.S.6 Identification of Proteins by Western Blotting
Separated proteins were transferred onto polyvinylidene difluoride (PVDF) 
membrane in 1x transfer buffer (16mM Tris base, 120mM glycine) at 300mA for 
90 minutes. The membrane was then left in blocking solution (10% Marvel in 
1x Tris-buffered saline -  Tween 20 (TBST; 20mM Tris-HCI pH 7.5, 500mM 
NaCI, 0.1% Tween 20)) on a rotary mixer. Following blocking, the membrane 
was washed 3 times in 10ml TBST, each for 10 minutes, on a rotary mixer. The 
membrane was then incubated with primary antibody in TBST containing Marvel 
(see Table 2-5 for amount), followed by 3 further 10 minute washes in 1x TBST 
and incubation with secondary antibody (5% Marvel in 1x TBST) at room 
temperature on a rotary mix. Three further 10 minute washes in 1x TBST were 
carried out, as before, prior to chemiluminescent detection using the ECL plus 
western blotting detection reagent. The membrane was incubated with the 
reagent for 5 minutes and then exposed to x-ray film. Conditions were 
optimised for each primary antibody; dilutions, amount of Marvel and times of 
incubation are shown in Table 2-5. All overnight incubation steps were carried 
out at 4°C and all other incubation steps carried out at room temperature.
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Antibody Size
(kOa)
Blocking 1° 2° Exposure
(minutes)
MYOG
F5D
25 overnight 1:25; overnight 
0.5% Marvel
1:20,000; 2hr
a-mouse
(sc-2005)
1
MYH3
F1-652
224 overnight 1:25; overnight 
0.5% Marvel
1:20,000; 2hr 
a-mouse
15
HMGCR
(H-300)
SC-33827
90 1 hr 1:400; overnight 
0.5% Marvel
1:10,000; 2hr 
a-rabbit (sc-2004)
1 or 5
FTP (H-300) 
SC-13965
46 Ihr 1:1000; overnight 
0.5% Marvel
1:20,000; Ihr 
a-rabbIt
1
GGTase-lp 
(XXI2)
SC-100820
42 Ihr 1:200; overnight 
0.5% Marvel
1:2000; 2hr 
a-mouse
25
GGTase-llp
(17-Q)
SC-100819
43 Ihr 1:200; overnight 
0.5% Marvel
1:2000; 2hr 
a-mouse
15
H-Ras (M90) 
SC-53959
21 Ihr 1:500; overnight 
0.5% Marvel
1:5000; 2hr 
a-mouse
10
M-Ras (N19) 
SC-8168
29 Ihr 1:750; overnight 
0.5% Marvel
1:5000; 2hr 
a-goat (sc-2020)
30 or 50
RaplA (017) 
sc-1482
21 Ihr 1:200; overnight 
0.5% Marvel
1:10,000; 2hr 
a-goat
5 or 20
Rapi (121) 
SC-65
21 1 hr 1:200; overnight 
0.5% Marvel
1:5,000; 2hr 
a-rabbit
10 or 20
Rab1A(C-19)
SC-311
-25 Ihr 1:500; overnight 
0.5% Marvel
1:5000; 2hr 
a-rabbit
10
P-actin
A5441
40 overnight 1:2000; Ihr 
5% Marvel,
1:20,000; 2hr 
a-mouse
1-5
LDH
ab2101-1
35 overnight 1:1000; 2hr 
1 % Marvel
1:30,000; Ihr 
a-goat
30
Table 2-5 Antibody conditions for western blotting
All overnight incubation steps were carried out at 4°C, and all other incubation steps at room 
temperature. 1° = primary antibody and 2° =secondary antibody; MYOG = myogenin; MYH3 = 
myosin heavy chain 3; HMGCR = 3-hydroxy-3-methylglutaryl coenzyme A reductase; LDH = 
lactate dehydrogenase; FT = protein farnesyltransferase; GGTase-l = protein 
geranylgeranyltransferase type I; GGTase-l I = protein geranylgeranyltransferase type II
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2.2.5.7 Membrane Stripping and Reprobinq
To allow reprobing for (3-actin as an internal loading control membrane was 
stripped of primary and secondary antibodies as follows: Membrane was
incubated for 10 minutes on a rotary mix at room temperature with mild stripping 
buffer (1.5% (w/v) glycine, 0.1% (w/v) SDS, 1% (v/v) Tween 20, pH 2.2). This 
was repeated with fresh stripping buffer, followed by 2x 10 minute washes with 
PBS and 2x 5 minute washes with TBST. The membrane was blocked as 
before (see section 2.2.3.6) and probed with the new antibodies. Each 
membrane was stripped a maximum of 3 times, due to the loss of protein at 
each stage.
2.2.3.8 Densitometry
Densitometry was used to determine the relative sizes of protein bands 
obtained through western blotting (see section 2.2.3.6). Blots were scanned 
into the computer using a Xerox 2400 flatbed scanner, making sure to scan the 
images in greyscale and on the highest possible resolution, and saved as jpeg 
files. The graphics programme Paint was then used to select the area of the 
blot containing the protein bands of interest, and this selection was saved as a 
24-colour bmp file. This bmp file was used in the programme GeneTools 
(Syngene, Cambridge, UK) to determine relative band sizes. Since this 
programme allows the user to select the exact area of the band, any 
background on the film should not interfere greatly with the results. Resulting 
data were normalised using the associated values obtained for the loading 
control (3-actin.
2.2.4 Measurement of Total Cellular Cholesterol Content
In the cell, the majority of cholesterol is found in membranes (Brown and 
Goldstein 1997). Therefore, in order to quantify cellular cholesterol content, it is 
first necessary to extract it from these cell membranes. To achieve this, a 
variation of the Folch method was used (Folch et al. 1957) which is commonly 
used for the extraction of lipids (Gamble et al. 1978; Khan et al. 2003).
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2.2.4.1 Extraction of Lipids from Cells
RD cells were seeded at a density of 2 x 10^ cells per well on 6-well plates and 
left to differentiate for 5 days in low-serum medium (RD-D; section 2.2.1.9). 
Huh7 and RD-U cells were seeded on 6-well plates 24 hours prior to 
experiment, at densities of 3 x 10^ cells per well and 4 x 1 0 ^  cells per well 
respectively. Cells were exposed to various statin concentrations or a vehicle 
control (section 2.2.1.11) for 48 hours. For control experiments, using only 
vehicle control, Huh7 cells were seeded in T25 flasks at either 8 x1 0^  cells per 
flask or at a range of densities between 4x10^  and 1x10® cells per flask.
After the dosing period, medium was aspirated and cells washed twice in PBS. 
Cells were removed from the plate by trypsinisation (section 2.2.1.5), using 
500pl trypsin-EDTA per well. 1ml complete medium was added and the 
resulting cell suspension transferred to an Eppendorf tube. Cells were pelleted 
in a micro centrifuge (5 minutes at 500g). The supernatant was removed and 
discarded, and the pellet washed in PBS, followed by further centrifugation to 
allow for any disturbance of the cell pellet during wash step. Supernatant was 
removed and discarded, and 200)liI of a chloroform-methanol solvent mix (2:1 
v/v) was added to each pellet, followed by brief vortexing. Samples were 
centrifuged for 10 minutes at 18,000g in a micro centrifuge. Supernatant from 
this step (containing the lipid phase) was transferred to a new Eppendorf tube 
and dried under vacuum, to remove remaining solvent. Extracted lipids were 
then resuspended in 200pl 1x reaction buffer from the Amplex Red Cholesterol 
Assay Kit (0.1 M potassium phosphate, pH 7.4, 50mM NaCI, 5mM cholic acid, 
0.1% Triton X-100). The pellet was resuspended in 0.5M NaOH, and protein 
quantification carried out using the Lowry method (section 2.2.3.3). All samples 
were stored at -20°C until use.
2.2.4.2 Cholesterol Quantification
Total cholesterol was quantified using the Amplex Red Cholesterol Assay Kit. 
In this fluorometric method, cholesterol is oxidised by cholesterol oxidase to 
produce H2O2 and a ketone product. The probe Amplex Red (10-acetyl-3,7- 
dihydroxyphenoxazine) reacts stoichiometrically with the H2O2, in the presence
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of horse radish peroxidase (HRP), to produce resorufin which can be detected 
using a fluorometer (Amundson and Zhou 1999; Sutter et al. 2005).
In brief, a cholesterol standard curve (0 -  8pg/ml) and a positive control of 
lOpM H2O2 were prepared by dilutions of the provided components into 1x 
reaction buffer (see section 2.2.4.1). 50jliI of standards, positive control and 
samples (diluted as necessary in 1x reaction buffer) were pipetted, in triplicate, 
into separate wells of a 96-well black-bottomed microplate. An Amplex Red 
working solution was prepared (SOOpM Amplex Red reagent, 2U/ml HRP, 2U/ml 
cholesterol oxidase, 0.2U/ml cholesterol esterase) and 50pl added to each 
microplate well. Each plate was incubated for at least 30 minutes at 37°C, 
protected from light, and fluorescence was measured in a Spectra Max Gemini 
XS microplate spectrofluorometer (Molecular Devices, California, USA) 
(excitation 544nm, emission 590nm). Values were corrected for background 
fluorescence and cholesterol content determined by comparison to the standard 
curve. Cholesterol values were then normalised to the associated protein data 
(see section 2.2.4.1).
2.2.5 Statistical Analysis of Data
Where data from a single experiment was presented, mean and standard 
deviation (SD) were used where the number of repeat measurements was four 
or greater, whereas median and range were used where this number of repeats 
was less than four. Standard error of the mean (SEM) was used to show the 
precision of the mean, where data was derived from several repeat experiments 
(Resting and Altman 2002). Statistical significance was determined using the 
most relevant statistical test, as indicated, where P < 0.05 was considered to be 
significant. In general, one-way analysis of variance (ANOVA) followed by 
Bonferroni post hoc test was used to compare data from multiple samples, 
grouped by a single factor, and unpaired t-test was used to compare data from 
two samples, for example treated and untreated cells. Two-way AN OVA was 
used to compare data grouped by two factors. All tests were carried out using 
GraphPad Prism version 5 (California, USA).
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3 Characterisation of Human Liver and Muscle Cell Lines
3.1 Introduction
Circadian rhythms are known to influence a wide variety of biological processes, 
including many aspects of metabolism. Diurnal variation in cholesterol 
metabolism has been shown to occur, in part due to circadian transcription of 
key regulatory genes in this pathway: 3 -hyd roxy-3-m ethyl g I uta ry I coenzyme A 
reductase (HMGCR), the enzyme inhibited by the statins; low-density 
lipoprotein receptor (LDLR)', and the cytochrome p450 (CYP) enzymes involved 
in bile acid synthesis (Zmrzljak and Rozman 2012). Circadian rhythms can also 
affect the toxicity of xenobiotics, due to rhythmic variation in pharmacokinetic 
and pharmacodynamic factors, and it has been shown that in certain cases 
adverse drug effects can be reduced by changing drug dosing schedules 
accordingly (Levi and Schibler 2007). To examine whether differences exist 
between the circadian aspects of statin efficacy and toxicity, and whether 
greater separation can consequently be achieved between the two, the 
temporal effects of statins were to be studied in vitro. Initially the most 
appropriate model system was identified and characterised prior to further 
study.
The use of immortalised cell lines is an attractive option for such in vitro 
modelling. Human cell lines have previously been used to model and study the 
effects of statins; the RD muscle cell line has been used to study the myotoxic 
effects of statins, while the HepG2 liver cell line was used to look at the 
cholesterol-lowering effects (Kobayashi et al. 2008). Therefore both of these 
cell lines are good candidates to model the effects of statin exposure in muscle 
and liver. In addition, since it is possible to observe rhythmic gene expression 
in cultured human cells following a serum pulse, it has been suggested that 
studying the peripheral clocks of human cultured cells provides a good in vitro 
model for studying the molecular oscillator in human tissues (Takiguchi et al. 
2007).
The HepG2 liver cell line is derived from a human hepatocellular carcinoma and 
the rhythmic expression of core clock genes, clock-controlled genes and several
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CYP enzymes, has already been demonstrated in this cell line (Koyanagi et al. 
2006; Matsunaga et al. 2008; Takiguchi et al. 2007). For this reason it should 
represent a good model for examining the rhythm-dependent effects of statins 
on the liver.
Circadian rhythmicity is less well characterised in skeletal muscle, compared to 
tissues such as liver, although some evidence has been observed (Zhang et al. 
2009). Transcriptome profiling in mouse skeletal muscle has revealed 215 
transcripts (out of 36,182) with a circadian pattern of expression; this included 
several important muscle-specific proteins such as the transcription factor 
myogenic differentiation 1 (MY0D1) and the ubiquitin ligase atrogin-1 
(McCarthy et al. 2007). Robust circadian rhythms have recently also been 
demonstrated in the skeletal muscle of rats (Miyazaki et al. 2011), zebrafish 
(Amaral and Johnston 2012), horses (Martin et al. 2010) and in the Movas-1 
mouse smooth muscle cell line (Chalmers et al. 2008).
However, to date circadian rhythmicity has not been studied in RD human 
skeletal muscle cells. In order to use this muscle cell line as a model for looking 
at the temporal effects of statin administration, the ability of this cell line to 
establish and maintain circadian rhythms must first be verified. Therefore, in 
this chapter the hypothesis that RD cells have molecular clocks that are capable 
of generating robust circadian gene expression was tested.
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3.2 Characterisation of RD Ceil Differentiation
The RD muscle cell line is derived from a human embryonic 
rhabdomyosarcoma, a tumour of skeletal muscle origin, and these cells express 
a number of muscle-specific genes (Knudsen et al. 1998). The expression of 
several of these genes only occurs after the initiation of muscle cell 
differentiation (Knudsen et al. 1998). For this reason, RD muscle cell 
differentiation is initiated before their use in experiments (Nishimoto et al. 2003), 
as this will lead to a more accurate representation of skeletal muscle. A variety 
of different differentiation conditions have been used in the literature (Bouche et 
al. 2000; Carey et al. 2006; Knudsen et al. 1998; Nishimoto et al. 2003; Vachon 
et al. 1996) and so before using these cells, the optimum differentiation 
conditions for this model must be determined.
3.2.1 Expression of Muscle-Specific Markers
In order to determine the optimum time required for differentiation, RD muscle 
cells were differentiated by incubation post-confluence in low (1%) serum for 
between 2 and 10 days and the morphological and molecular changes were 
examined (section 2.2.1.9). Cell photographs, taken at 2-day intervals during 
this differentiation process (Figure 3-1 ), showed an increasing number of long 
myotube-like structures as differentiation progressed; the arrows in Figure 3-1 
indicate examples of myotube formation occurring by days 2 and 4.
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However, one property of this particular cell line is that on induction of 
differentiation these cells do not exit the cell cycle and so do not stop 
proliferating (Knudsen et al. 1998). Therefore, wells became overgrown in the 
later days of the time course, meaning it became difficult to monitor the 
progress of differentiation by microscopy. Due to this difficulty, the expression 
of several known muscle-specific markers was also measured using TaqMan 
(Figure 3-2).
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Figure 3-2 Molecular characterisation of RD muscle cell differentiation
RD cells were grown to confluence and then induced to differentiate by a change to low-serum 
(1%) medium on day 0. Total RNA was extracted from cells and reverse transcribed using 
random hexamers and the enzyme Superscript II Reverse Transcriptase (Invitrogen). 
Expression of three muscle markers, myogenic differentiation 1 {MY0D1), myogenin (MYOG) 
and myosin heavy chain 3 {MYH3), was measured by quantitative RT-PCR (TaqMan), using 
comparison with genomic DMA at known concentrations (copy number) to enable quantification. 
Values plotted represent mean ± standard deviation (SD), from a single experiment where N=4. 
Statistical significance determined by one-way AN OVA followed by Bonferroni post hoc test: 
** = P < 0.01, *** = p < 0.001, **** = P < 0.0001 compared to day 0.
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TaqMan analysis showed that RD cells express the muscle-specific 
transcription factors MY0D1 and myogenin (MYOG). A statistically significant
4-fold increase in the expression of MYOG was observed between day 0 and 
day 2 of differentiation (P < 0.001, one-way analysis of variance (ANOVA) with 
Bonferroni post hoc test). This increase occurred in the same time scale as the 
observed morphological changes. In addition, the level of skeletal muscle- 
specific myosin heavy chain 3 (MYH3) was very low prior to differentiation (day 
0); however, there was a statistically significant 7-fold increase in MYH3 
expression between days 2 and 4 of differentiation (P < 0.01, Bonferroni post 
hoc test). MY0D1 was found to already be expressed at day 0, with no 
significant change in expression observed early in the differentiation process, 
although a significant decrease in both MYOG and MY0D1 expression was 
observed by day 10 (p < 0.05 when comparing day 10 to days 2, 4 and 6 for 
expression of both genes; Bonferroni post hoc test.)
These results indicate that cell differentiation has already begun after incubation 
for 2 days in low serum medium, when MYOG expression increases and 
myotubes are observed in culture, and that differentiation is complete by day 4, 
when MYH3 is being expressed.
Western blot analysis showed that the transcript level changes were mirrored at 
the level of protein expression, following 5 days of differentiation (Figure 3-3).
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MYH3
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Figure 3-3 Protein expression of muscle-specific markers in Huh7 and RD cells
Total protein was extracted from Huh7 cells, undifferentiated RD cells (RD-U) and RD cells 
following 5 days of differentiation in 1% serum (RD-D). Protein concentration was determined 
using the Lowry method and 15pg was separated by SDS-PAGE. The levels of myogenin 
(MYOG) and myosin heavy chain 3 (MYH3) were detected using specific antibodies, and p- 
actin was used as a loading control; N=3. Western blot analysis was carried out by Kate Plant 
and Jenny Spinks.
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Limited expression of myogenin was observed in undifferentiated RD cells (RD- 
U), but greater expression of myogenin protein was observed in cells that had 
been differentiated for 5 days in low-serum medium. No myogenin was 
detected in Huh7 liver cells. High MYH3 protein levels were observed in 
differentiated RD cells, but not in undifferentiated or Huh7 cells. This supports 
the data from microscopy and TaqMan analysis, and further supports the 
conclusion that it has been possible to differentiate RD cells here.
3.2.2 Expression of Cholesterol Metabolism-Related Genes
In order to determine whether differentiation would have an effect on cholesterol 
metabolism, the expression of HMGCR and LDLR was measured. TaqMan 
analysis confirmed the expression of both genes in undifferentiated RD cells, 
and there was no significant change in expression levels during the first 6 days 
post-differentiation (Figure 3-4).
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Figure 3-4 Cholesterol metabolism during RD muscle cell differentiation
RD cells were grown to confluence and then induced to differentiate by a change to low-serum 
differentiation medium on day 0. Expression of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGCR) and low-density lipoprotein receptor (LDLr) was measured by quantitative 
RT-PCR (TaqMan). Values plotted represent mean ± standard deviation (SD), from a single 
experiment where N=4. Statistical significance determined by one-way ANOVA followed by 
Bonferroni post hoc test: * = P < 0.05 compared to day 0.
However, both showed a significant decrease in expression following 10 days of 
differentiation, with approximately a 4-fold decrease in LDLR expression (P < 
0.05 when compared to days 0 and 2; Bonferroni post hoc test) and a 2.5 fold-
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decrease in HMGCR expression (P < 0.05 when compared with days 2, 4 and 
6; Bonferroni post hoc test).
3.2.3 Clock Gene Expression
The expression of several key clock genes was also determined in order to both 
verify that RD cells express components of the molecular clock, since circadian 
rhythmicity has not previously been studied in this cell line, and to examine the 
effect of differentiation on these expression levels. TaqMan analysis confirmed 
the expression of brain and muscle arnt-like protein-1 (BMAL1), period 2 
(PER2), cryptochrome 1 (CRY1) and D site of albumin promoter (albumin D- 
box) binding protein (DBP) in RD cells (Figure 3-5).
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Figure 3-5 Expression of clock genes during RD muscle cell differentiation
RD cells were grown to confluence and then induced to differentiate by a change to low-serum 
differentiation medium on day 0. Expression of the clock genes brain and muscle arnt-like 
protein-1 (BMAL1), period 2 {PER2), cryptochrome 1 (CRY1) and D site of albumin promoter 
(albumin D-box) binding protein (DBP) was measured by quantitative RT-PCR (TaqMan). 
Values plotted represent mean ± standard deviation (SD), from a single experiment where N=4. 
Statistical significance determined by one-way ANOVA followed by Bonferroni post hoc test: 
** = p < 0.01 compared to day 0.
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Levels of BMAL1, PER2 and CRY1 expression did not significantly change 
during the 10 days post-differentiation; however a 4.5-fold increase was 
observed between days 0 and 10 in the level of expression of DBP (P < 0.01, 
Bonferroni post hoc test). This confirmation of clock gene expression suggests 
that there could be a functional molecular clock in these cells.
Taken together, these results show that RD cells can be induced to differentiate 
in low serum medium, and that this differentiation has occurred after 4 days. 
However, for many of the genes examined there is a significant decrease in 
expression following 8 or 10 days of differentiation. Therefore, for all 
subsequent experiments a differentiation time of 5 days was selected, since 
cells will have differentiated and this will allow an additional 48 hours for 
experiments prior to any significant decrease in gene expression.
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3.3 Characterisation of Circadian Rhythms
Having confirmed the expression of several key genes in the RD cell line and 
optimised cell differentiation, the next step was to study temporal gene 
expression in RD muscle cells. It is currently thought that there is an 
endogenous molecular clock in every individual cell; however, in the absence of 
external cues the circadian rhythms across a population of cells in culture are 
desynchronised (Nagoshi et al. 2004; Welsh et al. 2004). The application of a 
stimulus, such as a serum shock with 50% horse serum, has been shown to 
synchronise the rhythms of cells in culture, therefore enabling the analysis of 
circadian gene expression (Balsalobre et al. 1998). This method for 
synchronising cell rhythms is known as the serum pulse technique (section 
2.2.1.10).
3.3.1 Pilot Experiment
Prior to studying circadian gene expression in RD cells, a pilot experiment was 
first carried out using 3 cell lines that are known to have previously shown 
circadian rhythmicity. As already described, rhythmic gene expression has 
previously been demonstrated in the HepG2 human liver cell line (Koyanagi et 
al. 2006; Matsunaga et al. 2008; Takiguchi et al. 2007). Rhythmic gene 
expression has been less well studied in the Huh7 human liver cell line, but 
nevertheless circadian rhythmicity has been demonstrated in the core clock 
gene PERI, the deadenylase nocturnin (Li et al. 2008), and the cytokine 
thrombopoietin (Tracey et al. 2012). The 3T3-L1 murine preadipocyte cell line 
has also previously shown rhythmic expression of key clock genes (Otway et al. 
2009).
Following a serum pulse, RNA was extracted at 4 time points to allow 
monitoring of gene expression over 36 hours, with time points selected for each 
cell line to match rhythmic expression profiles previously reported in the 
published literature (Koyanagi et al. 2006; Li et al. 2008; Otway et al. 2009). 
The time points were carefully chosen to enable observation of an expected 
peak of expression after 24-28 hours, as well as troughs after 12-16 and 36 
hours, in 3T3-L1 and HepG2 cells but a peak after 16-20 as well as troughs 
after 8-12 and 24-32 hours in Huh7 cells. Expression of the representative core
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clock gene, Per2, and clock-controlled gene, Dbp, was analysed (Figure 3-6) 
since these genes often show the most robust rhythmic expression patterns in 
cultured cells (Otway et al. 2009).
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Figure 3-6 Temporai expression of PER2 and DBP in 3 different cell lines
3T3-L1, HepG2 and Huh7 cells were synchronised using a serum pulse (at 1=0). RNA was 
extracted from 3T3-L1 and HepG2 cells at T=0, 14, 26, 36 and from Huh7 cells at T=0, 12, 18 
and 26. Temporal gene expression of period 2 {PER2) and D site of albumin promoter (albumin 
D-box) binding protein (DBP) was measured by quantitative RT-PCR (TaqMan). Unnormalised 
data are presented as mean ± standard deviation (SD), relative to expression at T=0, from a 
single experiment where N=4.
TaqMan analysis revealed statistically significant rhythmic expression of both 
Per2 (P = 0.0072, one-way analysis of variance (ANOVA)) and Dbp (P < 
0.0001, one-way ANOVA) in 3T3-L1 cells, with the expected peak at 26 hours 
and trough at 14 hours.
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There were no statistically significant changes observed in expression of PER2 
and DBP in either HepG2 cells (P = 0.9851 and 0.3527 respectively, one-way 
ANOVA) or Huh7 cells (P = 0.4590 and 0.1793 respectively, one-way ANOVA).
Normalisation with the housekeeping genes 18S, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) or p-actin did not significantly alter expression 
patterns for either PER2 or DBP in any of the 3 cell lines used (two-way 
ANOVA; appendix 8.1).
The fact that rhythmic gene expression was detected in the 3T3-L1 cells 
indicated that the circadian rhythms of individual cells were being synchronised 
here by the serum pulse. It is possible that the lack of clear observation of 
rhythmic gene expression in the liver cell lines could be due to the small number 
of time points used in this experiment; therefore a more comprehensive analysis 
was carried out, using only 1 of the liver cell lines, the Huh7 cell line, alongside 
the RD cell line which has previously not been examined for circadian 
rhythmicity.
3.3.2 Circadian Anaiysis in Huh7 and RD Ceiis
A serum-pulse was used to synchronise both Huh7 (Figure 3-7) and RD-D 
(Figure 3-8) cells, and TaqMan analysis was used to examine gene expression 
over a longer time course of 56 hours, to enable the observation of 2 full 24- 
hour cycles after cell synchronisation.
3.3.2.1 Analvsis of Temporal Gene Expression in Huh7 Cells
In Huh7 liver cells (Figure 3-7), no statistically significant effect of time was seen 
on the expression of the core clock gene PER1 (P = 0.6926, one-way ANOVA). 
This is the only core clock gene that has previously been analysed for rhythmic 
gene expression in this cell line (Li et al. 2008), with an observed peak in 
expression after 16-20 hours as well as troughs after 8-12 and 24-32 hours in 
both Huh7 and a variety of other cells types (Chalmers et al. 2008; Li et al. 
2008; Wu et al. 2007). This rhythmic expression profile would also have been 
expected here.
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Figure 3-7 Temporal gene expression in Huh7 liver cells
Huh7 cells were synchronised using a serum pulse (at T=0). RNA was extracted every 4 hours, 
for 56 hours, and temporal gene expression was measured by quantitative RT-PCR (TaqMan). 
Unnormalised data are presented as mean ± standard deviation (SD), relative to expression at 
T=0, from a single experiment where N=4. Statistical significance determined by one-way 
ANOVA followed by Bonferroni post hoc test: * = P < 0.05.
Statistical significance for an effect of time on expression of the core clock gene 
PER2 was shown only between data points at time 0 and 40 hours after the 
serum pulse (P < 0.05, Bonferroni post hoc test). However, since large 
changes in gene expression are often seen immediately after a serum pulse 
and prior to the observation of a circadian expression profile, this had no clear 
relevance for determination of rhythmic expression. Likewise, the only
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statistically significant changes in expression of the transcription factor reverse 
erythroblastosis virus a (REV-ERBa) were those based on data from time points 
immediately following the serum pulse ( 0 - 8  hours) or on the 56 hour time point, 
when gene expression was starting to decrease at the end of the experiment.
HMGCR was included in this analysis since diurnal variation has been 
previously shown in both its transcription and enzyme activity in other models, 
and these variations potentially impact upon both statin efficacy and toxicity. 
However, there was no statistically significant effect of time on HMGCR gene 
expression in Huh7 cells in this analysis (P = 0.1192, one-way ANOVA).
Only DBP, a transcription factor that regulates the expression of many clock- 
controlled genes, showed an indication of rhythmic variation in gene expression 
with peaks of expression at 24 and 44 hours. There was a statistically 
significant difference between expression at 16 and 44 hours (P < 0.05, 
Bonferroni post hoc test), where these time points represent a trough and a 
peak respectively, and these observed peaks would be consistent with DBP 
rhythmic expression profiles reported elsewhere (Otway et al. 2009).
3.S.2.2 Analvsis of Temporal Gene Expression in RD-D Cells 
It has been shown that circadian gene expression profiles of key clock genes in 
skeletal muscle are frequently similar to those seen in liver (Miyazaki et al.
2011), and therefore the expectations for rhythmic variation of these genes in 
RD cells would be similar to those for Huh7 cells. However, in RD-D muscle 
cells (Figure 3-8) there was no statistically significant effect of time on the 
expression of the core clock genes CRY1, PER1, PER2, transcription factors 
REV-ERBa and DBP, or HMGCR. This is after taking into account the large 
changes in expression, particularly in CRY1, PER1 and PER2, immediately 
following the serum pulse.
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Figure 3-8 Temporal gene expression in RD-D muscle cells
RD-D cells were synchronised using a serum pulse (at 7=0). RNA was extracted every 4 hours, 
over a time of 56 hours, and temporal gene expression was measured by quantitative RT-PCR 
(TaqMan). Unnormalised data are presented as mean ± standard deviation (SD), relative to 
expression at T=0, from a single experiment where N=4. Statistical significance determined by 
one-way ANOVA followed by Bonferroni post hoc test: * = P < 0.05.
There was also no statistically significant effect of time on the expression of 
muscle-specific transcription factors MY0D1 and MYOG. This is surprising, as 
an effect might have been expected since MyoD1 has shown circadian 
expression of RNA in rat skeletal muscle (Miyazaki et al. 2011) and circadian 
expression of both RNA and protein in mice (Andrews et al. 2010; Zhang et al.
2012).
The core clock gene BMAL1 has previously shown rhythmic gene expression in 
cultured cells, with expression peaks at 12-20 hours and 32-40 hours as well as 
troughs at 20-28 hours in both adipose-derived stem cells (Wu et al. 2007) and 
Movas-1 mouse smooth muscle cells (Chalmers et al. 2008). In this analysis 
with RD-D cells, statistical significance was found between BMAL1 gene 
expression at 16 hours, a potential peak, and gene expression at 32 and 48 
hours, 2 potential troughs (P < 0.05, one-way ANOVA).
3.3.2.3 Normalisation of Gene Expression Data
The gene expression data presented in Figure 3-7 and Figure 3-8 is not 
normalised; however, in quantitative PGR (qPCR) studies it is common for data 
to be normalised to the expression of internal control genes (often referred to as 
“housekeeping genes”). The use of internal control genes for the normalisation 
of such data is primarily to minimise any error that may occur from 
discrepancies in the initial cDNA input, which may arise from differing 
efficiencies of the cDNA synthesis reactions. These genes should not vary in 
expression in the tissue(s) or cell line(s) being investigated, or as a result of the 
experimental treatment (Vandesompele et al. 2002).
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For this analysis, 18S ribosomai RNA (rRNA) and p-actin were chosen as 
housekeeping genes. 18S rRNA has commonly been used for normalisation, 
and hence was also tried here, p-actin has been shown to exhibit very little 
circadian variation in several tissues when compared to other housekeeping 
genes (Kamphuis et al. 2005) and it has been used previously as an internal 
control for experiments in RD cells (Phillips et al. 2007; Yang et al. 2009). 
TaqMan analysis was therefore carried out, but revealed large variations in the 
expression of 18S and p-actin in both Huh7 and RD-D cells (Figure 3-9).
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Figure 3-9 Temporal gene expression of two different housekeeping genes in Huh7 and 
RD-D cells
Huh7 and RD-D cells were synchronised using a serum pulse (at T=0). Temporal gene 
expression of housekeeping genes 18S and ACTB was measured by quantitative RT-PCR. Data 
are presented as mean ± standard deviation (SD), relative to expression at T=0, from a single 
experiment where N=4.
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Temporal gene expression data from both Huh7 (Figure 3-10) and RD-D 
(Figure 3-11) cells was normalised to either 18S or p-actin. Initially data for the 
expression of PER2 and DBP was used since these were the two genes 
analysed previously in the pilot experiment.
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Figure 3-10 Effect of normalisation of Huh7 TaqMan data using two different 
housekeeping genes
Huh7 cells were synchronised using a serum pulse (at 1=0) and temporal gene expression of 
PER2 and DBP was measured by quantitative RT-PCR. Data are shown unnormalised and 
normalised to 18S or ACTB expression, and are presented as mean ± standard deviation (SD), 
relative to expression at T=0, from a single experiment where N=4.
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Normalisation of data from Huh7 cells introduced new, large peaks in the 
expression profiles of PER2 and DBP, as well as greater overall variability 
within the dataset, as seen particularly in data points from 0 - 1 6  hours when 
data was normalised to 18S. This was a direct reflection of the variation seen in 
the 18S TaqMan data, which could have arisen due to a genuinely large 
variation in the efficiencies of the individual reactions used to synthesize the 
cDNA used for TaqMan analysis or an actual variation in 18S gene expression. 
Since the normalised data profile seemed to relate directly to the housekeeping 
gene expression, it would suggest that the latter may play a more important role 
and therefore data normalisation may have the potential to mask any genuine 
temporal effects.
Bearing this in mind, when time points 0 - 1 6  were removed from the analysis 
there was no statistically significant difference in gene expression profiles for 
either PER2 (P = 0.8231, two-way ANOVA) or DBP (P = 0.7657, two-way 
ANOVA) between unnormalised data or data normalised to the housekeeping 
genes 18S or p-actin.
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Figure 3-11 Effect of normalisation of RD-D TaqMan data using two different 
housekeeping genes
RD-D cells were synchronised using a serum pulse (at T=0) and temporal gene expression of 
PER2 and DBP was measured by quantitative RT-PCR. Data are shown unnormalised and 
normalised to 18S or ACTB expression, and are presented as mean ± standard deviation (SD), 
relative to expression at T=0, from a single experiment where N=4.
The normalisation of data from RD-D cells, to housekeeping gene 18S or |3- 
actin, also had no statistically significant effect on gene profiles of PER2 (P = 
0.7699, two-way ANOVA) or DBP (P = 0.9225, two-way ANOVA). Similarly, 
normalisation of the other genes analysed had no significant effect on gene 
expression profiles and did not lead to any unmasking of any previously unseen
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circadian effects (appendix 8.2). Therefore, the decision was made to leave 
TaqMan data unnormalised.
In summary, no clear circadian rhythms of gene expression have been 
observed in either Huh7 (Figure 3-7) or RD-D (Figure 3-8) cells. Out of all of 
the genes examined, the only potentially significant temporal variations in gene 
expression were observed with the transcription factor DBP in Huh7 cells and 
the core clock gene BMAL1 in RD-D cells.
3.3.2.4 Relative Abundance of Clock Genes
Data obtained from the TaqMan analysis of temporal gene expression was used 
to compare the abundance of the different gene transcripts between Huh7 and 
RD-D cells (Figure 3-12). The data used was from the T = 0 time point of the 
analysis, meaning that this represents transcript abundance prior to cells 
receiving a serum pulse.
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Figure 3-12 Comparison of gene expression in Huh? iiver and RD-D muscie ceiis
RT-PGR (TaqMan) data from T=0 time point of serum pulse experiments in Huh? liver (Figure 
3-7) and RD-D muscle (Figure 3-8) was used to compare the abundance of different genes 
between cell lines. Gene expression of BMAL1 and CRY1 was not determined (ND) in Huh7 
liver cells. Data represent mean ± standard deviation (SD), from a single experiment where 
N=4
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From this comparison, it seems that there is greater expression of the core 
clock gene PER1 in RD-D than in Huh7 cells (P = 0.0930, unpaired two-tailed t- 
test), whereas PER2 expression may be greater in Huh7 liver cells than in RD- 
D (P = 0.1755, unpaired t-test). REV-ERBa expression is similar in both Huh7 
and RD-D cells (P = 0.1981, unpaired t-test), but there is significantly greater 
expression of the clock controlled transcription factor DBP in RD-D than Huh7 
(P = 0.0058, unpaired t-test). Expression levels of CRY1 and BMAL1 were only 
analysed in RD-D cells. The level of CRY1 expression in RD-D cells was not 
significantly different from that of the other clock genes, apart from BMAL1 
(one-way AN OVA). The core clock gene BMAL1 had the lowest expression, 
with a transcript level that was almost 3 times lower than the next lowest 
expressed transcript in RD-D cells, REV-ERBa. This is consistent with what 
was also observed during RD cell differentiation (Figure 3-5).
3.4 Discussion
In order to study the circadian aspects of statin-induced myopathy it is important 
to establish a robust in vitro model. For this reason the first stage of this project 
was to characterise RD muscle cell differentiation, by looking at the 
morphological and molecular changes that occurred during this process, 
followed by characterisation of circadian rhythms in this same cell line 
(objectives 1 and 2; section 1.5).
3.4.1 RD Cell Differentiation
Muscle cell differentiation is a highly ordered, multi-step process in which, on 
mitogen withdrawal, proliferating myoblasts differentiate into myocytes, which 
exit from the cell cycle and fuse to form multinucleated myotubes and myofibres 
that express a number of structural and enzymatic muscle-specific proteins 
(Andres and Walsh 1996). This process is regulated by four myogenic 
regulatory factors (MRFs): MY0D1, MYF5, MYOG, and MRF4, which are 
muscle-specific basic helix-loop-helix transcription factors (Moran et al. 2002) 
that are activated at differing stages of the differentiation process (Figure 3-13). 
MY0D1, a “primary MRF”, is expressed early in the differentiation process. It is 
expressed both before and after differentiation in vitro and is thought to be 
important for myoblast determination in vivo (Megeney and Rudnicki 1995).
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MYOG, a so-called “secondary MRF”, is expressed upon differentiation and 
then plays a role in terminal differentiation (Megeney and Rudnicki 1995). The 
results obtained here, both in terms of the observation of an increasing number 
of myotubes in the cell culture and the observed changes in gene expression, 
are consistent with the occurrence of RD cell differentiation.
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Figure 3-13 Regulation of skeletal myogenesis
Myogenesis is regulated by the myogenic regulatory factors (MRFs): MYF5, MYODl, MYOG 
and MRF4, which are transcription factors that activate expression of muscle-specific genes, 
such as a-actin, myosin heavy chain (MHC) and muscle creatine kinase (MCK). On 
differentiation, the inhibitor of differentiation protein (ID) is down regulated, allowing MRFs to 
form functionally active heterodimers with the ubiquitously expressed E proteins. Each MRF 
plays a role at a different stage of differentiation, as shown. MY0D1 and MYF5 are 
expressed early during muscle development and play a role in myoblast determination, 
whereas MYOG and MRF4 are expressed later in the differentiation process. Figure adapted 
from (LIuis et al. 2006).
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MY0D1 was seen to be expressed prior to, and throughout, differentiation. The 
former could suggest that even before RD cells are stimulated to fully 
differentiate they are committed to the skeletal-muscle cell lineage. A large 
increase in MYOG expression was noted 2 days after the change to low-serum 
medium, which would be consistent with the onset of early differentiation and 
the formation of myocytes. It is interesting to note that upon differentiation there 
is a difference between the extent of MYOG RNA induction and protein 
induction (Figure 3-2 and Figure 3-3). This indicates that there may be 
posttranscriptional regulation of myogenic regulatory factors, and shows the 
importance of examining changes in protein expression as well as in gene 
expression.
Myosin plays an important role in muscle contraction (Bandman 1992). It is a 
marker of terminal differentiation (Bennett and Tonks 1997) and myosin heavy 
chain (MHC) has previously been used to monitor the differentiation status of 
RD cells (Ma et al. 2003). MYH3 is an embryonic skeletal muscle MHC isoform 
(Moran et al. 2002) and so its expression was examined here as the RD cell line 
originates from an embryonic rhabdomyosarcoma (Knudsen et al. 1998) and is 
known to express this MHC isoform (Rubin et al. 2011; Schiaffino et al. 1986; 
Yang et al. 2009). The large increase in MYH3 expression by day 4 of RD cell 
differentiation is similar to what has previously been observed during 
differentiation of the C2C12 mouse myoblast cell line (Bennett and Tonks 1997; 
Moran et al. 2002) and further supports the conclusion that terminal RD cell 
differentiation has been observed here.
The TaqMan analysis that has been carried out also verifies that this cell line 
expresses a number of cholesterol metabolism genes {HMGCR and LDLR) and 
clock genes (BMAL1, PER2, CRY1, DBP). Expression levels for most of these 
genes seem to remain unchanged during the differentiation process. There is, 
however, a significant decrease in expression levels of HMGCR and LDLR by 
day 10, which is similar to the observed decrease in MY0D1 and MYOG 
expression levels, and could be due to the continued proliferation of these 
particular cells throughout differentiation (Figure 3-1); by day 10 the cells are 
becoming overgrown and therefore perhaps starting to die by apoptosis.
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However, in contrast there is no similar decrease observed in expression of 
MYH3 or DBP. This implies that the decrease could also be due to changes in 
cell requirements upon differentiation, where differentiated cells need less 
MY0D1 and MYOG and have a reduced requirement for cholesterol synthesis. 
The reason for the continued steady increase in DBP expression is as yet 
unknown but it could be possible that, as a transcription factor, as well as 
playing a role in the output of the core clock DBP may play an as yet 
unidentified role in the process of myogenic differentiation.
It is important to recognise that the referred-to differentiation of a population of 
RD cells will always be limited. As was previously described (section 3.2.1), 
rhabdomyosarcoma cells are deficient in their ability to exit the cell cycle and 
complete terminal differentiation, despite their commitment to the muscle cell 
lineage and expression of the myogenic regulatory factors MY0D1 and MYOG. 
Several possible explanations for this deficiency have been proposed (Aguanno 
et al. 1990; Knudsen et al. 1998; Tapscott et al. 1993), including the presence 
of inactive MYODl that is still able to bind DNA but not activate transcription 
(Tapscott et al. 1993). Several research groups have been able to partially 
rescue the phenotype of limited RD cell differentiation, demonstrating growth 
inhibition as well as induction of both partial differentiation and the expression of 
muscle-specific proteins (Aguanno et al. 1990; Bouche et al. 2000; Wang et al. 
2010b), or the restoration of MYODl activity (Guo et al. 2003; Ostrovsky et al. 
2002; Puri et al. 2000). However, despite all of these treatments and 
modifications, it is clear that the rescue remains only partial and that resulting 
cell populations remain mixed, containing RD cells at varying stages of 
differentiation, making it unclear how beneficial these additional steps are. 
Within the experimental paradigm used here, it is clear that reliable cell 
differentiation is being observed, as demonstrated by expression of MYH3, 
even if this differentiation is not complete. Therefore, since any additional 
approaches have the potential for generating further experimental variability, I 
will continue to use this cell line, using serum deprivation to initiate cell 
differentiation, as a starting point for generating the in vitro model for studying 
statin administration.
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One main reason for the characterisation of the differentiation process was to 
find the most suitable length of time to use for muscle cell differentiation prior to 
future experiments in this particular project. RD cells used by other research 
groups have been left in low-serum differentiation medium for varying lengths of 
time prior to further experiments, including for 4-5 days (Knudsen et al. 1998), 6 
days (Vachon et al. 1996) or 7 days (Nishimoto et al. 2003). From the results 
obtained, it was decided that cells should be left in low serum differentiation 
medium for 5 days prior to future experiments. After this time the muscle 
regulatory factors MY0D1 and MYOG are being expressed near their highest 
level, there is a high level of MYH3 expression indicating that there are 
differentiated cells, and expression levels of the cholesterol metabolism genes 
and clock genes remain stable. Using 5 days for differentiation will also allow 
enough time to carry out any required time courses before the cells get too 
overgrown and gene expression levels start to decrease.
3.4.2 Analysis of Circadian Rhythms
Having observed these changes in gene expression during RD muscle 
differentiation, temporal gene expression was then studied in this cell line 
following a serum pulse. Circadian rhythms have now been observed in most 
peripheral tissues and also in many human cell lines (Ko and Takahashi 2006), 
but there have, to date, been no reported studies into circadian rhythmicity in 
this particular human muscle cell line.
TaqMan analysis of temporal gene expression in both Huh7 (Figure 3-7) and 
differentiated RD (Figure 3-8) cells indicated that the genes examined were not 
rhythmic in these cell populations. The lack of observed rhythmicity is of some 
surprise, especially in light of the fact that rhythms have to date been observed 
in a large range of different cell lines, using this same serum pulse protocol to 
synchronise the rhythms of individual cells within a population.
There is also increasing evidence regarding circadian rhythmicity in skeletal 
muscle (Andrews et al. 2010) and so it might be expected that RD skeletal 
muscle cells would contain molecular clocks which could be synchronised in 
culture. On the other hand, it could perhaps be that disruption of circadian
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rhythmicity is a phenotype of the rhabdomyosarcoma tumour from which this 
cell line is derived. There is currently no evidence for this, and these cells 
clearly do express a variety of core clock genes; however it is interesting to note 
that expression of BMAL1 is very low in RD cells, compared to the expression 
of other clock genes (Figure 3-12). It is unclear from the literature whether 
BMAL1 is always expressed at a low level in cultured cells or whether this is 
specific to RD cells. If it is the latter then perhaps this could partially explain the 
lack of observed rhythmicity, since it is known that deficiency in BMAL1 can 
lead to arrhythmicity (Bunger et al. 2000). It would also be interesting to know 
whether or not this low expression is mirrored in the expression of the 
dimérisation partner of BMAL1, circadian locomotor output cycles kaput 
(CLOCK).
However, lack of a functional molecular clock in RD cells would not explain the 
lack of rhythmic gene expression also observed in Huh7 cells (Figure 3-7). 
Unlike for RD cells, circadian rhythmicity has previously been demonstrated in 
this cell line (Li et al. 2008) and so it could somehow be that there was a 
problem with the protocol that was used here. This would be supported by the 
fact that, in the pilot experiment, although rhythmic expression of PER2 and 
DBP was observed in the 3T3-L1 cell line (Figure 3-6), rhythmic gene 
expression was not clearly observed in human HepG2 and Huh7 cells. In 
further support of this, although there were also no clear rhythms in temporal 
gene expression observed in Huh7 or RD-D cells in the more comprehensive 
analysis, there were indications of slight rhythmic variations in the expression of 
DBP in Huh7 cells and BMAL1 in RD-D cells. In Huh7 cells, there was a 
statistically significant difference between expression of DBP at 16 hours (a 
potential trough) and 44 hours (a potential peak), and in RD-D cells statistical 
significance was found between BMAL1 gene expression at 16 hours (a 
potential peak) and at 32 or 48 hours (2 potential troughs). These temporal 
variations match the expression profiles seen previously in 3T3-L1 cells (Otway 
et al. 2009) and HepG2 cells (Koyanagi et al. 2006). In addition, the errors on 
the data from TaqMan analysis were quite large. All of this could indicate that 
the serum pulse was only partially achieving its intended goal of cell 
synchronisation. In order to investigate this possibility, it would have perhaps
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been interesting to see whether either serum starvation prior to serum shock 
(Tracey et al. 2012) or cell synchronisation using the glucocorticoid hormone 
analogue dexamethasone rather than horse serum (Balsalobre et al. 2000) 
would have had any impact on the observation of circadian rhythmicity.
It has been demonstrated that the housekeeping genes that are most commonly 
used for data normalisation are not always the most appropriate genes 
(Kamphuis et al. 2005), and that the decision of housekeeping gene should be 
made in light of each individual experimental situation (Vandesompele et al. 
2002). This is perhaps especially important to bear in mind in circadian 
experiments when a large number of genes, other than the genes of interest, 
are likely to also exhibit circadian variation. In this particular case, any control 
gene used would need to be expressed in both liver and muscle, to not vary in a 
circadian manner and not be affected by the statin treatment which would be a 
part of later experiments. In this case it was clear that there was large variation 
in the expression of each of the housekeeping genes used (Figure 3-9), which 
could potentially complicate the interpretation of data when normalised and so 
the decision was taken to leave data unnormalised. In addition there was no 
significant difference to the observation of circadian rhythmicity between 
unnormalised data or data normalised to either of the two housekeeping genes 
18S or (3-actin (Figure 3-10). Therefore, it seems unlikely that the choice of an 
incorrect housekeeping gene was responsible for the observation of 
arrhythmicity in this particular case.
It remains possible that circadian rhythmicity may be observable in 
undifferentiated RD cells where no rhythms were observed here in differentiated 
cells (Figure 3-8). Alternatively, perhaps protein expression may have shown 
temporal variation even where RNA did not, since changes in functional protein 
are not always directly related to changes at the RNA level (Brockmann et al. 
2007; Greenbaum et al. 2003; Griffin et al. 2002). However, given the lack of 
evidence for rhythmicity in gene expression that has been observed so far, a 
decision was made not to commit further resources to continue investigating 
this line of research.
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3.4.3 New Aims and Objectives:
Therefore, having characterised the differentiation process of RD muscle cells 
(objective 1; section 1.5) but having been unable to verify the ability of this cell 
line to establish and maintain a circadian cycle in vitro (objective 2, section 1.5), 
a new set of objectives needed to be decided upon. Having established human 
liver and muscle models, I shall continue to compare the responses of liver and 
muscle cells to statin treatment, now focusing on investigating differences in the 
effects on cell viability, amount of cellular cholesterol and on prénylation, which 
may give us further clues into the mechanism of statin-induced muscle toxicity.
The new aim is to use liver and muscle cells in culture as a model system for 
studying the effects of statin administration on both cholesterol and isoprenoid 
biosynthesis, via the following objectives:
Objective 2: Examine the effects of statins on cell viability to determine whether 
there are differences between liver and muscle.
Objective 3: Assess the relative expression of HMGCR, and changes in cellular 
cholesterol in response to statin treatment, in liver and muscle.
Objective 4: Assess whether differences measured in objectives 2 and 3 
correspond to effects of statin treatment on protein prénylation.
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3.5 Summary
Circadian rhythms have been shown to impact upon the toxicity of xenobiotics. 
To examine whether differences exist between the circadian aspects of statin 
efficacy and toxicity the temporal affects of statins can be studied using an in 
vitro model. In order to compare the responses of liver (the target tissue) and 
skeletal muscle (the site of toxicity) to temporal statin administration two human 
cell lines were chosen: RD human embryonic rhabdomyosarcoma cells, which 
express a number of muscle-specific genes following differentiation, and HepG2 
human hepatocellular carcinoma cells.
The morphological and molecular changes that occurred during RD muscle cell 
differentiation were characterised. RD differentiation was observed in response 
to a change to low-serum medium, as determined by large increases in the 
expression of muscle-specific transcription factor MYOG and the marker of 
terminal differentiation MYH3. Levels of MYH3 rose rapidly after 4 days in low 
serum medium and remained high throughout the remainder of the 10-day 
experiment, whereas levels of MYOG began to decline after 8-10 days. As a 
result of this analysis, it was decided to use a time of 5 days for the 
differentiation of RD cells in future experiments.
RD cells were also observed to express a number of important cholesterol- 
related and clock genes. However, significant rhythmic gene expression was 
not observed in response to a serum pulse, in either liver or muscle cells, but 
was observed in the positive control 3T3-L1 cell line. Therefore, a new set of 
objectives were defined, whereby the focus of future experiments would remain 
on examining the differences in the response of liver and muscle to statin 
administration, but without the circadian aspect.
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4 Differential Sensitivity of Liver and Muscle Cell Lines to 
Statin Treatment
4.1 Introduction
Statins act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCR), the enzyme that catalyzes the rate-limiting step in cholesterol 
synthesis (Shitara and Sugiyama 2006). Decreased de novo cholesterol 
synthesis leads to an upregulation of the LDL receptor, increased uptake of low- 
density lipoprotein (LDL) from the bloodstream and an overall reduction in 
patient plasma levels of cholesterol in the form of LDL (Brown and Goldstein 
2004). As patient plasma LDL-cholesterol is a direct marker of cardiovascular 
risk, the action of the statins reduces risk of cardiovascular disease in patients 
(Mensink et al. 2003). The extent of the reduction in LDL is dependent on the 
specific statin used in treatment and on the dose (Chong et al. 2001 ).
There are a number of different statins currently clinically available, including 
simvastatin, lovastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin. 
All statins exert their effects via the same mechanism (Chong et al. 2001); 
however, they have differences in their physicochemical properties (Table 1-3). 
These include differences in their chemical structure (Figure 1-4), their 
bioavailability, half-life, potency, lipophilicity, metabolism and transport (Chong 
et al. 2001 ; Shitara and Sugiyama 2006; Vaklavas et al. 2009). In addition, both 
simvastatin and lovastatin are administered as a prodrug, containing an inactive 
lactone ring, which is converted into the biologically active open acid form in the 
body. All other statins are given in the open acid form (Chong et al. 2001; 
Shitara and Sugiyama 2006).
Myopathy, both in general and in its severest form as rhabdomyolysis, has been 
observed as an adverse effect with all statins (Bolego et al. 2002), although 
there are marked differences in myopathy incidence rates (Staffa et al. 2002). 
The fact that cerivastatin was withdrawn from the worldwide market in 2001 due 
to its high incidence of cases of fatal rhabdomyolysis (Bellingham 2001) 
highlights the significance of the problem of statin-induced muscle toxicity.
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However, the exact mechanism of this greater muscle sensitivity has not been 
fully elucidated (Baker 2005).
In the previous chapter, the muscle cell line RD was characterised in terms of 
its differentiation, for use together with the control liver cell line Huh7 as part of 
a model system. The next stage was to begin characterising the responses of 
these liver and muscle cell lines to statin treatment, in terms of overall cell 
toxicity and cholesterol metabolism. Cell toxicity assays have been carried out, 
in order to test the hypothesis that greater toxicity would be observed in the RD 
muscle cells than in Huh liver cells, since muscle toxicity is an important 
adverse effect of statins in the clinic. This study represents the first 
comprehensive comparative analysis of statin toxicity in both liver and muscle 
cell lines.
In addition, the expression of HMGCR has been compared between cell lines, 
and the effect of statin treatment on the level of total cellular cholesterol 
examined, in order to investigate whether any differences observed in toxicity 
translate to differences in statin-induced cholesterol reduction.
4.2 Characterisation of Statin-Mediated Cell Toxicity
In order to begin characterising the effects of statin treatment in RD and Huh7 
cells, MTT assays were carried out to assess metabolic and cellular viability 
after cells were exposed to different concentrations of statin for 48 hours 
(section 2.2.1.12).
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Huh7 cells have been used previously for MTT assays in this research group, 
using a period of 150 minutes for the incubation of cells with MTT reagent (Mary 
Hong, personal communication, 10 November 2009). However, RD cells have 
not previously been used by this group, and therefore a preliminary experiment 
was carried out using untreated cells in order to determine optimum assay 
conditions prior to statin treatment (Figure 4-1).
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Figure 4-1 Optimisation of time of incubation with MTT reagent
MTT reagent was added to untreated RD-U and RD-D cells in 6-well plates (T = 0) and 
absorbance was read (section 2.2.1.12) after incubation for 90, 150 and 240 minutes. Different 
wells of cells were used for each time point. Values plotted represent mean ± standard 
deviation (SD), from a single experiment where N=3.
One hundred and fifty minutes was found to be the minimum time at which 
absorbance no longer increased linearly with incubation time, using both 
undifferentiated RD (RD-U) and differentiated RD (RD-D) cells. This would 
therefore allow sufficient time for the conversion of MTT reagent by viable cells, 
and was chosen for incubation of all cells with MTT reagent in following assays.
Subsequently, MTT assays were carried out using the full range of available 
statins: simvastatin (acid and lactone), lovastatin (acid and lactone), 
cerivastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin (Figure 4-2).
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Figure 4-2 Cell viability in response to statin treatment
Huh7 (shown in red), RD-U (blue) and RD-D (black) cells were treated with statin for 48 hours 
and MTT assays carried out to measure cell viability. Graphs are shown in decreasing order of 
statin lipophiiicity. Final absorbance is expressed as a percentage of the control (defined as 
100%). At least three independent experiments were carried out, using 6 replicate wells in 
each. Mean values were generated from each experiment, and combined to produce the data 
shown here. Error bars represent standard error of the mean (SEM). Data were analysed by 
two-way analysis of variance (ANOVA) and P vaiues are shown where the difference between 
resDonses of different cell lines was determined to be statisticallv sionificant IP < 0.05V
There was a significant dose-dependent reduction in cell viability, in all cell 
types, on treatment with all statins (P = 0.0041, atorvastatin; P < 0.0001, all 
other statins, two-way analysis of variance (ANOVA)). The largest reductions in 
cell viability were observed on treatment with lipophilic simvastatin (acid) and 
cerivastatin, whereas loss of cell viability was only observed with very high 
concentrations of the hydrophilic pravastatin (ImM and greater).
It was not possible to determine robust IC50 values for all of the statins in all 
cell types, since full dose-response curves could not always be obtained, due to 
limits in statin solubility and the need to not exceed 0.1% DMSO in cell medium. 
However, where IC50 values could be determined, they were consistent with 
other values found in the literature (Table 4-1).
IC50 (nM)
Statin Huh7 RD-U
(Kobayashi
2008) RD-D
Simvastatin (acid) 102.2 2.36 ± 0.39 3.99 0.296 ± 0.20
Simvastatin (lactone) 0.27 ±0.10 3.60 ± 5.27 -
Lovastatin (acid) 52.2
Lovastatin (lactone) 15.98 -
Cerivastatin 2.06 ± 0.48 1.77 4.437 ± 1.90
Fluvastatin 8.51 ± 5.49 6.02 ± 1.83 8.34 2.624 ± 2.56
Atorvastatin 9.26
Rosuvastatin 160.9 >100
Pravastatin 4890
Table 4-1 IC50 values for the reduction in celluiar viability on statin treatment
Values are shown as mean ± SEM, where possible, or otherwise as a single value, determined 
from the relevant graph (shown in Figure 4-2) using GraphPad Prism version 5 (section 2.2.5). 
Not all IC50 values could be determined from this data. IC50 values taken from Kobayashi et 
al. 2008, as determined by MTT assay using RD-U cells, are also given for comparison. 
Kobayashi et al. 2008 used only the acid forms of simvastatin and lovastatin, as prepared from 
their lactone forms prior to treatment.
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In general, greater cell toxicity for a given concentration of statin was observed 
in the RD cells, either differentiated or undifferentiated, compared to the Huh7 
cells. The extent of this difference was dependent on the statin and the overall 
difference in responses between cell lines was only determined to be 
statistically significant with simvastatin (P < 0.0001, acid form and P = 0.0049, 
lactone, two-way ANOVA), cerivastatin (P < 0.0001), atorvastatin (P = 0.0044) 
and rosuvastatin (P = 0.0144) (Table 4-2). The difference between toxicity in 
the different cell types was found to be of greater significance with lipophilic 
simvastatin and cerivastatin than with hydrophilic rosuvastatin.
Statin P value summary P value
Simvastatin (acid) * * * * <0.0001
Simvastatin (lactone) ** 0.0049
Lovastatin (acid) ns 0.1137
Lovastatin (lactone) ns 0.1128
Cerivastatin * * * * <0.0001
Fluvastatin ns 0.3394
Atorvastatin ** 0.0044
Rosuvastatin * 0.0144
Pravastatin ns 0.6118
Table 4-2 Significance of ceii type in determining response to statin treatment
Data from MTT assays (Figure 4-2) were analysed by two-way analysis of variance (ANOVA) to 
determine whether there was a significant difference between the responses of different cell 
types to statin treatment. Ns = not significant, * = P < 0.05, ** = p < 0.01, **** = P < 0.0001.
it is also interesting to note that there appears to be a difference in the cell 
viability responses of RD-U and RD-D cells to statin treatment. Not all of the 
relevant IC50 values could be determined, making a quantitative comparison 
difficult. However, Bonferroni post hoc analysis suggested that these 
differences were not statistically significant (P > 0.05).
In summary, these data demonstrate effects of cell type and of different statins 
on cell toxicity in response to statin treatment.
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4.3 Analysis of Cholesterol Metabolism In Liver and Muscle Cells
Having characterised cell viability in response to statin treatment it was 
important to also examine cholesterol metabolism in these different cell lines, to 
see whether there were any differences that could account for the differences in 
cell toxicity.
4.3.1 HMGCR Expression
Since HMGCR, the enzyme that catalyses the rate-limiting step in cholesterol 
biosynthesis, is the target of the statins (section 4.1), an initial step in 
characterising cholesterol metabolism in RD and Huh7 cells was to examine the 
relative abundance of this enzyme.
Analysis of HMGCR gene expression in cells growing in normal conditions 
revealed a statistically significant difference between transcript levels of 
HMGCR in RD and Huh7 cells (Figure 4-3). HMGCR transcript levels were 1.5 
fold lower in RD-U cells than Huh7 cells (P < 0.05, Bonferroni post hoc), and 3- 
fold lower in RD-D cells than Huh7 cells (P < 0.001).
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Figure 4-3 HMGCR gene expression in different ceii types
Total RNA was extracted from Huh7, RD-U and RD-D cells in standard growth conditions and 
expression of HMGCR was measured by quantitative RT-PGR (TaqMan). Data are presented 
as mean ± standard deviation (SD), from a single experiment where N=4. Statistical 
significance was determined by one-way ANOVA followed by Bonferroni post hoc test, * = P < 
0.05, *** = p < 0.001 compared to Huh7 expression.
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Western blot analysis of total protein showed that HMGCR protein expression 
was similarly found to be considerably lower in RD-U than Huh7 cells (Figure 
4-4). HMGCR protein levels were even lower in RD-D cells, as evidenced by 
the need to increase the exposure time in order to detect HMGCR in this cell 
type. Densitometry suggested that there was a 6-fold difference in protein 
expression between Huh7 and RD-U cells however densitometry was not 
possible on protein levels in RD-D cells due to the large difference in signal 
intensity between the cell types.
Huh7 RD-U RD-D
HMGCR (1 min exposure)
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3-actin
Figure 4-4 HMGCR protein expression in different cell types
Total protein was extracted from Huh7, RD-U and RD-D cells in standard growth conditions and 
15pg was separated by SDS-PAGE. The level of HMGCR (90kDa) was detected by western 
blot and p-actin was used as a loading control. Two different exposure times were used to 
allow detection of HMGCR in all cell types. N = 2.
These data demonstrate that HMGCR is expressed in all cell types of interest: 
Huh7, RD-U and RD-D cells. At both the transcript and the protein level, there 
is a much greater expression of this enzyme in Huh7 liver cells than in RD 
muscle cells. Interestingly, a difference was also observed between HMGCR 
expression in RD-U and RD-D cells, with lower expression in RD-D cells, 
particularly at the protein level. The different levels of HMGCR expression 
between the cell types may need to be taken into account when interpreting 
results from future experiments.
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4.3.2 Total Cellular Cholesterol
Having verified the presence of HMGCR in all cell types, the next stage was to 
determine what effect statin treatment would have on total cellular cholesterol 
content in these cells, since reduction of cholesterol is the main aim of statin 
use in the clinic.
Assays were carried out in which cells were treated with statin for a 48 hour 
period, after which cholesterol was extracted and quantified (section 2.2.4). 
This time period was chosen based on those reported in the literature 
(Kobayashi et al. 2008; Mullen et al. 2010), and to remain consistent with the 
conditions used for the previous MTT assays (Figure 4-2). Simvastatin (acid), 
cerivastatin and pravastatin were chosen for use in this analysis since both 
simvastatin and cerivastatin showed a statistically significant difference in 
toxicity between RD muscle and Huh7 liver cells (Figure 4-2). In contrast, 
pravastatin treatment resulted in toxicity only at high concentrations and 
showed no statistically significant difference in toxicity between cell lines, and 
was included as a relatively non-toxic comparator.
Initially, cells were treated with IpM of each of the chosen statins. This 
concentration was chosen based on the work of Kobayashi and colleagues 
(Kobayashi et al. 2008), and results from the MTT assays: In these MTT 
assays, treatment with IpM simvastatin and cerivastatin resulted in differences 
between the responses of RD muscle and Huh7 liver cells without causing an 
excess of cell death that could complicate extracting sufficient cholesterol for 
quantification (Figure 4-2). Where appropriate, the statistical significance of 
statin treatment on total cellular cholesterol in individual cell lines was 
determined using unpaired two-tailed t-test.
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There appeared to be a decrease in total cellular cholesterol in Huh7, RD-U and 
RD-D cells upon 1pM simvastatin treatment, and in Huh7 and RD-D cells on 
1pM cerivastatin treatment (Figure 4-5). However, where statistical analysis 
was appropriate, these changes were not found to be significant using unpaired 
t-tests; (P = 0.2262 (Huh7) and 0.0574 (RD-U) on treatment with 1pM 
simvastatin.) There appeared to be no change in cholesterol level upon RD-U 
treatment with cerivastatin or in any of the cell types on pravastatin treatment.
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Figure 4-5 Effect of IpM statin treatment on total cellular cholesterol
Huh7, RD-U and RD-D cells were treated with 1pM simvastatin (acid), cerivastatin or 
pravastatin for 48 hours, after which membrane cholesterol was extracted using chloroform: 
methanol, quantified using the Amplex Red Cholesterol Assay Kit and normalised to total 
protein. DMSO was used as a vehicle control for simvastatin and water for cerivastatin and 
pravastatin. Values plotted represent mean ± SEM from two (cerivastatin and pravastatin) or 
three (simvastatin) independent experiments, where there were 3 replicates in each 
experiment.
98
Since no change in cholesterol was observed on treatment with IpM 
pravastatin, and changes with simvastatin treatment were not found to be 
statistically significant, the same analysis was then carried out after treating 
cells with 10pM simvastatin and pravastatin. Data is not shown for the use of 
10pM cerivastatin since at this concentration the amount of cell death, 
particularly in the RD-U cells, was so great that it was not possible to extract 
sufficient cholesterol from the remaining cells as to enable quantification.
Treatment with 10pM of both simvastatin and pravastatin seemed to result in a 
decrease in total cellular cholesterol in Huh7 cells (P = 0.00535 and 0.2144 
respectively). A statistically significant cholesterol decrease was observed in 
RD-D cells on treatment with both simvastatin (P = 0.0027) and pravastatin (P = 
0.0023) (Figure 4-6). Therefore, since these are the concentrations that 
resulted in a statistically significant cholesterol decrease lOpM simvastatin and 
pravastatin were chosen for use, alongside IpM cerivastatin, in future 
experiments.
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Figure 4-6 Effect of lOpM statin treatment on total cellular cholesterol
Huh7, RD-U and RD-D cells were treated with lOpM simvastatin (acid) or pravastatin for 48 
hours, after which membrane cholesterol was extracted, quantified and normalised to total 
protein. Values plotted represent median ± range; from a single experiment where N=3. 
Statistical significance determined by unpaired t-test, ** = p < 0.01 compared to relevant 
control.
There appeared to be some variability with this method of cholesterol extraction 
and quantification. This is particularly apparent when comparing the level of 
cholesterol between control treatments, for example cellular cholesterol ranged 
from 10.6 - 20.1pg/mg protein in control Huh7 cells and from 3.6 - 9.3 pg/mg
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protein in control RD-U cells (Figure 4-5 and Figure 4-6). Therefore, 
experiments were carried out in order to investigate the source of this variation.
In order to assess whether the vehicle control used could have had an effect on 
level of cholesterol measured Huh7 cells were seeded into 6-well plates and 
T25 flasks and treated with a range of different controls (Figure 4-7). Controls 
used were water (control for cerivastatin and pravastatin), 0.1% DMSO 
(simvastatin control) and 1% DMSO. A medium-only control was not included 
here since the water-containing control was considered equivalent to this. The 
effect of exclusion of non-essential amino acids (NEAA) from Huh7 cell medium 
was also examined. No statistically significant difference was found between 
control treatments (P = 0.2838 (6-well plates), P = 0.1447 (T25 flasks), one-way 
ANOVA).
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Figure 4-7 Effect of control treatment on total cellular cholesterol In Huh7 cells
Huh7 cells in 6-well plates (A) or T25 flasks (B) were treated with 0.1% DMSO, water, 1% 
DMSO, or serum-free media without the addition of non-essential amino acids (NEAA) for 48 
hours, after which membrane cholesterol was extracted, quantified and normalised to total 
protein. Values plotted represent median ± range; from a single experiment where N=3.
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In previous experiments, cholesterol content was normalised to total cellular 
protein, to take cell number into account, but this may not allow for all effects of 
variation in cell density. However, no significant difference was observed 
between cholesterol content of Huh7 cells seeded in T25 flasks at two different 
densities (P = 0.9442, unpaired t-test). A 3rd, lower, seeding density appeared 
to lead to similar normalised cholesterol content however statistical analysis 
could not be carried out due to insufficiency of data (Figure 4-8).
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Figure 4-8 Effect of seeding density on total cellular cholesterol in Huh7 cells
Huh7 cells were seeded in T25 flasks using a range of seeding densities (as shown) and 
treated with 0.1% DMSO for 48 hours, after which membrane cholesterol was extracted, 
quantified and normalised to total protein. Values plotted represent median ± range from a 
single experiment where N=3 (medium and high densities), or a single value (low density) 
where sufficient values could not be obtained.
In summary, these data clearly show that that there is a cholesterol pool in both 
of our model cell lines, Huh7 and RD, and that statin treatment appears to 
decrease the total cellular cholesterol level. However, variation with the method 
of cholesterol quantification prevented statistical significance being achieved, 
with the cause of this variability undetermined.
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4.4 Discussion
Myopathy is a well known adverse effect of statin treatment in some patients, 
with effects ranging from mild to fatal. Importantly, the mechanism of this 
muscle toxicity remains unclear, making it difficult to minimise the risk of toxicity. 
In order to gain further understanding, this study first compared statin-mediated 
cell toxicity in Huh7 liver and RD muscle cells, to test the hypothesis that RD 
muscle cells would show greater susceptibility to the toxic effects of statins. 
This represented the first comprehensive comparative analysis of statin toxicity 
in both liver and muscle cell lines. Subsequently, since HMGCR is the enzyme 
inhibited by the statins, expression of this enzyme was compared between cell 
lines at both transcript and protein levels. Finally, cellular cholesterol content in 
response to statin treatment was also quantified, in order to further examine 
differences in the responses of these two cell lines.
4.4.1 Cell Viability
MTT assays are widely used for assessing the viability of cells (Saad et al. 
2006). They rely on the reduction of a tétrazolium bromide salt to a water- 
insoluble formazan salt by dehydrogenase enzymes in active mitochondria of 
living cells (Mosmann 1983). The assay therefore provides a measure of the 
metabolic activity of cells and does not assess other parameters of cell growth, 
such as cell division. However, they remain very useful for giving an indication 
of cell viability in response to xenobiotics and they have been used here to 
assess cell viability in response to treatment of both Huh7 and RD cells with a 
range of statins (section 4.2).
4.4.1.1 Differences between Liver and Muscle
The results obtained here showed that there was greater toxicity in RD muscle 
than Huh7 liver cells in response to treatment with all statins, with statistical 
significance between the responses on treatment with simvastatin, cerivastatin, 
atorvastatin and rosuvastatin. This is consistent with the observation of skeletal 
muscle toxicity as a well known adverse effect of the statins in the clinic 
(Hedenmalm et al. 2010), and confirms the hypothesis as well as further 
supporting the relevance of this model system for the study of the effects of 
statins.
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In addition to a difference between sensitivity of liver- and muscle-derived cells 
to the toxic effects of statin exposure, treatment appeared to result in greater 
cell toxicity in RD-U compared to RD-D cells, with statins other than 
atorvastatin, rosuvastatin and pravastatin. These data are consistent with the 
recent finding that differentiated C2C12 mouse skeletal muscle cells are more 
resistance to cell death by apoptosis than undifferentiated cells, due to an 
elevation of anti-apoptotic proteins (Xiao et al. 2011). From the data in this 
study not all IC50 values could be obtained, due to technological 
considerations, and this prevented a quantitative comparison in some cases. 
However, Bonferroni post hoc analysis suggests that the differences between 
RD-U and RD-D responses were not statistically significant, but further work is 
required to fully examine this finding in a robust manner.
4.4.1.2 The Effect of Different Statins and the Role of Statin Exposure
The results of these MTT assays reveal a difference in toxicity between not only 
liver and muscle cells, but also between treatment with different statins, with 
more lipophilic statins such as simvastatin, lovastatin and cerivastatin showing 
the greatest toxicity, particularly in muscle cells. This is consistent with the 
observation of the highest incidence of myopathy with simvastatin, lovastatin 
and cerivastatin treatment in patients (Staffa et al. 2002).
In general, the exposure is thought to play a major role in determining the 
toxicity of a drug (Caldwell et al. 1995; Hedenmalm et al. 2010), with systemic 
exposure to xenobiotics determined by a complex interaction of absorption, 
distribution, metabolism and excretion (ADME) (Caldwell et al. 1995). With the 
statins, this role of drug exposure in toxicity is supported by the fact that 
pharmacokinetic interactions that increase systemic and skeletal muscle statin 
exposure, such as concomitant treatment of a patient with a statin and a 
xenobiotic that affects metabolism by cytochrome P450 (CYP) enzymes, have 
been shown to increase myopathy incidence (Bolego et al. 2002; Law and 
Rudnicka 2006; Mastaglia and Needham 2012; Sidaway et al. 2009). In 
addition, genetic polymorphisms in the gene encoding organic anion 
transporting polypeptide 1B1 (0ATP1B1), a transporter involved in the hepatic 
uptake of many of the statins, has been associated with a higher risk of
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myopathy (Link et al. 2008). A correlation has previously been shown between 
accumulation of statins and cytotoxicity in vitro in RD-U cells, with greater sub- 
cellular accumulation of the lipophilic statins being reported (Kobayashi et al. 
2008).
The liver is the target organ of the statins, and it has been suggested that non­
specific distribution into other tissues, via passive diffusion, by the more 
lipophilic statins could explain their increased potential for statin-related muscle 
problems (Vaklavas et al. 2009). However, myopathy has also been reported 
with hydrophilic pravastatin, which is not subject to significant passive diffusion, 
arguing against this hypothesis. It is now known that there are a number of 
transporters which are expressed in muscle tissue and recognise statins as 
substrates, and these are more likely to be responsible for uptake of statins into 
muscle cells (Shitara and Sugiyama 2006). Examples include organic anion 
transporter 3 (OATS) (Takeda et al. 2004) and 0ATP1A4 (Sakamoto et al.
2008) which have been shown to mediate pravastatin transport, and 0ATP2B1, 
which is expressed in both liver and muscle and can transport atorvastatin and 
rosuvastatin (Knauer et al. 2010) as well as pravastatin (Sakamoto et al. 2008).
It would be of interest to determine the transporter profile of the RD cell line and 
how this compares to skeletal muscle tissue in vivo. It has been shown that the 
level of expression of transporters, as well as drug metabolising enzymes, can 
at times be different between cultured cell lines and native tissue (Hilgendorf et 
al. 2007) and this could have implications for drug distribution. It has also been 
suggested that differences in transporter profile could partially explain why 
pravastatin has been shown to have limited effects in some in vitro systems of 
rat origin, when it clearly can lead to muscle toxicity in human patients 
(Sakamoto et al. 2008). However, the transporter profile in the human RD 
muscle cell line is not currently known and so it cannot be certain whether this is 
also the case in this model system. It is true that the MTT assays did reveal a 
lesser toxic effect with pravastatin than many of the other statins, but, as 
already discussed, this does also reflect differences in myopathy incidence 
observed between statins in the clinic and so the use of pravastatin in this study 
will be continued.
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Differences in statin cellular exposure are likely to play some role in statin- 
induced muscle toxicity, however they probably do not completely account for 
differences in the sensitivity between tissues. One recent rat study 
demonstrated that in vivo there was no difference in systemic or skeletal muscle 
statin exposure before or during myopathy, and that there was no difference in 
exposure between different animals and different muscle types that exhibited 
different sensitivity to muscle toxicity (Sidaway et al. 2009). Since responses of 
RD and Huh7 cells to statin treatment have been characterised here in terms of 
gross changes in cellular viability, it is now important to look in more detail at 
molecular changes occurring in these cell lines in response to statins for further 
elucidation.
4.4.2 Cholesterol Metabolism
4.4.2.1 Differences in HMGCR Expression
These analyses have shown that HMGCR, the enzyme that catalyses the rate- 
limiting step in cholesterol biosynthesis and is inhibited by the statins (Shitara 
and Sugiyama 2006), is present in all cell types. This was important to 
establish prior to further investigations into the mechanisms of statin-induced 
muscle toxicity, using these cell lines.
Higher levels of HMGCR were observed, at both the transcript and protein level, 
in Huh7 cells compared to RD muscle cells. Although cholesterol synthesis 
occurs in almost all cells, the liver is the main site of cholesterol biosynthesis 
(Catapano 2007; Shitara and Sugiyama 2006). Therefore, the presence of a 
higher level of HMGCR in Huh7 liver cells is not entirely unexpected, although 
such a large difference, particularly in the protein levels, was surprising. It is 
perhaps interesting to note that there is a larger fold-difference in HMGCR 
expression levels between liver and muscle cells than observed in cholesterol 
levels. This difference might reflect altered rates of efflux of cholesterol from 
these cells, or that liver cells have a larger reserve of metabolic capacity for the 
synthesis of cholesterol compared to muscle cells.
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A difference was also found between HMGCR expression in RD-U and RD-D 
cells, with much lower levels of expression in RD-D cells. One potential 
explanation could be a greater need of RD-U cells to produce cholesterol for the 
synthesis of new membranes, which is reduced as RD cells differentiate. It has 
also been suggested that HMGCR could play an important role in the induction 
of differentiation, in particular due to the production of isoprenoids for protein 
prénylation. In rat L6 skeletal muscle cells HMGCR was found to be 
upregulated at a very early stage of differentiation (6 hours), followed by a 
subsequent downregulation to allow differentiation to occur (Martini et al. 2009). 
Since RD-D cells have been allowed to differentiate for 5 days prior to 
experiments (section 2.2.1.9), it is possible that this downregulation is what is 
being observed here.
It would be interesting to know whether these effects are observed only in this 
rate-limiting enzyme, or whether this is also the case for other enzymes in the 
cholesterol synthesis pathways and for the total flux through the biosynthetic 
pathway in these cell lines. The different levels of HMGCR expression between 
the cell types may need to be taken into account when interpreting results from 
future experiments.
4.4.2.2 The Effect of Statin Treatment on Total Cellular Cholesterol
Having shown the presence of HMGCR in all cell types, subsequent data 
demonstrated that cholesterol was also present in all cell types of interest and 
decreases in total cellular cholesterol on statin treatment were observed.
In this study, a period of 48 hours was used for statin treatment prior to 
cholesterol quantification. This remained consistent with the conditions used for 
MTT assays as well as taking studies from the literature into account. 
Previously one research group reported seeing no effect on total cellular 
cholesterol after C2C12 mouse myoblasts and HepG2 human liver cells were 
treated with lOpM simvastatin for 6 or 18 hours (Mullen et al. 2010). However, 
another research group was able to observe a decrease in intracellular 
cholesterol in HepG2 cells after 24 and 48 hour treatment with a IpM 
concentration of a range of statins (Kobayashi et al. 2008). Given that
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cholesterol synthesized within a cell will have many fates, including sub-cellular 
sequestration, it is possible that cells are buffered against acute exposure to 
statins due to sub-cellular pharmacokinetic considerations. Chronic exposure 
may have a more unequivocal effect, but this must be balanced with the 
increased cell toxicity associated with such prolonged exposures.
Three statins were chosen for use in this cholesterol analysis: simvastatin 
(acid), cerivastatin and pravastatin. Simvastatin remains one of the most 
frequently prescribed statins in the UK (Bakhai et al. 2012; Jick et al. 2012) and, 
together with cerivastatin, showed the greatest difference in toxicity between 
RD muscle and Huh7 liver cells (Figure 4-2). The open acid form of simvastatin 
was used here since this is the form that is biologically active, without need for 
prior metabolism (Shitara and Sugiyama 2006). Cerivastatin is also of interest 
in this study due to its high incidence of myopathy in patients (Bolego et al. 
2002). In contrast, pravastatin has shown much lower levels of toxicity both in 
MTT assays (Figure 4-2) and in the clinic (Staffa et al. 2002), as well as having 
shown less of a difference in toxicity between RD muscle and Huh7 cells 
compared to simvastatin or cerivastatin (Figure 4-2). It can therefore be used 
for comparison.
There appeared to be decreases in cholesterol content of Huh7 and RD-D cells 
in response to IpM cerivastatin treatment, and in Huh7 cells in response to 
lOpM simvastatin and pravastatin treatment. There were statistically significant 
decreases in cholesterol in RD-D cells with lOpM simvastatin (P = 0.0027) and 
pravastatin (P = 0.0023).
There was a large degree of variability in the data obtained, which could explain 
why some of the observed decreases in cholesterol were not found to be 
statistically significant. This variability was both between replicates within an 
individual experiment and between experiments. This was particularly evident 
in the variable levels of cholesterol in control cells. Due to this variability, 
statistical analysis was not carried out to examine differences in levels of 
cholesterol and cholesterol reduction on statin treatment between cell lines. 
However, it appeared that there may be slightly lower levels of cholesterol in RD
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muscle compared to Huh7 liver cells, which could be explained by the lower 
level of HMGCR in these cells. There also seemed to be no obvious 
differences in cholesterol reduction in response to statin treatment that could 
account for the differences in toxicity between the liver and muscle cell lines.
In order to investigate the cause of the variability, experiments were carried out 
to examine the effect of several variables on the level of cholesterol measured. 
Since statin stock solutions were made using different solvents, depending on 
the solubility of the statin, an experiment was carried out to determine whether 
this could account for the variability in control cholesterol levels between statin 
treatments. Simvastatin was dissolved in DMSO and, since high levels of 
DMSO can be toxic to cells, stock was always diluted by 1000-fold to ensure 
that the final percentage of DMSO in cell medium did not exceed 0.1%. 
Cerivastatin and pravastatin were both dissolved in water. No significant 
difference was found in cholesterol levels between Huh7 cells in either 6-well 
plates or T25 flasks treated with 0.1% DMSO, water or 1% DMSO.
Another potential cause of discrepancy between experiments is cell density. 
Although cells are seeded at the same initial density, a variety of factors, such 
as cell passage number, can lead to slight differences in cell growth rate and, 
ultimately, in cell density. However, no difference was observed in normalised 
cholesterol levels between Huh7 cells seeded in T25 flasks at 3 different 
seeding densities.
These two experiments using untreated Huh7 cells were therefore unable to 
determine the cause of the variation in the data. Nevertheless, despite this 
variation, the experiments gave us sufficient information to progress as they 
clearly showed that there was a cholesterol pool in both of our model cell lines, 
Huh7 and RD, and that statin treatment did result in a decrease in total cellular 
cholesterol level.
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4.4.3 Choice of Statin Concentration
With the use of xenobiotics in in vitro models there is always the issue of 
choosing therapeutically relevant concentrations (Bjorkhem-Bergman et al. 
2011). With simvastatin, concentrations of up to IpM have been observed in 
the plasma of patients (Mullen et al. 2010), meaning that the concentrations 
used for the cholesterol analysis here are not too dissimilar from the 
physiological range.
However it has also been suggested that localised concentrations in some 
tissues could be higher than this, due to the activity of transporters, and that this 
could be variable between individuals (Sirvent et al. 2005). Indeed in treated 
rats simvastatin concentration was found to be 4-fold higher in the liver than in 
the plasma, with an even greater difference for cerivastatin (Sidaway et al.
2009). Statin concentrations have been found to be a third lower in rat skeletal 
muscle than in plasma for simvastatin, with an even greater difference with 
cerivastatin (a sixth lower) and rosuvastatin (1/16) (Sidaway et al. 2009). 
Similar findings have been reported in guinea pig skeletal muscle for 
cerivastatin, rosuvastatin and atorvastatin (Madsen et al. 2008). The plasma-to- 
muscle ratios are not currently known for humans (Knauer et al. 2010) and 
localised concentrations in muscle may be increased in patients when statin 
treatment is given in combination with a fibrate or a CYP inhibitor (Mullen et al.
2010).
The biological effect of statins is a decrease in cholesterol (Chong et al. 2001) 
and it has been shown here that decreases in cholesterol can be observed on 
treatment with lOpM simvastatin and pravastatin, and IpM cerivastatin (section 
4.3.2). Therefore, since these are the statin concentrations which reproduce 
the expected biological effect of the statins, and are concentrations at which RD 
muscle cell toxicity can be observed with simvastatin and cerivastatin, these are 
the concentrations that were used in future experiments.
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4.5 Summary
Responses of Huh7 liver and RD muscle cells to statin treatment have been 
characterised in terms of both cellular viability and cholesterol metabolism.
Using MTT assays, significant reductions in cell viability were observed for all 
three cell types (Huh7, RD-U and RD-D) on treatment with simvastatin (acid 
and lactone), lovastatin (acid and lactone), cerivastatin, fluvastatin, atorvastatin, 
rosuvastatin and pravastatin in a dose-dependent manner. The largest 
reductions in cell viability were observed with the more lipophilic statins: 
simvastatin (acid), lovastatin (acid) and cerivastatin, whereas loss of cell 
viability was only observed with very high concentrations of the hydrophilic 
pravastatin (1mM and greater). Higher cell toxicity was also observed for all 
statins in the RD cells, either differentiated or undifferentiated, compared to the 
Huh7 cells, where this difference was statistically significant with simvastatin, 
cerivastatin, atorvastatin and rosuvastatin. Taken together, these data 
represent the first comprehensive comparative analysis of statin toxicity in 
human liver and muscle cell lines.
The level of HMGCR, the rate-limiting enzyme in cholesterol biosynthesis and 
the enzyme inhibited by the statins, was analysed. HMGCR was found to be 
expressed at both the transcript and protein level in all cell types, although to a 
lesser extent in RD muscle cells (particularly when differentiated). Decreases in 
total cellular cholesterol were observed on treatment with 10pM simvastatin and 
pravastatin, and 1pM of cerivastatin. Since these are the concentrations that 
replicate the biological effect of the statins (a decrease in cholesterol), these are 
the concentrations that were then used in future experiments, examining other 
molecular changes that occur in these cells on statin treatment.
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5 The Effects of Statins on Prénylation in Liver and Muscle 
Cells
5.1 Introduction
Due to the large number of intermediates in the mevalonate pathway (Figure 
1-3), inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) 
by statins not only inhibits cholesterol synthesis but also impacts upon a 
number of other cellular processes, including protein prénylation (Vaklavas et 
al. 2009).
Farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) are 
intermediates of the mevalonate pathway. In protein prénylation, these 
isoprenoids donate farnesyl (15-carbon) or geranylgeranyl (20-carbon) groups, 
respectively, for post-translational covalent addition to cysteine residues at or 
near the C-terminus of proteins. This addition is thought to be essential for the 
biological function of many proteins by enabling them to anchor to cell 
membranes, specifying cellular localisation (McTaggart 2006). There is 
increasing evidence that disruption of various prénylation targets could lead to 
myopathy (Blanco-Colio et al. 2002; Matzno et al. 2005; Sakamoto et al. 2011).
The three distinct protein prenyltransferase enzymes that are responsible for 
the addition of prenyl groups to proteins are farnesyltransferase (FT), 
geranylgeranyltransferase-l (GGT-I) and geranylgeranyltransferase-lI (GGT-II). 
Other than a small number of specific cases of overlap (sections 1.3.5.2i and ii), 
each enzyme is thought to have a distinct subset of substrates (Figure 5-1). 
Substrates for FT include Ras guanine nucleotide-binding proteins (GTPases) 
and the nuclear lamins; GGT-I adds geranylgeranyl groups to Ras-related 
GTPases, including of the Ras and Rho subfamilies, and the y  subunits of 
heterotrimeric G-proteins; GGT-II is responsible for the prénylation of Ras- 
related GTPases in the Rab subfamily (Casey and Seabra 1996).
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Figure 5-1 Protein prénylation
Farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GPP), isoprenoid products of 
the mevalonate pathway, donate farnesyl or geranylgeranyl groups respectively for the post- 
translational prénylation of proteins. The 3 prenyltransferase enzymes which catalyse this step 
are farnesyltransferase (FT), geranylgeranyltransferase-l (GGT-I) and 
geranylgeranyltransferase-l I (GGT-II). Each enzyme has a distinct group of substrates.
Work discussed in previous chapters has established human liver and muscle 
cell-based models and characterised their response to statin treatment, in terms 
of both cell viability and changes in cholesterol levels. In this chapter, the effect 
of statin treatment on the cellular process of protein prénylation, by each of the 
three prenyltransferase enzymes, was examined in these liver and muscle 
models, with the hypothesis that statins would preferentially disrupt prénylation 
within muscle, the site of observed human toxicity.
5.2 Rationale for Experimental Design
Protein was extracted from Huh7, RD-U and RD-D cells treated with vehicle 
control, statin or mevalonic acid in addition to statin, and then subjected to 
analysis by western blot (section 2.2.3) to detect any changes in the prénylation 
status of selected target proteins as well as to examine the expression of the 
prenyltransferase enzymes.
Simvastatin (acid), cerivastatin and pravastatin, were used in this analysis as 
these are the statins used previously to examine the effects of statin treatment 
on total cellular cholesterol (section 4.3.2). A decrease in cholesterol, the 
expected biological effect of the statins, was observed on treatment with lOpM 
simvastatin and pravastatin, and 1pM cerivastatin, and so these were the initial
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concentrations also used here. Both simvastatin and cerivastatin treatments 
were previously shown to result in greater toxicity in RD muscle cells than Huh7 
liver cells (section 4.2). In contrast, pravastatin treatment resulted in toxicity 
only at high concentrations and showed no statistically significant difference in 
toxicity between cell lines, therefore it can be used for comparison.
Mevalonic acid (mevalonate) is an intermediate in the mevalonate pathway that 
is just downstream of the site of statin inhibition. Its addition has been shown to 
compensate for the statin-induced block of the mevalonate pathway, thereby 
indicating whether any effects that are observed are due to the specific 
inhibition of HMGCR or to non-specific effects.
Cells were also treated with 3 inhibitors of prénylation: FTI-277, GGTI-2133 and 
perillyl alcohol. FTI-277 is a trifluoroacetate salt that inhibits FT by acting as a 
highly potent Ras CAAX peptidomimetic, mimicking the Ras C-terminal CAAX 
FT recognition motif and site of prénylation (Lerner et al. 1995; Sigma-Aldrich 
2011a). GGTI-2133 is a non-thiol peptidomimetic that inhibits GGT-I with an 
140-fold selectivity over FT (Sigma-Aldrich 2011b). There are only a limited 
number of specific inhibitors of GGT-II available (Leung et al. 2006), none of 
which were commercially obtainable. Therefore perillyl alcohol was used, which 
is a monoterpene that inhibits both GGT-I and II, with 2-fold greater potency for 
the inhibition of GGT-II (Ren et al. 1997; Tanaka et al. 2010).
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5.3 The Effects of Statins on Prénylation
The small GTPases represent the largest group of proteins where prénylation is 
vital for their membrane localisation and function (McTaggart 2006). In this 
analysis, the prénylation of several small GTPases in response to statin 
treatment was examined. Rap1A was chosen as a representative small 
GTPase prenylated by GGT-I, with H-Ras as a substrate of FT and with Rab1A 
as a substrate of GGT-II.
5.3.1 RaplA
Rap1A is a 22kDa Ras-related GTPase which is prenylated by GGT-I and is 
thought to play roles in cell adhesion, the establishment of cell polarity and the 
regulation of cell-cell contacts (Frische and Zwartkruis 2010). It is one of two 
very closely related isoforms of Rapi (Bos 1997; Frische and Zwartkruis 2010) 
and it has previously been shown that levels of unprenylated RaplA increase 
on treatment with simvastatin in both HepG2 liver cells and C2C12 mouse 
myotubes (Mullen et al. 2010). It was important to verify whether this effect is 
also observed in human cell lines and whether there is a difference between the 
effects of different statins.
In order to investigate the geranylgeranylation state of RaplA two antibodies 
were used. One antibody (referred to as RaplA) recognises only the 
unprenylated form of the protein (Antoine et al. 2010; Reszka et al. 2001) and 
the other (referred to as Rapi) recognises both Rapi isoforms whether 
prenylated or unprenylated (Reszka et al. 2001), thereby giving an indication of 
total Rapi protein expression. This meant that it was possible to use total 
protein extracts in this case (section 2.2.3.1).
There was no unprenylated RaplA detected in any of the control samples, 
suggesting that this prénylation step is highly efficient. Unprenylated RaplA 
was observed in all three cell types following treatment with lOpM simvastatin 
or IpM cerivastatin, but not lOpM pravastatin (Figure 5-2). In all cases, this 
was largely rescued on co-addition of mevalonic acid, showing that the increase 
in unprenylated RaplA was due to statin inhibition of HMGCR rather than a 
non-specific effect.
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Figure 5-2 Effect of statin treatment on RaplA prénylation
Total protein was extracted from cells treated for 48 hours with vehicle control, statin, or 
mevalonic acid in addition to statin. Simvastatin (simva) and pravastatin (prava) were used at a 
concentration of 10pM and cerivastatin (ceriva) at 1|iM. DMSO was used as a vehicle control 
for simvastatin and water for cerivastatin and pravastatin. Mevalonic acid was used in excess, 
at 100pM. Protein concentration was determined using the Lowry method and 30pg was 
separated by SDS-PAGE and transferred to PVDF membrane. The level of unprenylated 
RaplA (21kDa) was detected in Huh7 (A), undifferentiated RD (RD-U) (B) and differentiated RD 
(RD-D) (C) cells using a specific antibody, and compared to the levels of total Rap1 and of the 
loading control, (3-actin. Protein size was determined by comparison to a coloured protein 
marker. Western blots are representative of three independent experiments.
p-actln was used as a loading control, as its expression is unchanged on statin 
treatment and therefore any variation detected can be attributed to uneven 
protein loading. The only changes observed in total Rap1, in samples from 
Huh7 cells (Figure 5-2A), corresponded to similar differences in p-actin. 
Therefore, the observed increase in the unprenylated form of RaplA was not 
due to an increase in protein expression upon statin treatment. There were also 
no changes in p-actin that would allow uneven loading to account for the 
changes observed in unprenylated RaplA.
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In order to investigate whether this detection of unprenylated RaplA was due to 
a specific effect of the statins on the process of prénylation, cells were treated 
with the prenyltransferase inhibitors described in section 5.2. Treatment with 
the GGT-I inhibitor GGTI-2133 resulted in observation of unprenylated RaplA in 
all cell types (Figure 5-3).
RaplA
Rapi
3-actin
Huh7 RD-U RD-D
F Gl G ill F Gl Gill F Gl Gll Inhibitors
Figure 5-3 Effect of prénylation inhibitors on RaplA prénylation
Total protein was extracted from Huh7, RD-U and RD-D cells treated for 48 hours withlOpM 
farnesyltransferase inhibitor FTI-277 (F), lOjiM geranylgeranyltransferase-l inhibitor GGTI-2133 
(Gl) or lOOpM perillyl alcohol (Gll), and 30pg was separated by SDS-PAGE. Western blots are 
representative of three independent experiments.
This was similar to the effect seen with simvastatin and cerivastatin treatment. 
However, treatment with neither the FT inhibitor FTI-277 nor perillyl alcohol 
resulted in any comparable detection of unprenylated RaplA. Since specifically 
inhibiting GGT-I has the same effect as statin treatment, this supports the idea 
that statins are having an inhibitory effect on protein prénylation and confirms 
that RaplA is a GGT-I substrate.
5.3.1.1 Dose-Dependent Effects of Statin Treatment on RaplA Prenvlation
Since treatment with lOpM simvastatin and IpM cerivastatin treatment resulted 
in a similar increase in unprenylated RaplA in all cell types, the dose- 
dependent effects of simvastatin and cerivastatin on RaplA prénylation were 
examined. For this, concentrations were chosen from across the range of the 
dose-response curves (Figure 4-2). The greatest effects on treatment with 
30pM of these statins, the highest concentration used in this analysis, 
previously led to the reduction of cell viability to 60% in Huh7 cells, 23% in RD- 
U cells and 39% in RD-D cells; where 100% was defined as cell viability on 
treatment with vehicle control.
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On simvastatin treatment, there was a dose-dependent increase in the inhibition 
of RaplA prénylation in all cell types (Figure 5-4), with unprenylated RaplA 
observed at all concentrations equal to or greater than 10pM simvastatin in 
Huh7 cells (Figure 5-4A); in both RD-U and RD-D cells unprenylated RaplA 
was evident for all concentrations equal to or greater than 1pM (Figure 5-4B 
and 0). Hence, in this model, disruption of RaplA prénylation occurs at a 10- 
fold lower concentration in muscle than in liver following simvastatin treatment.
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Figure 5-4 Effect of simvastatin treatment on RaplA prénylation
Total protein was extracted from cells treated for 48 hours with vehicle control (DMSO) or a 
range of simvastatin concentrations and 15pg was separated by SDS-PAGE. The level of 
unprenylated RaplA (21kDa) was detected in Huh7 (A), RD-U (B) and RD-D (C) cells using a 
specific antibody, and compared to the levels of total Rapi and of the loading control, 3-actin. 
Protein size was determined by comparison to a coloured protein marker.
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On cerivastatin treatment, there was likewise a dose-dependent decrease in 
RaplA prénylation (Figure 5-5). Prénylation of RaplA was also inhibited at 10- 
fold lower concentrations of cerivastatin than simvastatin, with some 
unprenylated RaplA being observed even with concentrations of cerivastatin as 
low as 0.1 pM in all cell types. Cerivastatin seemed to also have a greater effect 
on the disruption of prénylation in muscle compared to liver, although the 
difference was only 3-fold compared to the previously observed 10-fold 
difference in sensitivity to simvastatin.
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Figure 5-5: Effect of cerivastatin treatment on RaplA prénylation
Total protein was extracted from cells treated for 48 hours with vehicle control (DMSO) or a 
range of cerivastatin concentrations and 15[ig was separated by SDS-PAGE. The level of 
unprenylated RaplA (21kDa) was detected in Huh7 (A), RD-U (B) and RD-D (C) cells using a 
specific antibody, and compared to the levels of total Rapi and of the loading control, 3-actin.
Overall, both simvastatin and cerivastatin showed a dose-dependent inhibition 
of RaplA prénylation. However, cerivastatin showed effects at lower 
concentrations than simvastatin, and prénylation was inhibited a lower 
concentrations in muscle compared to liver, in this model. The observation of
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greater sensitivity to disruption of prénylation in muscle compared to liver further 
supports a mechanism where disruption of intermediates in the mevalonate 
pathway is indeed a cause of statin-induced muscle toxicity.
5.3.2 H-Ras
In order to examine whether statin treatment had similar effects on the 
prénylation of other small GTPases, further western blot analysis was 
undertaken. These subsequent analyses were carried out using membrane and 
cytosolic protein extracts (section 2.2.3.2), rather than total protein extracts as, 
unlike the RaplA antibody used, the other antibodies did not directly distinguish 
between prenylated and unprenylated forms of the protein. Since, under normal 
conditions, GTPases are anchored to cell membranes by their added prenyl 
groups (Jin et al. 1996), a reduction in prénylation will result in less protein able 
to remain in the membrane and will lead to possible detection in cytosolic 
fractions. Therefore, observing the change in subcellular localisation of the 
protein may be used as an indirect measure of the inhibition of prénylation by 
statins (Blanco-Colio et al. 2002; Casey et al. 1989; Coxon et al. 2005).
H-Ras is one of four classical Ras proteins which, along with N-Ras, K-Ras4A 
and K-Ras4B, was identified originally as an oncogene (Guo et al. 2005). H- 
Ras acts as a molecular switch; The binding of GTP induces a conformational 
change in the protein, allowing it to then bind to downstream effectors (Castro et 
al. 2005) and initiate protein kinase cascades, such as the MARK (mitogen- 
activated protein kinase) cascade (Matozaki et al. 2000; Vojtek and Der 1998), 
in order to exert its effects on gene transcription, cellular growth and 
differentiation (Keduka et al. 2009). The addition of a farnesyl group to H-Ras 
by FT is essential for its membrane anchoring, and is thereby also essential for 
allowing it to carry out its role in cellular signalling (Dirks and Jones 2006).
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In agreement with this, H-Ras was found almost exclusively in the membrane 
fraction of control cells (Figure 5-6). Cerivastatin treatment resulted in a 
reduction in the amount of H-Ras in the membrane fraction, indicating 
decreased prénylation. This reduction was seen in all cell types, with H-Ras 
being detected in the corresponding cytosolic fractions in Huh7 and RD-D cells. 
This effect of cerivastatin on H-Ras membrane association was largely rescued 
by mevalonic acid co-treatment, demonstrating this to be a specific impact on 
the mevalonate pathway.
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Figure 5-6 Effect of statin treatment on membrane association of H-Ras
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with vehicle control, statin, or mevalonic acid in addition to statin, and 4pg was 
separated by SDS-PAGE. Simvastatin and pravastatin were used at a concentration of 10pM 
and cerivastatin at 1pM. DMSO was used as a vehicle control for simvastatin and water for 
cerivastatin (and pravastatin). Mevalonic acid was used in excess, at 100|iM. The level of H- 
Ras (21kDa) in each fraction was detected in Huh7 (A), RD-U (B) and RD-D (C) cells using a 
specific antibody. Protein size was determined by comparison to a coloured protein marker.
In contrast, treatment with pravastatin had no effect on the subcellular 
localisation of H-Ras in any of the cell types, and the only apparent reduction of 
membrane-associated H-Ras due to simvastatin treatment was in Huh7 cells 
co-treated with mevalonic acid. The latter was surprising, since previously the 
addition of mevalonic acid rescued the effect of statins; it is possible that this
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could be an artefact arising from a problem with this section of the original gel or 
membrane, which may be clarified by further analysis of this membrane.
Since treatment with cerivastatin resulted in a change in H-Ras localisation in all 
cells, cells were treated with prenyltransferase inhibitors to see if this would lead 
to similar changes. As expected, there was a reduction in H-Ras observed in 
the membrane fraction of RD-U and RD-D cells treated with the FT inhibitor FTI- 
277 (Figure 5-7), providing evidence that the changes in H-Ras localisation 
observed in muscle cells on statin treatment are due to inhibition of 
farnesylation. Interestingly, in Huh7 liver cells a reduction in membrane 
associated H-Ras was observed on treatment with geranylgeranyltransferase 
inhibitor GGTI-2133 and not with FTI-277, as in RD cells.
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Figure 5-7 Effect of prénylation inhibitors on membrane association of H-Ras
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with 10pM farnesyltransferase inhibitor FTI-277 (F), 10|iM
geranylgeranyltransferase-l inhibitor GGTI-2133 (Gl) or lOOpM perillyl alcohol (Gll) and 4pg 
was separated by SDS-PAGE. The level of H-Ras (21kDa) in each fraction was detected using 
a specific antibody.
In general, inhibition of prénylation resulted in a decrease of membrane- 
associated H-Ras, an effect also observed in all cell types upon cerivastatin 
treatment. Therefore, it can be inferred that cerivastatin has an effect on the 
prénylation of the small GTPase H-Ras in addition to that of RaplA.
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5.3.3 M-Ras
M-Ras (also known as R-Ras3 due to its similarities to R-Ras and R-Ras2 
(Ehrhardt et al. 1999)) is one of the more recently described members of the 
Ras subfamily of GTPases, having been originally cloned from the cDNA 
libraries of mouse skeletal muscle and rat brain. It was initially thought that the 
expression of this 29kDa protein was restricted to brain, muscle and heart 
(Kimmelman et al. 1997; Matsumoto et al. 1997). However, it has since been 
shown that its expression is actually much more widespread, including spleen, 
thymus, liver, lung, pancreas, placenta, skin, kidney, fibroblasts, hematopoietic 
and epithelial cells (Ehrhardt et al. 1999) as well as MCF-7 breast, HeLa 
cervical and LNCaP prostate cancer cell lines (Castro et al. 2011). M-Ras 
shows 47% identity with H-Ras (Ehrhardt et al. 1999) and they share many 
upstream regulators and downstream effectors. Nevertheless, M-Ras has 
several distinctive effectors, for example RA-GEF-2 and MR-GEF (Guo et al.
2005), and M-Ras is thought to have evolved independently of H-Ras and other 
members of the Ras family (Keduka et al. 2009). It is thought that M-Ras, 
unlike H-Ras, is a substrate of GGT-I (Kimmelman et al. 1997; Matsumoto et al.
1997).
The western blot analysis of M-Ras is not as clear as those western blots 
looking at H-Ras expression, due to the quality of the available antibody. 
However, it is still evident that M-Ras is found in the prenylated, membrane- 
bound form under normal conditions (Figure 5-8). It is also clear that there is a 
decrease in the amount of M-Ras in the membrane of RD-U cells (Figure 5-8B), 
along with a concomitant increase in M-Ras in the cytosol of RD-D (Figure 
5-80) on cerivastatin treatment, as is also the case with H-Ras (Figure 5-6). 
These effects were rescued on co-treatment with mevalonic acid. It is unclear 
as to whether this occurs in Huh7 cells; however a repeat experiment, perhaps 
with an alternative antibody, would clarify this.
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Figure 5-8 Effect of statin treatment on membrane association of M-Ras
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with vehicle control, statin, or mevalonic acid in addition to statin, and 4pg was 
separated by SDS-PAGE. Simvastatin and pravastatin were used at a concentration of 10jiM 
and cerivastatin at IpM. DMSO was used as a vehicle control for simvastatin and water for 
cerivastatin and pravastatin. Mevalonic acid was used in excess, at 100pM. The level of M-Ras 
(29kDa) in each fraction was detected in Huh7 (A), RD-U (B) and RD-D (C) cells using a specific 
antibody. Protein size was determined by comparison to a coloured protein marker.
There also appears to be an increase in M-Ras observed in the cytosol of all 
cells on treatment with the GGT-I inhibitor GGTI-2133 but not with the FT 
inhibitor FTI-277 (Figure 5-9). This would seem to confirm the predictions that 
M-Ras is a substrate of GGT-I and again shows statin treatment to have a 
similar effect to direct inhibition of protein prénylation.
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Figure 5-9 Effect of prénylation inhibitors on membrane association of M-Ras
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with 10pM simvastatin, lOpM farnesyltransferase inhibitor FTI-277 (F) or lOpM 
geranylgeranyltransferase-l inhibitor GGTI-2133 (Gl), and 4pg was separated by SDS-PAGE. 
The level of M-Ras (29kDa) in each fraction was detected using a specific antibody.
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5.3.4 Rab1A
Rab1 is a 25kDa small GTPase important in the secretory pathway for 
regulating vesicle traffic from the endoplasmic reticulum (ER) to the Golgi- 
apparatus, as well as intra-Golgi traffic. Rab1 is found in all cell types (Leung et 
al. 2006), including the liver (Jin et al. 1996) and skeletal muscle (Bao et al.
1998). It has been reported that Rabi is one of the forms of Rab most 
susceptible to depletion of GGPP (Tanaka et al. 2010) and recently it has been 
shown that inactivation of Rabi may play an important role in fluvastatin toxicity 
in rat myofibres (Sakamoto et al. 2011; Tanaka et al. 2010). There are two 
different isoforms of Rabi, RablA and RabIB, which share 92% identity and 
are thought to be functionally interchangeable (Nuoffer et al. 1994). RablA is 
the predominant isoform in human skeletal muscle, and so was chosen here as 
a representative GGT-II substrate.
Western blot analysis showed two distinct bands in the cytosolic fractions of 
Huh7 and RD-D cells and more faintly in all membrane fractions (Figure 5-10). 
It could be that these correspond to differently processed forms of the RablA 
protein, with resulting differences in molecular weight, or it could be that the 
higher molecular weight band represents non-specific binding of the antibody, 
with RablA being represented solely by the lower molecular weight band in 
these samples.
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Figure 5-10 Effect of statin treatment on membrane association of RablA
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with vehicle control, statin, or mevalonic acid in addition to statin, and 4pg was 
separated by SDS-PAGE. Simvastatin and pravastatin were used at a concentration of lOpM 
and cerivastatin at IpM. DMSO was used as a vehicle control for simvastatin and water for 
cerivastatin and pravastatin. Mevalonic acid was used in excess, at 100pM. The level of 
RablA (25kDa) in each fraction was detected in Huh7 (A), RD-U (B) and RD-D (0) cells using a 
specific antibody. Approximate location of the relevant section of the coloured protein marker is 
shown.
Treatment with cerivastatin, but not simvastatin or pravastatin, resulted in a 
decrease in the amount of the lower molecular weight protein observed in the 
membrane fractions of all cells (Figure 5-10), which is similar to the effects of 
the statin on membrane association of H-Ras (Figure 5-6) and M-Ras (Figure 
5-8). This lower molecular weight protein was detected in cytosolic fractions 
only from Huh7 (Figure 5-1OA) and RD-D (Figure 5-1OC) cells treated with 
cerivastatin and from RD-D (Figure 5-1 OC) cells treated with simvastatin.
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There also seems to be less RablA in the membrane fraction from Huh7 cells 
treated with simvastatin and mevalonic acid. This effect is the same as that 
seen when these same PVDF membranes were analysed for H-Ras expression 
(Figure 5-6). This is further indication that there may have been problems with 
the original protein loading or with the processing of this particular area of the 
PVDF membrane.
Treatment with perillyl alcohol, to inhibit both GGT-I and GGT-II, resulted in a 
lower amount of RablA observed in the membrane fraction from RD-U cells 
(Figure 5-11). However, it seems that this effect was observed to an even 
greater extent on inhibition of FT in RD-U and RD-D cells, and on inhibition of 
GGT-I in Huh7 cells. This pattern of reduced membrane-association seems to 
be the same as when the same samples were analysed for localisation of H- 
Ras on treatment with prenyltransferase inhibitors (Figure 5-7), despite the fact 
that H-Ras and RablA are reported to be prenylated by different 
prenyltransferase enzymes. This is surprising, and could indicate that either the 
prenyltransferase enzymes, or these prenyltransferase inhibitors, are not as 
specific under all conditions as traditionally thought.
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Figure 5-11 Effect of prénylation inhibitors on membrane association of RablA
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with lOpM farnesyltransferase inhibitor FTI-277 (F), 10pM
geranylgeranyltransferase-l inhibitor GGTI-2133 (Gl) or lOOpM perillyl alcohol (Gll), and 4pg 
was separated by SDS-PAGE. The level of RablA (25kDa) in each fraction was detected. 
Approximate location of the relevant section of the coloured protein marker is shown.
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Another interesting point to note is that neither of the two molecular weight 
bands can be observed in the cytosolic fractions of cells treated with the 
prenyltransferase inhibitors, and only the lower molecular weight band can be 
observed in membrane fractions. The PVDF membranes with these samples 
were prepared at a later time than the membranes with the samples from statin 
treated cells. It could therefore be that these later western blot analyses are 
showing greater RablA specificity.
In summary, treatment with both cerivastatin and prenyltransferase inhibitors 
led to a reduction in membrane-associated RablA in both muscle and liver 
cells. However, this analysis was complicated by the detection of several 
protein bands, in both the cytosolic and membrane fractions, which could be 
due to non-specific antibody binding.
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5.3.5 Lactate Dehydrogenase (LDH)
In order to assess the quality of the membrane and cytosolic extracts from 
Huh7, RD-U and RD-D cells, the localisation of the cytosolic protein lactate 
dehydrogenase (LDH) was examined by western blot (Figure 5-12 and Figure 
5-13).
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Figure 5-12 Localisation of lactate dehydrogenase (LDH), in response to statin treatment
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with vehicle control, statin, or mevalonic acid in addition to statin, and 4pg was 
separated by SDS-PAGE. Simvastatin and pravastatin were used at a concentration of lOpM 
and cerivastatin at IpM. DMSO was used as a vehicle control for simvastatin and water for 
cerivastatin and pravastatin. Mevalonic acid was used in excess, at lOOpM. The level of LDH 
(35kDa) in each fraction was detected in Huh7 (A), RD-U (B) and RD-D (C) cells.
* Protein sample precipitated and resuspended prior to SDS-PAGE.
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Initially there were problems with the antibody that meant that it was not 
possible to examine LDH using the same membranes as used for previous 
analysis of H-Ras (Figure 5-6 and Figure 5-7), M-Ras (Figure 5-8 and Figure 
5-9) and Rab1A localisation (Figure 5-10 and Figure 5-11). Therefore, a 
second set of protein extracts were generated, separated by SDS-PAGE and 
transferred to PVDF membrane for use in LDH analysis, with the aim of 
subsequently also blotting these membranes for H-Ras, M-Ras and RablA as a 
repeat experiment.
In extracts from all cell types, on control treatment and treatment with both 
statins (Figure 5-12) and prénylation inhibitors (Figure 5-13) a much greater 
amount of LDH was observed in the cytosolic fraction than in the corresponding 
membrane fraction. A small amount of LDH remained in the majority of 
membrane fractions, indicating that the separation of cytosolic and membrane 
proteins achieved by this extraction method was not 100%. This could be 
further examined by analysing the same samples for the presence of proteins 
known to be exclusively found in the membrane, for example membrane 
transporters, but unfortunately time constraints did not allow this in this 
instance.
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Figure 5-13 Localisation of LDH, in response to treatment with prenyltransferase 
inhibitors
Fractions enriched with either cytosolic or membrane protein were extracted from cells treated 
for 48 hours with lOpM farnesyltransferase inhibitor FTI-277 (F), lOpM
geranylgeranyltransferase-l inhibitor GGTI-2133 (Gl) or 100pM perillyl alcohol (Gll), and 4pg 
was separated by SDS-PAGE. The level of LDH (35kDa) in each fraction was detected using a 
specific antibody. * Protein sample precipitated and resuspended prior to SDS-PAGE.
There appears to be some variation in the amount of LDH observed between 
protein samples. This could possibly be explained by the fact that some of the 
RD-U and RD-D samples (denoted * on Figure 5-12 and Figure 5-13)
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underwent protein precipitation and resuspension (section 2.2.3.4) due to the 
extracted protein not being concentrated enough for SDS-PAGE analysis. The 
samples that were not pre-treated in this way seem to show detection of greater 
amounts of LDH.
The difference between the amount of LDH in the cytosolic and membrane 
fractions is enough that any gross changes in subcellular localisation caused by 
reduced prénylation should still be observed using protein extracted using this 
method. However, due to the variability between samples, further analysis of H- 
Ras, M-Ras and Rab1 A was not carried out using these repeat membranes.
5.4 The Effect of Statins on Prenyltransferase Expression
The differences in prénylation observed on statin treatment could be due to 
either a change in the isoprenoids themselves, or in the expression of the 
prenyltransferase enzymes. In addition, it has been suggested that levels of 
prenyltransferase enzymes could vary between cell types, and that this could 
impact upon results observed (All et al. 2010). In order to rule out these 
possibilities, expression of each of the three prenyltransferase enzymes was 
measured, by western blot analysis, before and after treatment with statin or 
prénylation inhibitor.
FT and GGT-I are heterodimers that share a 48kDa a subunit but have different 
P subunits (46kDa and 42kDa respectively). GGT-I I consists of distinct a 
(60kDa) and p (40kDa) subunits. It is thought that the p subunits contain the 
substrate binding sites and that it is these different p subunits which provide the 
different substrate specificities of these enzymes (Casey and Seabra 1996; 
McTaggart 2006). For this reason, it is necessary to use antibodies specific to 
the p subunits rather than the alpha subunits.
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Expression of all three of these enzymes was confirmed in Huh7, RD-U and 
RD-D cells. There was no significant change in expression of FT, GGT-I or 
GGT-II in any of the cell types on treatment with statin alone or in combination 
with mevalonic acid (Figure 5-14 and Figure 5-15). The apparent decrease in 
GGT-lip in RD-U cells on treatment with cerivastatin (Figure 5-15B) 
corresponds to a lower level also of p-actin in this sample, and so is not a real 
effect of cerivastatin. Therefore, the changes in prénylation state of RaplA and 
the change in membrane association of H-Ras, M-Ras or RablA in response to 
statin treatment cannot be explained by alteration in the expression level of the 
prenyltransferase enzymes.
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Figure 5-14 Effect of statin treatment on expression of farnesyltransferase and 
geranylgeranyltransferase-l
Total protein was extracted from cells treated for 48 hours with vehicle control, statin, or 
mevalonic acid in addition to statin, and SOpg was separated by SDS-PAGE. Simvastatin and 
pravastatin were used at a concentration of lOpM and cerivastatin at IpM. DMSO was used as 
a vehicle control for simvastatin and water for cerivastatin and pravastatin. Mevalonic acid was 
used in excess, at lOOpM. Expression of farnesyltransferase (46kDa) and 
geranylgeranyltransferase-l (42kDa) was detected in Huh7 (A), RD-U (B) and RD-D (C) cells 
using specific antibodies, and compared to the level of the loading control, p-actin.
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Figure 5-15 Effect of statin treatment on expression of geranylgeranyltransferase-ll
Total protein was extracted from cells treated for 48 hours with vehicle control, statin, or 
mevalonic acid in addition to statin, and 30pg was separated by SDS-PAGE. Simvastatin and 
pravastatin were used at a concentration of lOpM and cerivastatin at IpM. DMSO was used as 
a vehicle control for simvastatin and water for cerivastatin (and pravastatin). Mevalonic acid 
was used in excess, at lOOpM. Expression of geranylgeranyltransferase-l I (43kDa) was 
detected in Huh7 (A), RD-U (B) and RD-D (C) cells using a specific antibody, and compared to 
the level of the loading control, p-actin.
Similarly, treatment with prenyltransferase inhibitors also did not alter 
expression of FT, GGT-I or GGT-II (Figure 5-16). In addition, this analysis 
shows that there may be slightly higher levels of prenyltransferase expression in 
muscle compared to liver cells, although densitometry would be needed to 
confirm this: Regardless, any differences would not be enough to explain the 
differences in sensitivity to the disruption of prénylation between muscle and 
liver cells observed previously (section 5.3.1.1). To my knowledge, this is the 
first time that the expression levels of these enzymes have been compared 
between liver and muscle.
FTP
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Figure 5-16 Effect of prénylation inhibitors on expression of farnesyltransferase, 
geranylgeranyltransferase-l and geranylgeranyltransferase-ll
Total protein was extracted from Huh7, RD-U and RD-D cells treated for 48 hours with lOpM 
farnesyltransferase inhibitor FTI-277 (F), lOpM geranylgeranyltransferase-l inhibitor GGTI-2133 
(Gl) or lOOpM perillyl alcohol (Gll), and 30pg was separated by SDS-PAGE. Expression of 
farnesyltransferase (46kDa), geranylgeranyltransferase-l (42kDa) and 
geranylgeranyltransferase-ll (43kDa) was detected using specific antibodies, and compared to
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5.5 Discussion
5.5.1 The Significance of Prenyiation
The post-translational modification of proteins by prénylation is of great 
physiological importance, with at least 100 proteins known to require this 
modification in order to carry out their role in a range of cellular processes (Lane 
and Beese 2006). This importance has been highlighted by the abnormalities 
observed in recently generated conditional knockout mice for the p subunits of 
FT (Fntb) and GGT-I (Pggtib), which therefore lack functional FT or GGT-I. 
Keratinocyte-specific Fntb knockout mice survived but developed severe hair 
loss, and cells from these mice could not proliferate in culture, whereas 
keratinocyte-specific Pggtib knockout mice died shortly after birth (Lee et al. 
2010).
The small GTPases represent the largest group of prenylated proteins. They 
are a large class of cell-signalling proteins that have important roles in the 
regulation of cellular proliferation, gene expression, cytoskeleton organisation, 
cell motility and intracellular vesicle trafficking (Cordle et al. 2005; Matozaki et 
al. 2000). Therefore, disruption of the prénylation of small GTPases can have 
wide-ranging physiological consequences, and has been postulated to play a 
role in statin-induced myopathy.
5.5.2 Prenyiation and the Statins
There is a growing body of evidence supporting the idea that statins can disrupt 
prenyiation of small GTPases, resulting in the disruption of normal cellular 
signalling. Such evidence includes the observation that inhibition of GGT-I and 
II, with perillyl alcohol treatment, has been shown to mimic the effect of 
fluvastatin on isolated rat skeletal myofibres, with these effects being rescued 
by co-addition of GGPP (Sakamoto et al. 2007). Treatment of rat skeletal 
myoblasts with cerivastatin has been shown to result in the activation and 
detachment of membrane-bound Ras, leading to apoptosis (Matzno et al.
2005). Statins have been shown to induce apoptosis in vitro in a range of 
different cells (Dirks and Jones 2006); for example, treatment of rat vascular 
smooth muscle cells with atorvastatin or simvastatin in vitro resulted in
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apoptosis that could only be rescued by addition of mevalonate, FPP or GGPP 
(Blanco-Colio et al. 2002).
However, much of the previous research has been carried out only in muscle 
and often in non-human tissue. It is therefore important to ensure that these 
effects are similarly observed in human cells. The analysis here also aimed to 
compare the effects in liver (the target tissue) with muscle (the main site of 
toxicity) across a range of statins, as it is thought that any differences observed 
between the responses of muscle and liver may give us further insight into the 
mechanism of statin muscle toxicity (Mullen et al. 2010). The hypothesis to be 
tested was that prenyiation, postulated to play a role in statin-induced 
myopathy, would show preferential disruption in muscle compared to liver.
5.5.2.1 Membrane Association of Small GTPases
The results described in this chapter confirm that statin treatment does have an 
effect on the prenyiation of small GTPases in both human liver and muscle 
cells. On cerivastatin treatment, detection of the FT substrate H-Ras, GGT-I 
substrate M-Ras and the GGT-II substrate RablA in the membrane protein 
fraction was greatly reduced in both human muscle and liver cells. Since 
prenyiation is vital for the membrane association of small GTPases, this change 
in subcellular localisation indicated a reduction in prenyiation.
In some cases, the reduced membrane-association was accompanied by 
detection of the protein in the corresponding cytosolic fractions, which could 
sometimes also be seen with simvastatin treatment. It is interesting that this 
corresponding cytosolic increase was not observed in all instances. It could 
perhaps be that the unprenylated protein is targeted for degradation, which 
would explain why it could not always be detected.
It is also interesting to note that these effects on prenyiation were only observed 
on treatment with lipophilic cerivastatin or simvastatin. Treatment with 
hydrophilic pravastatin, which was previously shown to elicit lower levels of 
toxicity (section 4.2), did not lead to a reduction in membrane-association under 
the conditions used.
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Since the reduction in membrane-associated (i.e. prenylated) proteins was 
observed both in liver and muscle cells, it would be beneficial to further dissect 
this inhibition of H-Ras, M-Ras and RablA prenyiation. This could be achieved 
through the extraction of cytosolic and membrane protein from cells treated with 
a range of simvastatin and cerivastatin doses, as was previously carried out 
during the examination of Rap1A prenyiation using total protein extracts 
(section 5.3.1.1).
A limitation of this data is the lack of complete confidence in the quality of 
cytosolic and membrane separation in those samples used to look at H-Ras, M- 
Ras and RablA localisation, in terms of the degree of separation obtained. 
LDH is exclusively a cytosolic protein (Saad et al. 2006), and so the amount of 
the protein present in cytosolic, compared to membrane, extracts was examined 
to act as a control and give an indication of the degree of separation achieved 
by the extraction process used. However, the results obtained were 
inconclusive due to variations within the particular set of protein samples used 
in this analysis (Figure 5-12 and Figure 5-13). This was likely the result of the 
protein concentration, by precipitation and resuspension in a smaller amount of 
solvent, in a number of these samples prior to analysis. The protein was 
resuspended in sodium hydroxide, which allowed for the determination of final 
protein concentration using the Lowry method but was later found to interfere 
with SDS-PAGE. This meant that the sodium hydroxide needed to be 
neutralised prior to analysis (section 2.2.3.4), which may have affected the 
subsequent separation of proteins by gel electrophoresis. A repeat analysis of 
LDH localisation, using samples that had not been pre-treated in this way or 
had been resuspended in a solvent other than sodium hydroxide, may rectify 
this. Time did not allow in this case, however it would be beneficial to also 
analyse the localisation of a membrane protein in the different protein fractions. 
This could include the analysis of a membrane-specific protein, such as 
calnexin (Spindler et al. 2012), which has been shown not to be affected by 
statin treatment (Ostrowski et al. 2007). Finally, measurement of the 
expression level of the membrane transporter 0ATP2B1 would be beneficial, as 
it is known to be expressed in both liver and skeletal muscle (Knauer et al.
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2010) and is responsible for the uptake of hydrophilic statins into cells (section 
1.14).
S.5.2.2 Differential Disruption of Prenyiation
In addition to the effect on small GTPase localisation, a direct effect was 
observed on the prenyiation of the Ras-related GTPase RaplA through the use 
of two antibodies able to detect the unprenylated form of the protein or total 
protein expression respectively. Unprenylated RaplA was detected in both liver 
and muscle following simvastatin and cerivastatin treatment. This inhibition of 
RaplA prenyiation was dose-dependent in both cases with all cells showing 
much greater sensitivity to cerivastatin than simvastatin, with lower cerivastatin 
concentrations required to produce detectable levels of unprenylated RaplA.
The differences between the responses to simvastatin and cerivastatin 
treatment are unlikely to be dependent on differential uptake of the two statins. 
These are two of the most lipophilic statins, and they both show distribution to 
non-target tissues via passive diffusion. They are also both substrates of 
0ATP1B1 (section 1.1.4), a transporter predominantly found in the liver which 
plays an important role in the hepatic uptake of statins (Shitara and Sugiyama
2006).
RD muscle cells were more sensitive to treatment with both simvastatin and 
cerivastatin compared to Huh7 liver cells, with a much lower statin 
concentration needed to detect unprenylated RaplA in muscle. This finding 
supports the hypothesis, that statin treatment does lead to both greater toxicity 
and preferential disruption of protein prenyiation within muscle cells.
It is unlikely that this difference between muscle and liver is due to increased 
statin metabolism in Huh7 liver cells. The liver is the main site of xenobiotic 
metabolism in vivo (Caldwell et al. 1995), however it has been shown that in 
vitro Huh7 liver cells express very low levels of drug metabolising enzymes 
(Phillips et al. 2005). This could mean that the differential effect seen between 
muscle and liver in vivo may be even greater.
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5.5.2.3 Prenyltransferase Inhibitors
Treatment of cells with prenyltransferase inhibitors resulted in disruption of 
protein prenyiation, as observed through detection of unprenylated RaplA and 
reduction of H-Ras, M-Ras and RablA found in membrane protein fractions. 
This was similar to effects seen with simvastatin and cerivastatin treatment in 
these experiments, and agrees with previous findings of similar effects of statin 
and prenyiation inhibitor treatment in other models (Cao et al. 2009; Sakamoto 
et al. 2007; Wagner et al. 2011). This supports the idea that statins are 
affecting the process of protein prenyiation.
Treatment with the GGT-I inhibitor GGTI-2133 resulted in observation of 
unprenylated GGT-I substrate RaplA in all cell types (Figure 5-3). However, it 
is surprising that although H-Ras and RablA are reported to be substrates of 
different prenyltransferase enzymes (FT and GGT-II respectively), on treatment 
with prenyltransferase inhibitors the pattern of their reduced membrane- 
association was similar. For both small GTPases, treatment with GGTI-2133 
resulted in loss of membrane association in Huh7 liver cells, but in RD muscle 
cells this was observed on treatment with the FT inhibitor FTI-277.
Under normal conditions H-Ras is reputed to undergo farnesylation by FT. 
However, it is known that K- and N-Ras proteins are alternately prenylated by 
GGT-I in the human colon carcinoma cell line DLD-1 on treatment with FT 
inhibitors (Whyte et al. 1997). It is perhaps possible that when FT is inhibited in 
vitro in liver cells then H-Ras can similarly be alternately prenylated by GGT-I. 
This would explain why treatment of Huh7 cells with FTI-277 did not result in a 
decrease in membrane-associated H-Ras. In addition, GGTI-2133 can also 
inhibit FT, as described previously (section 5.2), but with lower potency than for 
GGT-I inhibition. The IC50 for GTI-2133 inhibition of FT is reported to be 5.4pM 
(Sigma-Aldrich 2011b), and hence the lOpM inhibitor concentration used herein 
should result in approximately 65% inhibition of activity. Therefore, the 
observed reduction of membrane-associated H-Ras on treatment of Huh7 cells 
with lOpM GTI-2133 is likely to be due to its inhibition of FT at this 
concentration, although this does not explain why this effect is seen in liver cells
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and not also in muscle cells. Another possibility is that the FT inhibitor used 
here is inhibiting GGT-II in the RD cell line, as has been previously observed in 
Caenorhabditis elegans (Lackner et al. 2005; McTaggart 2006). This would 
explain the reduction in RablA membrane-association in RD cells treated with 
FT inhibitor. Perhaps the similar expression profiles of H-Ras and RablA 
indicate that either the prenyltransferase enzymes, or these prenyltransferase 
inhibitors, are not as specific under all conditions as traditionally thought.
Future repeat experiments, perhaps with a range of lower inhibitor 
concentrations, would help to investigate these discrepancies and also help to 
rule out any possibility of having mixed up samples. Lower concentrations of 
GGTI-2133 will be less likely to have a possible effect on prenyiation by FT, 
(IC50 5.4pM) but will still inhibit GGT-I (IC50 38nM) (Sigma-Aldrich 2011b). 
Similarly, the use of lower concentrations of FTI-277 may help to clarity whether 
or not FTI-277 inhibition of GGT-II was the reason for observing loss of 
membrane association of RablA in muscle on treatment with this inhibitor.
5.5.3 Prenyltransferase Expression
No change in the expression levels of any of the 3 prenyltransferase enzymes 
was observed, in either liver or muscle cells, in response to treatment with 
statins or prenyltransferase inhibitors. If any of these enzymes are upregulated 
or down regulated in response to statin inhibition of prenyiation, then it would be 
expected to have occurred after the given treatment time of 48hours. The fact 
that no change was observed after this time excludes this as an explanation of 
the effects of statin treatment on prenyiation or as an explanation of the 
differences between the responses to simvastatin and cerivastatin. There were 
also no differences in enzyme levels between the cell types that would account 
for the different sensitivities of liver and muscle to disruption of protein 
prenyiation. Therefore, several alternative explanations for this differential 
sensitivity will be discussed in the final chapter.
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5.6 Summary
The post-translational modification of small GTPases by prenyiation plays a vital 
role in enabling their membrane localisation in order to carry out their varied 
roles in cellular signalling. It is thought that statins inhibit not only the 
production of cholesterol but also the production of the isoprenoids FPP and 
GGPP which are used to prenylate proteins. It has therefore been suggested 
that statins inhibit the prenyiation of proteins and that this is an important 
contributing factor in the development of statin-induced muscle toxicity.
The results presented here confirm that treatment with both simvastatin and 
cerivastatin does inhibit the prenyiation of a range of small GTPases in both 
human liver and muscle in a similar way to the inhibition of prenyiation observed 
on treatment with prenyltransferase inhibitors.
The inhibition of prenyiation of RaplA, a Ras-related GTPase, was more 
sensitive to treatment with cerivastatin than simvastatin in both muscle and 
liver. Inhibition of RaplA prenyiation was also more sensitive to statin 
treatment in muscle (the tissue where the most toxicity is observed) than in liver 
(the target tissue). These effects could not be explained by changes in total 
protein expression. This supports my hypothesis, that statin treatment does 
lead to both greater toxicity and preferential disruption of protein prenyiation 
within muscle cells.
There was no change observed in expression of any of the three 
prenyltransferase enzymes in liver or muscle in response to treatment with 
statins or prenyiation inhibitors. The changes in prenyiation status of RaplA, or 
any of the other small GTPases examined, therefore cannot be explained by 
changes in enzyme expression.
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6 Discussion
The physiological consequences of xenobiotic intervention are often complex. 
A drug frequently has many effects in addition to the intended ones. These can 
either benefit the patient or can lead to adverse drug reactions, depending on 
the treatment context and on the individual patient. This highlights the ever 
increasing need to understand the in-depth mechanisms of drug action, in order 
to improve patient treatment both through enabling the best used of established 
medication as well as directing the future design of new drugs.
The statins are an important class of drugs used to treat hypercholesterolaemia 
for the primary and secondary prevention of cardiovascular disease, currently 
the leading cause of death worldwide. They are widely used, with their use 
continually increasing, however a small percentage of patients experience drug 
side effects; the most significant of these is myopathy, which can range from the 
muscle aches or weakness of myalgia to the more serious condition of 
rhabdomyolysis (Harper and Jacobson 2007). In addition to the obvious 
adverse effects for the patients myopathy is also considered a leading cause of 
the high statin discontinuation rates (Bakhai et al. 2012), and therefore it is 
important to understand the mechanism of this myopathy to enable better 
management of statin treatment. It is currently thought that myopathy occurs 
due to the secondary effects resulting from statin inhibition of 3-hydroxy-3- 
methylglutaryl coenzyme A reductase (HMGCR), the rate limiting enzyme in 
cholesterol biosynthesis and the mevalonate pathway (Shitara and Sugiyama
2006). By inhibiting this enzyme, statin treatment lowers cholesterol in the form 
of low-density lipoprotein (LDL) but can also disrupt other aspects of the 
mevalonate pathway, such as protein prenyiation. It is this disruption of protein 
prenyiation that has been postulated to play a particular role in statin-induced 
myopathy, however the mechanism has not yet been fully elucidated (Vaklavas 
et al. 2009).
The aim of this study was to use two human cell lines as an in vitro model for 
comparing the effects of statins on both cholesterol synthesis and protein
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prenyiation between the liver, the intended target tissue for therapeutic benefit, 
and skeletal muscle, the major site of toxicity.
6.1 In Vitro Modelling of Statin-Induced Toxicity
Initially, the suitability of the RD rhabdomyosarcoma skeletal muscle cell line for 
use in this model system was determined (section 3.2). The morphological and 
molecular changes that occur during the differentiation process of these cells 
were examined. RD cells were found to express a number of muscle-specific 
markers, including the muscle-specific transcription factor myogenin and myosin 
heavy chain 3, as well as a number of other genes of interest such as HMGCR 
and the LDL receptor. On the basis of this investigation, a cell differentiation 
period of 5 days was chosen for use in later experiments.
The original hypothesis to then be tested was that the process of protein 
prenyiation exhibits circadian variation, as has already been shown for
cholesterol biosynthesis, and that this might enable temporal separation
between the cholesterol-lowering efficacy and the toxicity of statins. However, 
being unable to verify the ability of the RD cell line to establish and maintain a 
circadian cycle in vitro (section 3.3), the project took a slightly different direction, 
whilst still focusing on examining the differences between the responses of liver 
and muscle to statin treatment.
In order to investigate any such differences, a number of parameters were 
examined. MTT assays were carried out in order to examine the cell toxicity
response of Huh7 liver and RD muscle cells to treatment with a range of statins
(section 4.2). Significant reductions in cell viability were observed in all cells on 
statin treatment, with greater toxicity observed in response to treatment with 
more lipophilic statins, such as simvastatin, lovastatin and cerivastatin. Where 
it was possible to determine IC50 values, these were consistent with those 
previously reported by Kobayashi and colleagues using RD cells (Kobayashi et 
al. 2008). Greater toxicity was also observed in RD muscle cells compared to 
Huh7 liver cells on treatment with all statins, with this difference being 
statistically significant for treatment with simvastatin, cerivastatin, atorvastatin 
and rosuvastatin. Previous studies examining the toxicity of the statins have
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tended to either compare the toxicity of a large range of statins in only one 
tissue, such as muscle (Kobayashi et al. 2008), or to compare the responses 
between liver and muscle using only a small number of statins (Mullen et al. 
2010; Mullen et al. 2011). Therefore, since this study both compared responses 
between liver and muscle cell lines and used a large range of different statins, it 
represents the first comprehensive comparative analysis of statin toxicity.
The process of cholesterol synthesis was then investigated in these cells 
(section 4.3). Much lower expression of HMGCR was found, at both the 
transcript and protein level, in RD cells compared to Huh7 cells. This difference 
was particularly evident in differentiated RD cells. Cholesterol was found to be 
present in both Huh7 and RD cells, with lOpM simvastatin and pravastatin 
treatment, and IpM cerivastatin treatment, seeming to lead to a decrease in 
total cellular cholesterol in these cells. This cholesterol decrease was observed 
after 48 hour statin treatment, which agrees with previous observations of a 
cholesterol decrease after 24 and 48 hour treatment of HepG2 cells (Kobayashi 
et al. 2008) but not after 6 or 18 hour treatment of HepG2 cells and C2C12 
mouse myoblasts (Mullen et al. 2010).
Having characterised the response of Huh7 and RD cells to statin treatment, in 
terms of cell viability and changes in cholesterol levels, experiments were 
designed to test the hypothesis that statins preferentially disrupt the process of 
protein prenyiation within RD muscle cells (chapter 5), the site of greater 
toxicity. Huh7 and RD cells were treated with simvastatin, cerivastatin and 
pravastatin, mevalonic acid in addition to statin, or prenyiation inhibitors. 
Protein was extracted and then subjected to analysis by western blot to detect 
any changes in the prenyiation status of selected small GTPases. Inhibition of 
prenyiation was found by directly analysing changes in the unprenylated form of 
RaplA, using a specific antibody, and by examining the reduction in membrane 
association of H-Ras, M-Ras and RablA. Treatment with simvastatin and 
cerivastatin inhibited the prenyiation of RaplA, and frequently seemed to also 
affect the membrane association of the small GTPases H-Ras, M-Ras and 
RablA. These effects could not be explained by changes in total protein 
expression or changes in the expression of the prenyltransferase enzymes.
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In both muscle and liver the inhibition of prenyiation of RaplA, a Ras-related 
GTPase, was more sensitive to treatment with cerivastatin, the statin that was 
withdrawn from the market in 2001 due to high incidence of rhabdomyolysis 
(Bellingham 2001), than simvastatin. Inhibition of RaplA prenyiation in muscle 
cells was also more sensitive to simvastatin and cerivastatin treatment than in 
liver cells (section 5.3.1.1). This supports my hypothesis, that statin treatment 
does lead to both greater toxicity and preferential disruption of protein 
prenyiation within muscle cells and further supports a mechanism where 
disrupting production of intermediates in the mevalonate pathway is indeed a 
cause of statin-induced muscle toxicity.
A question arising from this conclusion is that of why there is this differential 
sensitivity between liver and muscle cells to the inhibition of prenyiation by 
statins. One possible explanation could be that there is a lower background 
level of prenyiation occurring in muscle compared to liver. This is unlikely to be 
due to differences in the levels of the prenyltransferase enzymes, since no large 
differences in expression were observed between the cell types (Figure 5-16); 
although this analysis only examined protein expression and did not investigate 
whether there were differences in prenyltransferase enzyme activity. However, 
the results did reveal a considerable difference in HMGCR expression, at both 
the transcript and the protein level, between Huh7 liver and RD muscle cells 
(section 4.3.1). This implies that there may be a much lower throughput along 
the mevalonate pathway in muscle when compared to liver, the main site of 
cholesterol synthesis (Catapano 2007). In the absence of statin treatment, 
there are sufficient isoprenoids in both liver and muscle cells to ensure 
complete prenyiation of RaplA, as far as can be detected by the western blot 
analysis; but a lower capacity of the mevalonate pathway could lead to a 
smaller resting pool of the isoprenoids FPP and GGPP within muscle and would 
mean that less inhibition of this pathway would be required before the effects on 
prenyiation would be seen in this tissue. In order to examine this as a 
possibility, it would be interesting to measure and compare the levels of FPP 
and GGPP, under resting conditions, in both liver and muscle, initially in the cell 
lines that were used here. This could be achieved by using a combination of 
HPLC (high performance liquid chromatography) and LC-MS (liquid
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chromatography -  mass spectrometry)-based techniques (Tong et ai. 2005). 
This method could also be used for looking at the rate at which a range of 
statins decrease this isoprenoid pool in both liver and muscle, both over time 
and on treatment with varying statin concentrations.
6.2 Prenyiation and Muscle Physiology
A second question is how this differential sensitivity of muscle to disruption of 
protein prenyiation could lead to the toxicity seen in muscle. There is the 
possibility that prenyiation, or at least the prenyiation of certain proteins, may be 
more obligate in muscle than in liver. Perhaps there are certain prenylated 
proteins that are more highly expressed in muscle than in liver or are 
particularly crucial for correct muscle function. M-Ras, initially thought to be 
such a target, is now known to be of more widespread importance, and so 
cannot now be included in this category (Ehrhardt et al. 1999). However if such 
targets do exist, and their prenyiation status is affected by statin treatment, then 
they could play an important role in statin muscle toxicity.
In the past, knockout models have frequently been used to elucidate the 
physiological importance of a target protein or pathway; however knowledge 
gained in this way regarding protein prenyiation remains limited. Recently, 
several conditional knockouts of prenyltransferase enzymes have been 
generated and studied, which is starting to fill this gap in knowledge: 
Conditional knockout of the p subunit of FT in mouse kératinocytes led to 
development of severe hair loss and an inability of these cells to proliferate in 
culture, whereas knockout of the GGT-I p subunit led to the death of mice 
shortly after birth (Lee et al. 2010), highlighting the essential role of protein 
prenyiation. Similar deficiencies in either FT or GGT-I in hepatocytes led to 
elevated plasma transaminases and abnormal histology of livers from the 
knockout mice, with FT knockout mice also growing slower than wild-type mice 
and GGT-I knockout mice showing reduced survival (Yang et al. 2012). In 
addition, conditional knockout of GGT-I has been shown to lead to 
hyperactivated mouse macrophages, which secreted inflammatory cytokines 
and induced an inflammatory response (Khan et al. 2011; Philips 2011). Other 
recently generated models include the conditional knockout of GGT-I in mouse
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haematopoietic cells (Sjogren et al. 2011), knockdown of prenyltransferase 
enzymes in zebrafish embryos (Cao et al. 2009), knockout mouse models of 
several Rho family GTPases (Heasman and Ridley 2008; Ueda et al. 2010) and 
mouse knockout of the skeletal muscle-specific G protein a subunit (Chen et al. 
2009a). Further study, particularly of these latter models, as well as the 
generation of muscle-specific conditional prenyltransferase knockout or 
knockdown models, may assist in the elucidation of the specific role of protein 
prenyiation in muscle.
Meanwhile, in order to link the molecular disruption caused by statins to muscle 
toxicity we can gain clues through alternative in vitro studies, in many of which 
statin treatment has been linked with the apoptosis of muscle fibres, and 
through the identification of syndromes which are associated with muscle 
disease (reviewed by (Baker 2005)). Many such studies have been described 
in previous chapters but some of these findings, and the resulting proposed 
links between statin treatment and muscular effects, are now summarised in 
Figure 6-1.
Statin treatment has been shown to affect many aspects of the mevalonate 
pathway in vitro, which in turn has the potential to affect a wide range of cellular 
processes (Figure 6-1). Statins have been shown to cause a reduction in 
isopentylation of sec tRNA and therefore reduce selenoprotein synthesis 
(Warner et al. 2000). There are approximately 25 human selenoproteins, but 
out of these selenoprotein N (Jurynec et al. 2008; Petit et al. 2003) and 
glutathione peroxidase (Kromer and Moosmann 2009) have been identified as 
having a potential role in linking the statins to effects on muscle physiology. 
Statin treatment has reduced synthesis of dolichol and thereby disrupted N- 
linked glycosylation (Mullen et al. 2010; Siddals et al. 2004) of proteins known 
to have an important role in normal muscle function (Barton et al. 2012). Statins 
have also been shown to disrupt the process of protein prenyiation (Sakamoto 
et al. 2011), through either farnesylation or geranylgeranylation, which is known 
to affect cellular signalling via small GTPases and lead to muscle cell apoptosis 
(Blanco-Colio et al. 2002; Matzno et al. 2005).
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There are therefore many potential explanations for statin myopathy; however one 
pathway that has been emerging in recent years as having a particularly important 
role is the phosphatidylinositol 3-kinase (PI3K) - Akt signalling pathway. Insulin­
like growth factor 1 (IGF-1) signalling, via this pathway, is known to have an 
important role in the regulation of skeletal muscle growth (Schiaffino and 
Mammucari 2011) but this signalling can be suppressed by the statins (Siddals et 
al. 2004). In addition, simvastatin treatment has been shown to lead to 
dephosphorylation of Akt in C2C12 mouse myotubes, but not in HepG2 liver cells, 
and co-treatment with simvastatin and IGF-1 has been able to rescue C2C12 
myotubes from apoptosis (Mullen et al. 2011). Suppression of normal signalling 
through the PI3K-Akt pathway leads to the expression of the muscle specific Skpl- 
Cul1-F-Box protein (SCF) ubiquitin E3 ligase atrogin-1 (Sacheck et al. 2004) 
through the dephosphorylation, nuclear translocation and activation of the 
transcription factor F0X03 (Sandri et al. 2004); it has now been shown that statin 
treatment can lead to the activation of atrogin-1 through this same pathway of 
F0X03 activation (Cao et al. 2009).
It has been suggested that statins suppress IGF-1 signalling through two 
mechanisms. Firstly, statins have been shown to affect the N-linked glycosylation 
and processing of IGF receptors (Siddals et al. 2004). Incorrectly processed IGF 
receptor could lead to impaired response to IGF growth factors in muscle cells.
Secondly, the inhibition of geranylgeranylation by statins has been shown to 
promote both upregulation of atrogin-1 and muscle damage in mouse myotubes 
and zebrafish, with myoblasts from atrogin-1 knockout mice proving resistant to 
this statin-induced muscle damage. This has led to the suggestion that there may 
be small GTPases that couple statin disruption of prenyiation to the upregulation of 
atrogin-1 and muscle damage (Cao et al. 2009). The small GTPase Rapi, which 
is prenylated by geranylgeranyltransferase-l (GGT-I), has been suggested as an 
attractive candidate for this link (Cao et al. 2009; Mullen et al. 2011). This is 
because it is thought to play a role in IGF-1 signalling, as it can be activated by
148
IGF-1 (Romano et al. 2006) and can then activate PI3K and Akt (Stork 2003; Van 
Kolen et al. 2006; Wang et al. 2001), and its prenyiation can also be disrupted by 
the statins. This is further supported by the recent finding that transient 
transfection of constitutively active Rapi into C2C12 myotubes was able to partially 
rescue simvastatin-induced inhibition of mitochondrial respiration (Mullen et al. 
2011). RaplA, one of two very closely related isoforms of Rapi (Bos 1997; 
Frische and Zwartkruis 2010), showed greater sensitivity to disruption of its 
prenyiation in muscle compared to liver cells in my study (section 5.3.1.1). 
Therefore, the inhibition of Rapi prenyiation as a mechanism by which statins can 
suppress IGF-1 signalling would offer a potential interpretation for the relevance of 
my findings to statin-induced myopathy, however further investigation would be 
required to clarify this.
The suppression of IGF-1 signalling by both of these mechanisms ultimately results 
in the upregulation of atrogin-1, which is known to play an important role in muscle 
atrophy. The importance of atrogin-1 in muscle atrophy was first identified through 
the use of microarray experiments when its expression was found to be strongly 
upregulated in atrophying muscle, with this upregulation being prior to detection of 
muscle weight loss (Gomes et al. 2001). It has since been discovered to both 
stimulate degradation of muscle proteins and inhibit protein synthesis (Wang et al. 
2010a). Potential degradation targets of atrogin-1 in muscle include myogenic 
differentiation 1 (MyoD1), the calcium-dependent phosphatase calcineurin, the 
translation initiation factor elF3-f, and intermediate filament components desmin 
and vimentin (Cao et al. 2009; Lokireddy et al. 2012). Degradation of these 
proteins would affect multiple processes that are essential for muscle cell function; 
such as differentiation of muscle satellite cells and thereby myoregeneration 
(MyoD1, calcineurin) (da Costa et al. 2007; Friday et al. 2000; Megeney and 
Rudnicki 1995); regulation of muscle fibre remodelling (calcineurin) (Bassel-Duby 
and Olson 2006; da Costa et al. 2007); synthesis of new proteins (elF3-f) (Csibi et 
al. 2008); and the integrity of the muscle cytoskeleton (desmin, vimentin) (Favre et 
al. 2011).
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6.3 Additional Future Work
In this study, only the prenyiation of small GTPases in liver and muscle has been 
examined in response to statin treatment; however, there are a number of other 
proteins that have also been proposed to have a role in mediating statin-induced 
muscle toxicity, indicating that multiple pathways may yet be important for this 
adverse effect. Therefore, future work could include similar western blot analysis 
of non-GTPase proteins in liver and muscle that are known to be prenylated and 
whose dysfunction has been implicated in muscular dystrophy, indicating their 
importance in muscle; such proteins would include the nuclear lamins (Lutz et al. 
1992; Wilson 2000). Additional mechanistic insight could be gained through further 
use of enzyme inhibitors and through the use of inhibitory RNA, to clarify whether 
changes in the extent of prenyiation, as measured by western blot analysis, 
translate to an impact upon muscle cell integrity.
It would also be of interest to examine the differences between liver and muscle in 
a wider range of cellular processes, in response to a range of statins. For 
example, defective glycosylation has also been linked to muscular dystrophy 
(Muntoni et al. 2004), and it has previously been shown that simvastatin treatment 
affects N-linked glycosylation in C2G12 mouse myoblasts but not in human HepG2 
liver cells (Mullen et al. 2010). However, it is not known if this would be the case in 
human muscle cells, such as the RD cell line used here, and whether there would 
be any differences between the responses to different statins. There are also 
many specific proteins that have been postulated to play a role in the mechanism 
of muscle toxicity where direct evidence is lacking. Such proteins include the 
glycoprotein dystroglycan and selenoprotein N and further investigation of their 
possible involvement, including differences between liver and muscle, may help to 
further clarify the mechanism of statin-induced muscle toxicity.
Finally, the issue of the contribution of circadian rhythms towards the development 
of statin-induced toxicity, as per my original hypothesis and objectives (section 
1.5), remains an interesting question, albeit one which I was unable to fully
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investigate here due to the limitations of the model system used. Additional future 
work in this area of muscle toxicity could therefore include a return to this initial 
hypothesis using a different model system, such as the mouse C2C12 myoblast 
cell line which, unlike the RD cell line, has previously been used for the analysis of 
the molecular clock in skeletal muscle (Zhang et al. 2012). Furthermore, since 
animal models have previously been used to analyse circadian variations in both 
liver (Akhtar et al. 2002) and skeletal muscle (Almon et al. 2008; McCarthy et al. 
2007) in vivo, they could also be used as a starting point to examine the rhythmicity 
of protein prenyiation in these tissues. The ubiquitous nature of circadian 
regulation, and the implication for xenobiotic toxicity, is increasingly being 
recognised as important (Gachon and Firsov 2011; Ohdo 2010) and therefore it is 
vital that we continue to develop model systems which can be used to investigate 
the potential applications for specific drugs, such as the statins.
6.4 Summary
In summary, this work has shown that, compared to Huh7 liver cells, RD muscle 
cells show both greater sensitivity to the toxic effects of statins and preferential 
disruption of protein prenyiation. This further supports a mechanism whereby 
disrupting production of the intermediates in the cholesterol synthesis pathway, 
including the isoprenoids used in protein prenyiation, is a significant cause of 
statin-induced muscle toxicity. The difference between muscle and liver cell 
responses is not due to a difference in the protein expression levels of the 
prenyltransferase enzymes but may perhaps be due to differences in isoprenoid 
levels, resulting from differences in the protein expression levels of HMGCR 
between the two. Differences in isoprenoid levels are likely to affect a number of 
processes, including protein prenyiation. In particular, the small GTPase RaplA 
showed differential disruption of its prenyiation between muscle and liver in this 
study, which may prove important in the mechanism of statin-induced muscle 
toxicity. This study highlights the importance of examining the effects of drugs at 
both the target site of action and at the site of toxicity, rather than only studying one 
site in isolation, in order to gain insight into the mechanism of adverse drug effects.
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8 Appendices
8.1 Normalisation of Temporal Gene Expression Data from Pilot 
Serum Pulse Experiment
8.1.1 3 T3-L1 Murine Preadipocyte Cell Line
3T3-L12.0-1 GAPDH
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Figure 8-1 Temporal gene expression of two different housekeeping genes in 3T3-L1 cells
3T3-L1 cells were synchronised using a serum pulse (at 1=0) and RNA was extracted at T=0, 14, 
26 and 36. Temporal gene expression of housekeeping genes glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and 18S was measured by quantitative RT-PCR (TaqMan). Data are 
presented as mean ± standard deviation (SD), relative to expression at T=0, from a single 
experiment where N=4.
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Figure 8-2 Effect of normalisation of 3T3-L1 TaqMan data using two different 
housekeeping genes
3T3-L1 cells were synchronised using a serum pulse (at 7=0) and temporal gene expression of 
PER2 and DBP was measured by quantitative RT-PCR (TaqMan). Data are shown 
unnormalised and normalised to GAPDH or 18S expression, and are presented as mean ± 
standard deviation (SD), relative to expression at T=0, from a single experiment where N=4.
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8.1.2 HepG2 and Huh7 Human Liver Cell Lines
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Figure 8-3 Temporal gene expression of three different housekeeping genes in HepG2 and 
Huh7 cells
HepG2 and Huh7 cells were synchronised using a serum pulse (at T=0). RNA was extracted 
from HepG2 cells at 1=0, 14, 26, 36 and from Huh7 cells at 1=0, 12, 18 and 26. Temporal gene 
expression of housekeeping genes GAPDH, 183  and ACTB  was measured by quantitative RT- 
PCR (TaqMan). Data are presented as mean ± standard deviation (SD), relative to expression at 
T=0, from a single experiment where N=4.
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Figure 8-4 Effect of normalisation of HepG2 TaqMan data using three different 
housekeeping genes
HepG2 cells were synchronised using a serum pulse (at T=0) and temporal gene expression of 
PER2 and DBP was measured by quantitative RT-PCR (TaqMan). Data are shown unnormalised 
and normalised to GAPDH, 18S or ACTB expression, and are presented as mean ± standard 
deviation (SD), relative to expression at T=0, from a single experiment where N=4.
183
Huh7
PER2 DBP2.5n
2.0 - 2.0 -
1.5- 1.5-
1.0 1.0
0.5-0.5-
0.0 0.0-I— '— I— '— I— '— I— '— I
12 16 20 24 28 00 4 8 4 8 12 16 20 24 28
2.5-1 2.5-1
2.0 - 2 .0 -
c0
1
1.5- 1.5-
I.Oh
g- ■
UJ 0.5- 
0)
I  «•«■I
>  2.5-1
1.0
0.5-
0.01 ■ 1 ■ I ■ I ‘ 1
12 16 20 24 288 0 4 8 12 16 20 24 280 4
2.5n
2.0-2 .0 -
1.5- 1.5-
1.0 1.0
0.5- 0.5-
0.00.0 -I—'—I—'—I—'—I—'—1
12 16 20 24 280 4 8 0 4 8 12 16 20 24 28
2.5-1
2.0 - 2.0 -
1.5-1.5-
1.0 1.0
0.5- 0.5-
0.0 0.0“I ' 1 ■ I ■ 1 ■ I 1
8 12 16 20 24 28 0 8 12 16 20 24 280 4 4
Time (hours)
Figure 8-5 Effect of normalisation of Huh7 TaqMan data using three different 
housekeeping genes
Huh7 cells were synchronised using a serum pulse (at T=0) and temporal gene expression of 
PER2 and DBP was measured by quantitative RT-PCR (TaqMan). Data are shown unnormalised 
and normalised to GAPDH, 18S or ACTB expression, and are presented as mean ± standard 
deviation (SD), relative to expression at T=0, from a single experiment where N=4.
184
8.2 Additional Normalisations of Temporal Gene Expression Data 
from Circadian Analysis in Huh7 and RD Cells
8.2.1 Normalisation of Temporai Gene Expression Data from Huh7 Ceiis 
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Figure 8-6 Effect of normalisation of Huh7 TaqMan data {PERI and REV-ERBa) using two 
different housekeeping genes
Huh7 cells were synchronised using a serum pulse (at T=0) and temporal gene expression of 
PER1 and REV-ERBa was measured by quantitative RT-PCR (TaqMan). Data are shown 
unnormalised and normaiised to 18S or ACTB expression, and are presented as mean ± 
standard deviation (SD), relative to expression at T=0, from a single experiment where N=4.
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Figure 8-7 Effect of normalisation of Huh7 TaqMan data (HMGCR) using two different 
housekeeping genes
Huh7 cells were synchronised using a serum pulse (at 1=0) and temporal gene expression of 
HMGCR was measured by quantitative RT-PCR (TaqMan). Data are shown unnormalised and 
normalised to 18S or ACTB expression, and are presented as mean ± standard deviation (SD), 
relative to expression at T=0, from a single experiment where N=4.
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8.2.2 Normalisation of Temporai Gene Expression Data from RD-D Ceiis 
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Figure 8-8 Effect of normalisation of RD-D TaqMan data (BMAL1 and CRY1) using two 
different housekeeping genes
RD-D cells were synchronised using a serum pulse (at 1=0) and temporal gene expression of 
BMAL1 and CRY1 was measured by quantitative RT-PCR (TaqMan). Data are shown 
unnormalised and normalised to 18S or ACTB expression, and are presented as mean ± 
standard deviation (SD), reiative to expression at T=0, from a single experiment where N=4. 
Statistical significance determined by one-way ANOVA foliowed by Bonferroni post hoc test; 
* = P < 0.05.
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Figure 8-9 Effect of normalisation of RD-D TaqMan data (PER1 and REV-ERBa) using two 
different housekeeping genes
RD-D cells were synchronised using a serum pulse (at 7=0) and temporal gene expression of 
PER1 and REV-ERBa was measured by quantitative RT-PCR (TaqMan). Data are shown 
unnormalised and normaiised to 18S or ACTB expression, and are presented as mean ± 
standard deviation (SD), reiative to expression at T=0, from a single experiment where N=4.
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Figure 8-10 Effect of normalisation of RD-D TaqMan data {MY0D1 and MYOG) using two 
different housekeeping genes
RD-D cells were synchronised using a serum pulse (at T=0) and temporal gene expression of 
MY0D1 and MYOG was measured by quantitative RT-PCR (TaqMan). Data are shown 
unnormalised and normalised to 18S or ACTB expression, and are presented as mean ± 
standard deviation (SD), relative to expression at T=0, from a single experiment where N=4.
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Figure 8-11 Effect of normalisation of RD-D TaqMan data {HMGCR) using two different 
housekeeping genes
RD-D cells were synchronised using a serum pulse (at 1=0) and temporal gene expression of 
HMGCR was measured by quantitative RT-PCR (TaqMan). Data are shown unnormalised and 
normalised to 18S or ACTB expression, and are presented as mean ± standard deviation (SD), 
relative to expression at T=0, from a single experiment where N=4.
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8.3 Conference Presentations
2009 - University of Surrey FHMS Annual Festival of Research (poster)
2010 - British Toxicology Society (BTS) Annual Congress 2010 (poster)
- University of Surrey FHMS Annual Festival of Research (poster)
2011 - BTS Annual Congress (poster, commended)
- University of Surrey FHMS Annual Festival of Research (poster)
2012 - BTS Annual Congress (oral presentation)
- Joint 19^ * International Symposium on Microsomes and Drug Oxidations 
(MDO) and 12^  ^ European meeting of the International Society for the 
Study of Xenobiotics (ISSX) (poster)
- University of Surrey FHMS Annual Festival of Research (poster)
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Title THE EFFECTS OF TIME OF TREATMENT ON STATIN MUSCLE TOXICITY:
INITIAL CHARACTERIZATION OF A HUMAN MUSCLE CELL LINE 
Authors ROWENA GEE. NICK PLANT, JONATHAN JOHNSTON, KATE PLANT
Group Biochemical Sciences Division: Pharmacology & Toxicology and Sleep & Chronobiology
Themes
Abstract Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. They are the first line of 
treatment for hypercholesterolemia, a known risk factor for the development of cardiovascular 
disease. Although statin therapy is generally considered to be safe, some patients experience 
muscle toxicity (myopathy), which is the most notable adverse effect of the statins and in the 
most severe cases can prove fatal. It is thought that myopathy most likely occurs due to the 
secondary effects of inhibiting HMG-CoA reductase, for example the effects on synthesis of 
other isoprenoids and the resulting disruption of protein prénylation.
Daily circadian rhythms are known to regulate a multitude of biological processes, and 
many aspects of cholesterol synthesis and metabolism have been shown to be under circadian 
control. To date, most studies looking into the optimum time for statin dosing focus on the 
effects of time on their cholesterol-lowering efficacy; however it is not currently known how 
temporal dosing of statins affects muscle toxicity. We propose that, like many aspects of 
cholesterol synthesis and metabolism, protein prénylation is also under circadian control. By 
looking into the effects of temporal dosing on cholesterol synthesis and protein prénylation, it 
may prove possible to achieve greater separation between the cholesterol-lowering effects of 
statins and unwanted toxicity. For this work we will use human liver and muscle cells in culture 
as a model system.
In the first phase of this project we have identified a human undifferentiated muscle 
cell line, the RD human rhabdomyosarcoma cell line which has previously been used for 
studying the myotoxic effects of statins. We have studied differentiating RD cells to 
characterise the morphological and molecular changes which occur during this process and to 
confirm the expression of genes involved in cholesterol metabolism and circadian rhythmicity. 
Current work is employing real-time PGR to investigate temporal changes o f gene expression.
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THE EFFECTS OF TIME OF TREATMENT ON STATIN MUSCLE TOXICITY: 
INITIAL CHARACTERIZATION OF A HUMAN MUSCLE CELL LINE
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1. INTRODUCTION
Statins are competitive inhitxtors of S-hydrojcy-S-mett^ylj^arvl coenzyme A iHMG-CoAi
reductase {HMGCR). the rale-limrtmg enzyme in cholesterol twosynthesis
They are used to treat hypercholesterolemia, a nsk factor for cardiovascular disease.
They are generally considered safe but a small numtier of patients experience muscle toxicity: 
this is thought to occur due to the secondary effects of inhtitmg HMGCR « Baker 2005i 
Studies so far have looked at the effect of tenterai dosing on efficacy but not on muscle toxicity. 
We propose that by altering the time of day statins are taken, it may prove possible to improve 
separation t>etween cholesterd low«1ng and unwanted muscle side effects.
For this we have identified a human muscle cell line, the RD human rhabdomyosarcoma cell 
line, to use as a model. This cell line has previously been used for studying the myotoxic effects 
of statins (Kobayashi 20081.
2. AIMS
To characterise the morphdogicai and molecular changes that occur in RD muscle cells dunng 
the process c# cell differentiation, so that we rmsht then use them as a model
3. METHODS
RD cels grown to cwifkience 
in standard grov4h medium 
(10% serum»
Figure 1: Differentiation protocol.
At 2 day intervals cells were photographed and total RNA was extracted for analysis by 
quantitative RT-PCR (Taqmani
4. RESULTS
l_Mus£le;S£eçiliç__Marker^
I  100,000- MyoCiMyogenin)
I** toaoQ-
'  Ovtt time, there are an 
increasing number of 
myotubes (long, more 
muscle-like structures,! 
-Arrows indicate example 
myotubes: scale bar is 
approximately 5fti M 
iVachon et ai. lSr96i
• One of the four myogenic regulatory factors 
(MRFsi. muscle-specific transcnption factors that 
play an important role in myogenic differentiation.
• The 4-fold «crease in MV0<3 expression 
observed between days 0 and 2 confirms that we 
are observing RD cell cfitfeientialion.
bays post change to difierentisUon medium
• Like myogenin. MYOOf is an MRF winch 
plays an important role in myogenic 
drfferentiation.
• However, unlike for MYOG no siyiificant 
increase in transcript level is seen early on 
in the drfferentiation process
Days post change to diftereniiation medium
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• Receptor involved in uptake of cholesterol 
m the form of LDL into ceHs
III. Clock gene expressioin
BMAU
I Brain and nxiscle 
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(Crypiocdrome 1)
II, Cholesterol Metabolism
• Catalyses the conversion c4 HMG-CoAto 
mevalonate. the rate limiting step in 
cholesterol biosynthesis.
LOLR
{Low-dcnsity lipoprotein 
receptor)
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will
Day* po»t change to diffarentiation medium
The Per genes are important components 
c4 the negative-feed}sck loop of the core 
ircadian clock.
Da^ post change to differentiation medium
• One of the key basic helix-ioop-helix-PAS 
transcnption factors involved in the 
mechanism of the core circadian clock.
• Present at a much lower level than the other 
transcripts.
RER2
(Period 2)
Days post change to differentiation medium
•Atranscription factor that may be directly 
lej^ilated by the core circadian clock and 
modulates important clock output genes
lull,
Days post change to differentiation medsu
• The Cry genes like the Per genes, are 
important components of the core clock.
DBP
(D site ofaibumn prem ier 
lalbumm D-box) binding protem)
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Figure 2: Drtferentiahon of RD cels in culture; photographs showing morphology changes over the 
10day period and changes in transcript levels as measured by quantitative RT-PCR iTaqmanr 
Statistical siyilficance determned by I-way ANOVA folowed by Bonferroni post hoc test: /
N "4 . error bars r^esent standard error of the mean.
P < 0.05. "  » P < 0.01. *** *  P < 0 001 compaied to day 0
5. DISCUSSION & FUTURE WORK
• We have confirmed the expression Of genes involved cholesterol metabolism and circadan 
thymtaty. as well as a number of muscle-specific genes m the RD muscle cell line
• The expression of many of these genes does not sigruficanlly change dunng the differentiation
' However, a significant increase m MYOG expression was observed between days 0 and 2, 
confirming that ceB differentiation was occurring.
• Other changes, such as the decrease in HMGCR and LDLR and increase in OBP expression, 
after the ftill 10 days, may be explained by the continued proliferation of the cells after the 
change to differentiation media.
• We have characterised the changes that occur during RD cell differentiation and confirmed 
that these ce8s Wiould tie allcwed to drfferentiate tor 5-6 days in future experiments
Future Work
• Western blotting to confirm these results at the protein level: In particular looking at MyoOI. 
for wfMch gene expression does not appear to change as significandy as for MyoG,
• Furtfver qPCR to lock at changes in the expression of a late-dlfferentialion gene, such as the 
myosai heavy chain
■ Using the serum pulse technique and further qPCR to look at temporal gene expression In RD 
cells and In the liver cell fine HepG2
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The Effects Of Time Of Treatment On Statin Muscle Toxicity: Preliminary Characterization Of 
A Human Muscle Cell Line
Rowena H Gee\  Nick J Plant% Jonathan D Johnston^ Kate E Plant^
Centre for Toxicology, FHMS, University of Surrey, Guildford, Surrey GU2 7XH. r.gee@surrey.ac.uk
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), 
the rate-limiting enzyme in cholesterol biosynthesis, and are used to treat hypercholesterolemia, a risk 
factor for cardiovascular disease. They are generally considered safe, but a small number of patients 
experience muscle toxicity; which is thought to occur due to the secondary effects of inhibiting 
HMGCR, for example the disruption of protein prénylation (Baker 2005). Studies so far have looked 
at the effect of temporal dosing on efficacy but not on muscle toxicity. Since muscle is known to also 
show circadian changes in gene expression in mice (McCarthy et al. 2007), we hypothesise that by 
altering the time of day statins are taken, it may prove possible to improve separation between 
cholesterol lowering and unwanted muscle side effects.
The RD human rhabdomyosarcoma cell line has previously been used for studying the myotoxic 
effects of statins (Kobayashi et al. 2008). In the current work, we first characterised the 
morphological and molecular changes that occur during RD cell differentiation. We have also begun 
to characterise the gene expression changes that occur across circadian time, initially focussing on 
clock genes (Per2, BMALl and CRYl) and HMGCR and the LDL receptor. Preliminary statin dosing 
experiments were also carried out in order to determine the optimum statin dose for future 
experiments.
RD cells were grown to confluence in standard growth medium (DMEM containing 10% fetal bovine 
serum), before the initiation of differentiation by changing to low-semm medium (1%). At 48 hour 
intervals cells were imaged and total RNA extracted for analysis by quantitative RT-PCR (Taqman). 
Statistical significance was determined by one-way ANOVA followed by Bonferroni post hoc test.
Over differentiation time an increased number of long myotubes was observed in culture. This was 
accompanied by an observed 4-fold increase in the expression of the muscle regulatory factor 
myogenin, which is consistent with the occurrence of cell differentiation; this peaked at day five 
before decreasing. The expression of key cholesterol metabolism-related and clock genes in the RD 
cell line was also examined, showing steady expression of HMGCR, the LDL receptor (LDLr), and 
clock genes PER2, BMALl and CRYl. In light of the results, it was decided to use a period of 5 days 
for RD cell differentiation prior to future experiments.
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assays were also carried out, in 
order to assess the effect of simvastatin on cell viability. RD cells were seeded at a density of 2 x 10^  
cells per well on 96-well plates and left to differentiate for 5 days in low-serum medium. Various 
concentrations of simvastatin were then added, in a total of lOOpl serum-free medium per well. For 
the final 2.5 hours of the 48 hour dosing period lOpl of PBS-containing MTT solution (5mg/mL) was 
added to the medium. The MTT medium was then replaced with lOOpl dimethylsulfoxide and the 
absorbance read at 540nm. Absorbance measured was expressed as a percentage of the control.
The observed IC50 value of simvastatin on the growth of differentiating RD muscle cells (0.58 pM)
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was in a similar range to values seen in the literature (Kobayashi et al. 2008). However, further assays 
using a larger range of concentrations are needed to confirm this.
References: Baker, S.K., 2005 Muscle Nerve 31, 572-580 
Kobayashi, M. et al. 2008 Life Sci. 82, 969-975 
McCarthy, J.J. et al. 2007 Physiol Genomics 31, 86-95
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THE EFFECTS OF TIME OF TREATMENT ON STATIN MUSCLE TOXICITY: 
PRELIMINARY CHARACTERIZATION OF A HUMAN MUSCLE CELL LINE 
Rowena Gee. Nick Plant, Jonathan Johnston, Kate Plant
Biochemical Sciences Division: Drug Design, Cancer & Toxicity and Sleep, Chronobiology & 
Neurodisorders themes.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, and are used to treat 
hypercholesterolemia, a known risk factor for cardiovascular disease. They are generally 
considered safe, but a small number of patients experience muscle toxicity; which is thought to 
occur due to the secondary effects of inhibiting HMGCR, for example the disruption o f protein 
prénylation.
Daily circadian rhythms are known to regulate a multitude of biological processes, and 
many aspects of cholesterol synthesis and metabolism have been shown to be under circadian 
control. Studies so far have looked at the effect of temporal dosing on statin efficacy but not on 
muscle toxicity. Since muscle is known to show circadian changes in gene expression in mice, 
we hypothesise that by altering the time of day statins are taken, it may be possible to improve 
separation between cholesterol lowering and unwanted muscle side effects.
The RD human rhabdomyosarcoma cell line has previously been used for studying the myotoxic 
effects of statins. In the current work, we first characterised the morphological and molecular 
changes that occur during RD cell differentiation. We have also begun to characterise the gene 
expression changes that occur across circadian time, in both RD cells and the human hepatoma 
cell line Huh7, initially focusing on clock genes (PER2, BMALl and CRYl), HMGCR and 
LDLR. Preliminary statin dosing experiments were also carried out in order to determine the 
optimum statin dose for future experiments.
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THE EFFECTS OF TIME OF TREATMENT ON STATIN MUSCLE TOXICITY: 
PRELIMINARY CHARACTERIZATION OF A HUMAN MUSCLE CELL LINE
Rowena H Gee\ Nick J Plant', Jonathan D Johnston', Kate E Plant'
'Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey GU2 7XH 
r.gee@surrey.ac.uk
1. INTRODUCTION
Statins are competitive intitotors of J-hydroxy-3-meihylglutaryl coenzyme A iHMG-CoAi 
reductase {HMGCR). the late-limiting enzyme in cholesterol tHosynthesis.
They are used to treat hypercholesterolemia, a nsk factor for carAovascular disease,
They are generally considered safe, but a small number of patients experience muscle toxicity: 
this is thought to occur due to the secondary effects of inhibiting HMGCR «Baker 2005j 
Studes so far have lodted at the effect of temporal dosing on efficacy but not on muscle toxicity. 
We propose that by altering the time of day statins are taken, it may prove possible to improve 
separation between cholesterol Icrwering and unwanted muscle side effects.
For this we have identified a human muscle cell line, the RD human rhabdomyosarcoma cell 
line, to use as a model. This cell line has previously been used for studying the myotoxic effects 
of statins (Nishmoto et al. 2003: Kobayashi et ai. 2008).
To characterise the morphological and molecular changes that occur in RD muscle cells during 
the process of cell differentiation, so that we might then use them as a model.
To carry out preliminary statin dosing experiments, to determine the optimum dose for future 
experiments.
3. METHODS
RD ceBs grovw to confluence 
In standard grov.th medium
(10% serum) _ ^
Figure 1: Differentiation protocol.
At 2 day intervals cells were photographed and total RNA was extracted for analysis by 
quantitative RT-PCR iTaqMan)
MTT assays were also carried out to look at the effects of sinrwastatin on cell viability. Cells 
were seeded into 96-well plates. After cell attachment the media was changed to serum free 
media containing various concentrations of simvastatin MTT was added 2.5 hours t>efore the 
end of the 48-hour dosing period and final absorbance read at 540nm.
4. RESULTS
./ I) Characterization of Muscle Differentiation 
jJ^ lusd^ Sgeçlfiç_^ ajJ<er^
MYOG iMvoQenin
S 80.000
Days post chmg* to differontlation medium
• Over time, there are an 
increasing number of 
myotubes dong, more 
muscle-like structures.) 
•Arrows indicate example 
myotubes; scale bar is 
approximately 50» M 
tVachon et al. 1996)
One of the four myogenic regulatory factors 
iMRFs). muscle-specific transcription factors that 
play an in^ortant role in myogenic differentiation 
The 4-fold increase in MYOG expression 
observed between days 0 and 2 confirms that we 
are observing RD cell differentiation
MYH3 
(Myosin Heavy Cham 3)
• Myosin is a contractile protein expressed as 
a late marker of differentiation
• A 7-fold increase observed tyetween days 0 
and 4 likewise confirms differentiation.
> ESSl J E l-
Dayt post change to «WfforontWtion i
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ii. Cholesterol Metabolism
• Catalyses the coiversion of HMG-CoAto 
mevalonate, the rate limiting step in 
cholesterol biosynthesis.
Days post change to differentiation medium g*
LDLR
iLow-density lipoprotein 
receptor)
• Receptor involved in uptake of cholesterol 
in the form of LDL into cells.
iii. Clock Gene Expression
< C BMALl
a  .  I Brain and muscle
•  Ajnt-like protein-1)
Days post change to differentiation medium
• One of the key basic helix-locp-helix-PAS 
transcription factors involved in the 
mechanism of the core circadian clock
• Present at a much lower level than the other 
transcripts.
Days post change to differentiation medium S
• The PER genes are important components
of the negative-feedback loop of the core 
circadan clock.
PER2
(Period 2)
mill
Days post chwige to differentiation medium
Figure 2: Differentiation of RD cefls in culture: A) photographs showing morphology changes ovei 
the to day period, and changes in transcript levels of Ai muscle-specific markers. Bi cholesterol 
metabolism genes and C) core clock genes, as measured by quantitatwe RT-PCR -TaqManj. 
Statistical significance determined by 1-way ANOVA followed by Bonferroni posi hoc test:
N «4. error bars represent standard error of the mean (SEMI 
* *  P < 0.05, ** ® P < 0.01, = P < 0.001 compared today 0
II) Characterization of Statin Toxicity
Î
Cefln-pe A'/eraae IC50 uiM' +/- SEM
HepG:
RD-U
5.01 * ) -1.56 
2.36 0.39 
0.296 *(- 0 20
Log[slmva$tatin]. <M)
Figwe 3: MTT assays for ceB viability: 48 hour ssnvastatm treatment of HepG2 ceMs. 
unckfferentiated RD ceBs (RD-U) and cfifferentiated RD cells (RD-D). Fnal absorbance expressed 
as a percentage of the control (defined as 100%).
N ■ 3. error bars represent standard error of the mean iSEM)
5. DISCUSSION & FUTURE WORK
• We have confirmed the expression of genes involved cholesterol metabolism and circadian 
rhyrmcity. as well as a number of muscle-specific genes, in the RD muscle cell line
• Significant increases were observed in the expression of MYOG (between days 0 and 2) and 
in MYH3 (between days 0 and 4). confirmng that cell differentiation was occurring.
• Other changes, such as the decrease in HMGCR and LDLR after the full 10 days, may be 
explained by the continued proliferation of the cells after the change to differentiation media.
• The expression of BMAU and PER2. genes involved in the core cIrcatSan clock, does not 
significantly change during the differentiation process.
• We have characterised the changes that occur during RD cell differentiation and based on 
these results we have detern'üned that RD cells should be allowed to cSfferenliate for 5-6 days 
in future expenments.
• Using MTT assays we have also started to characterise statin toxicity in HepG2 and RD cells, 
with differentiated RD cells showing greater sensitivity to simvastatin than either 
undifferentiated RD cells or HepG2 cells.
Future Work
• Western blotting to confirm these results at the protein level.
• Rnish characterization of statin toxicity in RD and HepG2 cells.
• Using the serum pulse technicfje and further qPCR to look at temporal gene expression in RD 
cells and in the Irver cell line. HepG2.
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Differential Sensitivity to Toxicity of Statins: A Comparison Of Liver And Muscle Cell Lines
Rowena H Gee*, Nick J Plant*, Jonathan D Johnston*, Kate E Plant*
Centre for Toxicology, FHMS, University of Surrey, Guildford, Surrey GU2 7XH. 
r.gee@surrey.ac.uk
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), 
the rate-limiting enzyme in cholesterol biosynthesis. They are widely used to treat 
hypercholesterolemia, a risk factor for cardiovascular disease. Whereas they are generally 
considered safe, muscular toxicity is a common side effect, thought to occur due to the secondary 
effects of inhibiting HMGCR, such as disruption of protein prénylation (Baker 2005).
Whereas previous studies have investigated the effect of statins on cholesterol metabolism in liver 
cells, few studies have investigated this effect in skeletal muscle, the major site of toxicity (Mullen 
2010). Through the use of two human cell lines we have undertaken a comparison of the effects of 
a variety of statins on cholesterol metabolism in liver and muscle. We hypothesise that differences 
observed between these cell lines may help to further elucidate the mechanism for statin-induced 
muscle toxicity. First, the RD human rhabdomyosarcoma cell line was chosen for its skeletal 
muscle phenotype, and its previous use for studying the myotoxic effects of statins (Kobayashi et al. 
2008); second, the HuH7 hepatocellular carcinoma cell line was used to represent human liver 
parenchyma.
Initially, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assays were carried 
out, assessing metabolic and cellular viability. RDdiff cells were seeded on 96-well plates and left to 
differentiate for 5 days in low-serum medium, while Huh7 and RDundifr cells were seeded 24 hours 
prior to experiment. Cells were exposed to various statin concentrations for 48 hours in serum-free 
medium, with MTT-containing PBS added for the final 2.5 hours. Media was replaced with DMSO 
and MTT absorbance read at 540nm. Absorbance was expressed as a percentage of the control, and 
values plotted as mean ± SEM of three independent experiments, where N=6 in each experiment. 
Statistical significance of differences in observed IC50 values determined by unpaired t-test.
We observed statistically significant reductions in cell viability for all three cell types, Huh7; 
RDundiff and RDdiff, on treatment with simvastatin (Na), simvastatin (lactone), lovastatin (Na), 
lovastatin (lactone), cerivastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin in a dose- 
dependent manner. The largest reductions in cell viability were observed with the most lipophilic 
statins: simvastatin (Na), lovastatin (Na) and cerivastatin, whereas significant loss of cell viability 
was only observed with very high concentrations of the hydrophilic pravastatin (lOOOpM and 
greater).
Higher cell toxicity was observed for all statins in the RD cells, either differentiated or 
undifferentiated, compared to the Huh7 cells. All observed IC50 values, that we have been able to 
determine, appear to be within a similar range of values as seen in the literature (Kobayashi et al. 
2008). As one example, IC50 values in response to fluvastatin treatment were 8.51 ± 5.49 pM 
(Huh7), 6.02 ± 1.83 pM (RDundiff) and 2.62 ± 2.56 pM (RDdiff).
Taken together, these data represent the first comprehensive comparative analysis of statin toxicity 
in human liver and muscle cell lines. Such characterisation is an important validation step in the
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characterisation of differences in the response of these cell lines to statins, and hence the elucidation 
of the full mechanism of toxicity.
References: Baker, S.K., 2005 Muscle Nerve 31, 572-580
Kobayashi, M. et al. 2008 Life Sci. 82, 969-975 
Mullen, P. et al 2010 Biochem. Pharmacol 79,1200-1209
Funding from The British Toxicology Society and The University of Surrey’s Centre for 
Toxicology.
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DIFFERENTIAL SENSITIVITY TO TOXICITY OF STATINS: A COMPARISON OF LIVER 
AND MUSCLE CELL LINES
R.H. Gee, N.J. Plant, J.D. Johnston, K.E. Plant
Drug Design, Cancer & Toxicity; Biochemical Sciences Division
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate- 
limiting enzyme in cholesterol biosynthesis. They are widely used to treat hypercholesterolemia, a risk factor 
for cardiovascular disease. Whereas they are generally considered safe, muscular toxicity is a common side 
effect, thought to occur due to the secondary effects of inhibiting HMGCR, such as disruption of protein 
prénylation.
Previous studies have investigated the effect of statins on cholesterol metabolism in liver cells, however few 
studies have investigated this effect in skeletal muscle, the major site of toxicity. Through the use of two 
human cell lines we have undertaken a comparison of the effects of a variety of statins on cholesterol 
metabolism in liver and muscle. We hypothesise that differences observed between these cell lines may help 
to further elucidate the mechanism for statin-induced muscle toxicity. The RD human rhabdomyosarcoma 
cell line was chosen for its skeletal muscle phenotype, and its previous use for studying the myotoxic effects 
of statins; the Huh7 hepatocellular carcinoma cell line was used to represent human liver.
Initially, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assays were carried out, 
assessing metabolic and cellular viability. We observed dose-dependent reductions in cell viability for all 
three cell types used, Huh7, RDundiff and RDdiff, on treatment with simvastatin (Na), simvastatin (lactone), 
lovastatin (Na), lovastatin (lactone), cerivastatin, fluvastatin, atorvastatin, rosuvastatin and pravastatin. The 
largest reductions in cell viability were observed with the most lipophilic statins: simvastatin (Na), lovastatin 
(Na) and cerivastatin, whereas significant loss of cell viability was only observed with very high 
concentrations of the hydrophilic pravastatin (lOOOmicroM and greater). Higher cell toxicity was observed 
for all statins in the RD cells, either differentiated or undifferentiated, compared to the Huh7 cells. Taken 
together, these data represent the first comprehensive comparative analysis of statin toxicity in human liver 
and muscle cell lines.
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DIFFERENTIAL SENSITIVITY TO TOXICITY OF STATINS: 
A COMPARISON OF LIVER AND MUSCLE CELL LINES
Rowena H Gee. Nkk J Plant, Jonathan 0 Johnston and Kate E Plant
Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey GU2 7XH 
r.gee@surrey.ac.uk
1. INTRODUCTION
Latins are competitive inhibrtors of 3-tiydroxy-3-rT>ettiy1glutdfyl coenzyme A (HMG>CoA> 
reductase <HMGCR). the rate-limiting enzyme in cholesterol biosynthesis.
They are used to treat hyperchdesterdema. a nsk factor for cardiovascular disease.
They are generally coosidwed safe, but a small number of patients expenence muscle toxicity: 
this is tfiought to occur due to the secondary effects of inhibiting HMGCR {Baker 2005).
The majority of previous studes have looked at the effect of statins on chdesterd metabolism 
m liver, rather than also in skeletal muscle, the main site of toxioty (Mullen et al 2010).
Through the use of two human cell lines we have undertaken a comparison of the effects of a 
variety of statins on chdesterd metabdism in both liver and muscle. For this work we have 
chosen a human muscle cell line, the RD human rhabdomyosarcoma cell hne, to use as a 
model This cell line has a skeletal muscle phenotype and has previously been used for 
studying the mydoxic effects of statins I Nishimofoef a/ 2003; Kobayashi ef a/ 200Ô1. We have 
chosen the HuHT human hepatocellulai caronoma cell line as our comparison liver cell line. 
Differences cbser\ed between the two cell knes may help to further eluadate the mechanism 
for statin-induced nwscle toxicity.
3. METHODS
• MTT assays were carried out to assess the effects of a variety of statins on cell viabgrty.
* The effect of statin treatment on total cellular chdesterd was measuied to examine statin- 
medated HfvfGCR inhibition A concentration of luM  was chosen based on the results of the MTT 
assays -  at 1;iM. cell death was not excessive but an effect could stiH be observed Chdesterd 
was cpjantified using the Arr^lex Red Chdesterd Assay kit See figure 1 for hirther details.
A) C*#« s««e*d Mo AbsGTtanct r«9d 
MTT^*d »l540nm
B) s*«d*d Inlo C«ll3 tiesltd wOh l;.M simvailatln. 
e-wtU plaies cail-vaslalm or pravastatin
Figure 1: E*peranental design for A) MTT assays and Bi chotesterol assays
4. RESULTS
I) Characterization of Statin-Mediated Cell Toxicity
« Simvastatin and lovastatin are adninistered as inactive prodrugs (lactone form) wfwch 
are then converted to the active open acid forms in the body. These are the most lipophilic of 
the statins, and therefore are thought to t>ecome most widely distnbuted non-specifically,
• Cerivastatin was wilhdawn from the market in 2001. due to its high incidence erf stabn •  
induced muscle toxicity
• Atorvastatin Is the most commonly prescribed statin.
• Rosuvastatin and pravastatin are hydrophilic, and therefore the least likdy to become 
dstritjuted non-specrfically
Sirrrvastatin (acid) Simvastatin (lactone)
Lovastatin (acid) Lovavastatin (lactone)
Log fstatin). (M)
Figure 2 continued
Cerivastatin
Huh? 
m RD-U 
••• RD-D
Fluvastatin
Atorvastatin
PravastatinRosuvastatin
^  -8 •? -6 -5 -4
Log (statin). (M)
Figure 2: MTT assays for ceB viabilty: 48 tiour statin treatment of Huh? ceHs, undifferentiated RD 
ce#s (RD-Ui and dfferentiated RD cells (RD-Di. Graphs shown in decreasing order of statin 
fepcphAcity Final absorbance exf^essed as a percentage of the control «defined as fOO%i.
Vakies plotted (present mean t  standard error of the mean iSEMi of at least three independent 
\  experiments, where N*6 n each experment
II) Effect of Statins on Total Cellular Cholesterol
REFERENCES
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RD ce#s I RD-D « after exposure fw 46 hours.
Values plotted represent mean i  SEM from one experiment where N=3 
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5. DISCUSSION & FUTURE WORK
This is the firsi comprehensive comparative analysts of statin toxicity m liver and muscle cell 
Imes (figure 2i
We observed a reduction in cell viability, in all three cell types, on treatment with all statms. in 
a dose-dependent manner.
Greater toxicity was observed for all statins in the RD cells compared to Huh7 cells.
Significant loss of cell viability was only observed with very high concentrations of the 
hydrophilic pravastatin (I000)if«1 and greateri
We also observed decreases in total chofesterol on treatment of our cells with IpM 
simva^atin and cerivastatin. but not witti p-ravastatin (figure 3i.
utme Work
Measure total cellular cholesterol after exposure to higher concentrations of simvastatin (acid) 
and pravastatin, and using a number of other statins
treasure other cellular effects in response to statin exposure, including reduction in protein 
prénylation to conelate this to the results from these analyses
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Differential effects of statins on protein prénylation in liver and muscle cell lines
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the 
rate-limiting enzyme in cholesterol biosynthesis, and are widely used to treat 
hypercholesterolemia, a risk factor for cardiovascular disease. Muscular toxicity is 
a side effect, thought to occur due to the secondary effects of inhibiting HMGCR, 
such as disruption of protein prénylation. Through the use of two human cell lines 
we have undertaken a comparison of the effects of statins on cell viability and 
protein prénylation in liver and muscle. We anticipate that differences observed 
may help to further elucidate the mechanism for statin-induced muscle toxicity.
Total protein extracted from cells treated with a range of simvastatin and 
cerivastatin concentrations was subjected to western blot analysis using the 
geranylgeranylated protein Rapi A as a marker of prénylation.
In both cell lines unprenylated Rapi A was observed following statin treatment; this 
was dose-dependent for both statins. Both cell lines were more sensitive to 
cerivastatin than simvastatin with a 10-fold difference in dose required to produce 
detectable levels of unprenylated Rapi A. On statin treatment, disruption of Rapi A 
prénylation occurred at a 10-fold lower concentration in muscle than in liver cells, 
both for cerivastatin (IpM and lOpM respectively) and simvastatin.
This data adds to our previous toxicity data, which showed that RD muscle cells 
were significantly more sensitive to both of these statins than Huh7 liver cells. This 
supports a mechanism whereby disruption in the intermediates in the cholesterol 
synthesis pathway, including the isoprenoids used in protein prénylation, is the 
primary cause of statin-induced muscle toxicity.
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The Muscle Cell Line RD Is More Sensitive To Statin-Mediated Disruption Of 
Protein Prénylation Than The Liver Cell Line Huh7: Implications for Statin- 
Mediated Toxicity
Rowena H. Gee. Nick J. Plant, Jonathan D. Johnston and Kate E. Plant, 
Department of Biochemistry and Physiology, University of Surrey, Guildford, United 
Kingdom
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the 
rate-limiting enzyme in cholesterol biosynthesis, and are widely used to treat 
hypercholesterolemia, a risk factor for cardiovascular disease. A common adverse 
effect associated with statin use is muscular aches, which can rarely progress to 
the potentially fatal rhabdomyolysis. The mechanism underlying this toxicity is still 
not fully understood, but secondary effects of HMGCR inhibition, such as disruption 
of protein prénylation, have been suggested as a likely mechanism. We have 
compared the effects of statins on both cell viability and protein prénylation in 
human liver and skeletal muscle cell lines, hypothesising that statins would 
preferentially disrupt prénylation within the muscle cells. Initially, 3-(4,5- 
dimethylthiazol-2-yl)2,5-diphenyl tétrazolium bromide (MTT) assays were carried 
out, in order to assess metabolic and cellular viability after cells were exposed to 
different statin concentrations. We observed significant reductions in cell viability 
for both cell lines, on treatment with simvastatin, cerivastatin and pravastatin in a 
dose-dependent manner. The largest reductions in cell viability were observed 
with the most lipophilic statins, simvastatin and cerivastatin, whereas significant 
loss of cell viability was only observed with very high concentrations of the 
hydrophilic pravastatin (lOOOpM and greater). Higher cell toxicity was observed for 
all statins in RD muscle cells compared to Huh7 liver cells. Subsequently, western 
blot analysis was used to examine the prénylation status of the geranylgeranylated 
protein Rap1 A in total protein extracts from cells treated with a range of simvastatin 
and cerivastatin concentrations. Unprenylated Rap1A was observed in both cell 
lines, in a dose-dependent manner, following treatment with simvastatin and 
cerivastatin. This prénylation deficiency was a specific effect resulting from statin 
inhibition of HMGCR since co-treatment with mevalonate, a downstream 
intermediate in the metabolic pathway, rescued the phenotype. Both cell lines 
were more sensitive to cerivastatin than simvastatin, with a 10-fold difference in 
dose required to produce detectable levels of unprenylated Rapi A. In addition, 
statin treatment resulted in disruption of Rapi A prénylation at a 10-fold lower 
concentration in muscle than in liver cells, both for simvastatin (IpM and lOpM 
respectively) and cerivastatin (O.IpM and IpM respectively). Together these data 
confirm that RD muscle cells, which are significantly more sensitive to statin 
treatment, do show preferential disruption of protein prénylation when compared to 
liver cells. This supports a mechanism whereby disruption in the intermediates in 
the cholesterol synthesis pathway, including the isoprenoids used in protein 
prénylation, is the primary cause of statin-induced muscle toxicity.
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DIFFERENTIAL EFFECTS OF STATINS ON PROTEIN PRENYLATION IN LIVER 
AND MUSCLE CELL LINES
R.H. Gee. N.J. Plant, J.D. Johnston, K.E. Plant
Drug Design, Cancer & Toxicity; Department of Biochemistry and Physiology
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the 
rate-limiting enzyme in cholesterol biosynthesis, and are widely used to treat 
hypercholesterolemia, a risk factor for cardiovascular disease. Muscular toxicity is 
a side effect, thought to occur due to the secondary effects of inhibiting HMGCR, 
such as disruption of protein prénylation. We have compared the effects of statins 
on both cell viability and protein prénylation in human liver and skeletal muscle cell 
lines, hypothesising that statins would preferentially disrupt prénylation within the 
muscle cells.
Total protein extracted from cells treated with a range of simvastatin and 
cerivastatin concentrations was subjected to western blot analysis using the 
geranylgeranylated protein Rapi A as a marker of prénylation.
In both cell lines unprenylated Rapi A was observed following statin treatment; this 
was dose-dependent for both statins. Both cell lines were more sensitive to 
cerivastatin than simvastatin with a 10-fold difference in dose required to produce 
detectable levels of unprenylated Rapi A. On statin treatment, disruption of Rapi A 
prénylation occurred at a 10-fold lower concentration in muscle than in liver cells, 
both for simvastatin (IpM and lOpM respectively) and cerivastatin (0.1 pM and IpM 
respectively).
These data add to our previous toxicity data, which showed that RD muscle cells 
were significantly more sensitive to both of these statins than Huh7 liver cells, and 
confirm that RD muscle cells do show preferential disruption of protein prénylation 
when compared to liver cells. This supports a mechanism whereby disruption in 
the intermediates in the cholesterol synthesis pathway, including the isoprenoids 
used in protein prénylation, is the primary cause of statin-induced muscle toxicity.
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The Muscle Cell Line RD Is More Sensitive To Statin-Mediated Disruption Of 
Protein Prénylation Than The Liver Cell Line Huh7: 
Implications For Statin-Mediated Toxicity
Rowena H. Gee. Nick J. Plant, Jonathan D. Johnston and Kate E. Plant
Departmcnl of Stochomistry and Pfiy»o1ogy. University of Surrey. Guilrfforri Surrey GU2 7XH 
___________________________r.gee^surrey.ae.uli___________________________
1. Introduction
• Statins are widely used to treat hypercholesterolemia, a risk factor for cardiovascular disease,
• They inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase {HMGCR). the rate-limiting enzyme in cholesterol tsosynttresis.
• A common adverse effect associated with statin use is muscular aches, which can rarely progress to the potentially fatal rhabdomyolysis.
• The mechanism underlying this toxicity is still not fully understood, but secondary effects of HMGCR inhibition, such as disruption of protein prénylation, have been suggested as a likely 
mechanism
2. Hypothesis and Objectives
Hypothesis:- muscle cells show greater sensitivity to both statin toxicity and disruption of protein prénylation than liver cells.
Objectives:
To use Huh? human hepatocellular carcinoma cells and RD human rhatxfomyosarcoma cells (undifferentiated and differentiated; in culture as a model system for comparing the effects of 
a variety of cholesterol-lowering statins on protein prénylation in both liver and skeletal muscle, where the liver is the target organ of the statins and skeletal muscle is the site of toxicity.
• MTT assays were carried out to assess the effects of a variety of statins on cell viability in both liver and muscle cells
• Western blot analysis was used to examine the prénylation status of geranylgeranylated protein RaplA on statin treatment, in both liver and muscle cells, and therefore to assess 
■whether differences in prénylation could account for differences in toxicity.
3. Results
/ 1) Characterization Of Statin-Mediated Cell Toxicity
• Simvastatin is one of the most lipophilic statins and is thought to become distributed to 
a 'Wide variety of tissues via passive diffusion Simvastatin also remains one of the most 
frequently prescritied statins in the UK
• Cerivastatin was withdrawn from the worldwide market in 2001. due to its high incidence 
of statin-induced muscle toxicity
• Pravastatin is hydrophilic and therefore the least likely to become widely distributed 
Pravastatin has also shown much lo'.ver levels of muscle toxicity in patients in the clinic.
Simvastatin
1
Pravastatin
Figurfl 1; Cell v i^ H ty  in response to statin treatment
Huh7 cells uncMferentiated RD cells <RD-U) and differentiated RD cefis <RD-D; were 
treated with statin for 48 hours and MTT assays were earned out to measure cell viatMlity. 
Final absorbance is expressed as a percentage of the control «defined as 100%> values 
plotted represent mean ± standard error of the mean (SEM) of ^  least three independent 
experiments, where 6 replicates were used in each experiment
II) Effects of Statins On Prénylation
• RaplA is a small GTPase that undergoes geranytgerar\ylation,
• Its prénylation status can be determined using a combination of antibodies.
RaplA -  detects the unprenylated protein 
Rapi -detects total protein 
Beta-actin -  used as a loading control
Figure 2: Effect of stalln treatnienf on RaplA prénylation
Total protem was extracted from Huh7. RD-U and RD-D cells treated for 48 hours with vehicle 
control, stabn. or mevatonrc acid in addition to statin Simvastatin and pravastatin were used at 
a concentration of lOyM and cenvastalin at IpM DMSO was used as a vehicle control for 
simvastatm and water for cenvastatm (and pravastatini Mevalonic acid was used In excess, at 
lOOgM. Western Wots ore rep-resentative erf three independent experiments.
Simvastatin
Beta-actin
Cerivastatin
Betd-actin
Figure 3: Dose-dependent effects of statin treAment on RaplA prénylation 
Total protein was extracted from ceils treated for 48 hours wiffi vehicle control or 
statin concentrations
a range of
4. Conclusions
il Statin treatment leads to differential cell toxicity
• Statin treatment led to a reduction In cell viability, in all cell types, in a dose-dependent manner (Figure 11
• The largest reductions in cell viability 'were otiserved on treatment with lipophilic simvastatin and cerivastatin. with loss of cell viatxlity observed only with very high concentrations of 
hydrophilic pravastatin (lOOOpM and greater)
• Greater toxicity '.\'as observed for all statins in RD muscle cells compared to Huh7 liver cells: this difference was statistically significant with simvastatin and cerivastatin treatment 
(P<00001. two-way ANOVA). This is consistent with the otjservation of skeletal muscle toxicity as a well known adverse effect oflhe statins in the clinic
ii) Statin treatment leads to differential disruption of protein prénylation
• Simvastatin and cerivastatin treatment led to detection of unprenylated RaplA (Figure 2).
• This '.vas not due to a change in levels of total Rapi protein and co-treatment with mevalonate rescued this change in prénylation status
• Muscle and liver cells were both more sensihve to cerivastatin than simvastatin (Figure 3).
• Lower concentrations of both simvastatin and cerivastatin were needed to disrupt protein prénylation in muscle compared to liver cells.
Togethcrthese data confirm that RD muscle cells, which arc significantly more sensitive to statin treatment, do show preferential disruption of protein prénylation when 
compared to liver cells. This supports a mechanism whereby disruption in the intermediates in ttie cholesterol synthesis pathway, including the isoprenoids used in 
. protein prénylation, is the primary cause of statin-induced muscle toxicity.
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